Document Type  Clinical Study Protocol 
Official Protocol Title  A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in 
Combination With Enzalutamide in Patients With Metastatic 
Castration -Resistant Prostate Cancer  
NCT Number  [STUDY_ID_REMOVED]  
Document Date  05 Nov 2018  
 
 
ZEN003694- 002 Clinical Study Protocol  Versio n:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 1 of 170  CLINICAL STUDY PROTOCOL  
TITLE A Phase 1b Safety and Tolerability Study of ZEN003694 in 
Combination with Enzalutamide  or Abiraterone  in Patients with 
Metastatic Castration -Resistant Prostate Cancer  
INVESTIGATIONAL 
NEW DRUG  NUMBER  127235 
STUDY DRUG  ZEN003694 
PROTOCOL NUMBER  ZEN003694 -002 
SPONSOR  Zenith Epi[INVESTIGATOR_885060].  
SPONSOR’S HEAD 
OFFICE  Suite 300, [ADDRESS_1238150] SW  
Calgary, Alberta 
Canada 
T3E 6L1 
SPONSOR’S 
REPRESENTATIVE  
US OFFICE   
  
 
 
 
 
 
SPONSOR’S  
MEDICAL MONITOR  
US OFFICE   
  
 
 
 
 
 
PROTOCOL  
AMENDMENT DATE Amendment 10 
05 November  2018 
 
Confidentiality Statement 
This document contains proprietary and confidential information of Zenith Epi[INVESTIGATOR_885060]. 
Acceptance of this document constitutes agreement by [CONTACT_1955][INVESTIGATOR_885061]. with the exception that this document may be disclosed to 
study personnel under your supervision who need to know the contents for conducting the study 
and appropriate Ethics Committees/Institutional Review Boards under the condition that the 
personnel have agreed to keep this information confidential.  The foregoing shall not apply to 
disclosure required by [CONTACT_1956]; however, Zenith Epi[INVESTIGATOR_885060]. shall 
be promptly notified of any such disclosure. 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238151] Aspartate aminotransferase  
AUC Area under the curve  
AUC0-∞ Area under the c urve, from time zero to infinity  
AUC0-[ADDRESS_1238152] time point with a 
quantifiable level of drug  
BCL-2 B-cell lymphoma 2  
BCL2L1 B-cell lymphoma 2 -like 1 
BET Bromodomain and extra-terminal motif  
BETi BET bromodomain inhibitor 
BID Twice Daily  
BRD2 Bromodomain -containing protein 2  
BRD3 Bromodomain -containing protein 3  
BRD4 Bromodomain -containing protein 4  
BRDT Bromodomain -testis-specific containing protein T  
BUN Blood urea nitrogen  
Cmax Maximum or peak concentration  
Cmin Minimum or trough concentration  
Css Concentra tion steady -state 
CBC Complete blood count  
CCR1 Chemokine (C -C motif) receptor 1  
CDMS Clinical data management system  
cfDNA Cell-free deoxyribonucleic acid ( DNA) 
  
CNS Central nervous system  
CR Complete response  
CRC Cohort Review Committee  
CRF Case report form  
CRPC Castration -resistant prostate cancer  
CT Computed tomography  
CTC(s) Circulating  tumor cell(s)  
CTCAE Common Terminology Criteria for Adverse Events  
ctDNA Circulating tumor deoxyribonucleic acid ( DNA) 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 3 of 170 CYP Cytochrome  P450  
CYP1A2  Cytochrome P450, family 1, subfamily A, polypeptide 2  
CYP2C8  Cytochrome P450, family 2, subfamily C, polypeptide 8 
CYP2C9  Cytochrome P450, family 2, subfamily C , polypeptide 9 
CYP2C19  Cytochrome P450, family 2, subfamily C  polypeptide 19 
CYP3A4  Cytochrome P450, family 3, subfamily A, polypeptide 4 
CYP17A1  Cytochrome P450, family 1 7, subfamily A, pol ypeptide 1, or 
steroid 17-alpha-hydroxylase/17,[ADDRESS_1238153]-in-human 
  
GCP Good Clinical Practice  
GLP Good Laboratory Practice  
GPR183 G Protein -Coupled Receptor 183  
GR Glucocorticoid receptor  
HBsAg Hepatitis B surface antigen  
HBV Hepatitis B virus  
HCV Hepatitis C virus  
HED Human equivalent dose  
hERG Human ether -à-go-go related gene ( an ion channel f ound in 
cardiac cell membranes )  
HIST2H2BE  Histone gene cluster 1, H2BE h istone family member E  
HIV Human immunodeficiency virus  
HNSTD Highest non -severely toxic dose  
HRR Hardy Rand and Rittler (plates for testing color vision)  
IC50 Half maximal inhibitory concentration  
ICF Informed consent form  
ICH International Conference on Harmonization  
IL1RN Interleukin  [ADDRESS_1238154]  
IV Intravenous  
kg Kilogram(s)  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 4 of 170 L Litre 
LC-MS/MS Liquid chromatography -tandem mass spectrometry  
LD Longest diameter  
LDH Lactate dehydrogenase  
mCRPC Metastatic castration -resistant prostate cancer  
mg Milligram(s)  
min Minute(s)  
mm3 Cubic milimeter  
MRI Magnetic resonance imaging  
mRNA Messenger ribonucleic acid  
msec Millisecond(s)  
MTD Maximum tolerated dose  
MUGA Multigated acquisition  (scan) 
MYC V-Myc avian myelocytomatosis viral oncogene h omolog 
NCI National Cancer Institute  
NF-kB Nuclear factor kappa -light-chain -enhancer of activated B cells  
ng Nanogram(s)  
OCT Optical Coherence tomography  
PCWG2 Prostate Cancer Working Group [ADDRESS_1238155] 1.1  Response Evaluation Criteria in Solid Tumors 1.1  
RNA Ribonucleic acid  
SAE Serious adverse event  
SAP Statistical analysis plan  
SD Stable disease  
STD10 Severely toxic dose in approximately 10% of animals  
S[LOCATION_003]R Suspected unexpected serious adverse event  
t1/[ADDRESS_1238156] Upper limit of normal  
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 5 of 170 Table of Contents  
1. SYNOPSIS ................................................................................................................. 11 
2. BACKGROUND ....................................................................................................... 39  
2.1 BET Inhibitors in Cancer ............................................................................................ 39  
2.2 Rationale and Mechanism for BET Inhibitors in Metastatic Castration -re sistant 
Prostate Cancer  ................................................................ ................................ ........... 39 
2.3 ZEN003694 ................................................................................................................. 41 
2.4 Nonc
linica l Data ......................................................................................................... 41  
2.5 Clinical Data ............................................................................................................... 43 
2.6 S
tudy Rationale ........................................................................................................... 44  
2.7 Dosing
 Ra tionale ......................................................................................................... 45  
3. OBJECTIVES ........................................................................................................... 48  
3.1 PART 1 OBJECTIVES: ZEN003694 in combination with enzalutamide ................. 48 
3.1.1 Part 1: Primary ............................................................................................................ 48  
3.1.2 P
art 1: Secondary ........................................................................................................ 48  
3.1.3 P
art 1: Exploratory ...................................................................................................... 48  
3.2 P
ART 2 OBJECTIVES: ZEN003694 in combination with abiraterone ..................... 49  
3.2.1 P
art 2: Primary ............................................................................................................ 49  
3.2.2 P
art 2: Secondary ........................................................................................................ 49  
3.2.3 P
art 2: Exploratory ...................................................................................................... 49  
4. P
ATIENT SELECTION .......................................................................................... 50  
4.1 Part 1: ZEN003694 in combination with enzalutamide .............................................. 50 
4.1.1 Part 1: Inclusion Criteria ............................................................................................. 50  
4.1.2 P
art 1: Exclusion Criteria ............................................................................................ 51  
4.2 P
art 2: ZEN003694 in combination with abiraterone ................................................. 53 
4.2.1 P
art 2: Inclusion Criteria ............................................................................................. 53  
4.2.2 P
art 2: Exclusion Criteria ............................................................................................ 54  
5. S
TUDY PLAN ........................................................................................................... 56  
5.1 Study Design ............................................................................................................... 56 
5.1.1 Dose Escalation ........................................................................................................... 56  
5.1.2 De
finition of Dose-limiting Toxicity .......................................................................... 59 
5.1.3 De
finition of the Maximum Tolerated Dose ............................................................... 61  
5.1.4 De
finition of the Recommended Phase 2 Dose .......................................................... 61  
5.1.5  Dose Confirmation ...................................................................................................... 61  
5.2 Safety Review ............................................................................................................. 62 
5.3 Number of Sites and Patients ...................................................................................... 63  
5.4 Study Duration ............................................................................................................ 63  
5.5 Premature Study Termination or Suspension of Enrollment ...................................... 63 
6. S
TUDY DRUG AND CONCOMITANT TREATMENT ..................................... 64 
6.1 ZEN003694 ................................................................................................................. 64 
6.2 Enzalutamide............................................................................................................... 64 
6.3 Abirateron e ................................................................................................................. 64 
6.4 Guidelines for Dose Escalation, Dose Modification and Management of ZEN003694-
related Toxicity ........................................................................................................... 65  
6.4.1 Dose Escalation in the Dose Escalation Phase of the Study ....................................... 65 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 6 of 170 6.4.2  Management of ZEN003694-related Toxicity in the Dose Escalation and Dose 
Confirmation Phases ................................................................................................... 65  
6.5 Part 1: Management of Enzalutamide-related Toxicity in the Dose Escalation and 
Dose Confirmation Phases .......................................................................................... 67  
6.6 Part 2: Management of Abiraterone-related Toxicity in the Dose Escalation and Dose 
Confirmation P
hases ................................................................................................... 68  
6.7 Treatment Compliance ................................................................................................ 69  
6.8 C
oncomitant Medications and Therapi[INVESTIGATOR_014].................................................................... 69 
6.8.1 P
art 1 and Part 2: Prohibited Concomitant Medications and Therapi[INVESTIGATOR_885062]00
3694 ................................................................................................................. 69 
6.8.2 Part 1: Prohibited Concomitant Medications and Therapi[INVESTIGATOR_885063] ...... 69 
6.8.3 P
art 2: Prohibited Concomitant Medications and Therapi[INVESTIGATOR_885064] .......... 71 
6.8.4 P
ermitted Concomitant Medications and Therapi[INVESTIGATOR_014] ................................................... 72 
7. S
TUDY DRUG AND MATERIALS ....................................................................... 74 
7.1 Study Drug Description .............................................................................................. 74  
7.1.1 Formulation ................................................................................................................. 74 
7.1.2 S
torage Conditions ...................................................................................................... 74  
7.2 Enz
alutamide............................................................................................................... 74 
7.3 Abira
teron e ................................................................................................................. 75 
7.4 Study Drug Accountability ......................................................................................... 75  
8. S
TUDY PROCEDURES AND ASSESSMENTS ................................................... 76  
8.1 Study Procedures by [CONTACT_4838] ........................................................................................... 76  
8.1.1 Screening Visit ............................................................................................................ 76  
8.1.2 C
ycle 1 Lead-in for Dose Escalation & Dose Confirmation (required for Cohorts DE-
B, DC
-B, DE-D, DC-D; also required for patients requiring enzalutamide Lead-in 
(Part 1: Sub-arm A2) or abiraterone Lead-in (Part 2: Sub-arm C2) ........................... [ADDRESS_1238157] (Cycles 5, 7, etc.) ........................................... [ADDRESS_1238158] (Cycles 6, 9, etc.) ............................................... 85 
8.1.8 Unsc
heduled Visits and Assessments ......................................................................... 86 
8.1.9 End of
 Tre atment Visit................................................................................................ 86  
8.1.10 Safety Follow-up Visit ................................................................................................ 
87 
8.2 Study Assessments ...................................................................................................... 88  
8.2.1  Informed Consent........................................................................................................ 88  
8.2.2  Inclusion/Exclusion Criteria ....................................................................................... 88  
8.2.3  Medical History and Demographics ........................................................................... 88 
8.2.4 Physical Examination/Symptom-directed Physical Examination ............................... 89  
8.2.5  Height and Weight ...................................................................................................... 89  
8.2.6  ECOG Performance Status ......................................................................................... 89  
8.2.7  Vital Signs ................................................................................................................... 89 
8.2.8  Laboratory Parameters ................................................................................................ 89  
8.2.9  Echocardiogram or MUGA ......................................................................................... 90  
8.2.10 12-lead ECG................................................................................................................ 90 
8.2.11 Pharmacokinetic Sampling ......................................................................................... 90  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 7 of 170 8.2.12 Pharmacodynamic Sampling ...................................................................................... 91  
8.2.13 Adverse Events ........................................................................................................... 93  
8.2.14 Concomitant Medica
tions ........................................................................................... 94  
8.2.15 Tumor Assessment 
– Imaging/Radiologic Evaluation ............................................... [ADDRESS_1238159] Approval ..................................... 108 
14.3 Patient Informed Consent/Assent ............................................................................. [ADDRESS_1238160] ........................................................................................................... 110 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 8 of 170 15.3  Recordkeepi[INVESTIGATOR_007] .......................................................................................................... 111  
16. PUBLICATIONS .................................................................................................... 113  
17. CONFIDE NTIALITY ............................................................................................ 114  
18. REFERENC ES ........................................................................................................ 115  
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238161] OF TABLES 
Table 1:  PART 1 ONLY:  ZEN003694 + Enzalutamide ..............................................................28 
Table 2:  PART 2 ONLY:  ZEN003694 + Abiraterone .................................................................34
 
Table 3:  Dose-limiting Toxicity and Cohort Man
agement ...........................................................57 
Table 4:  Part 1 Dose Escalation Scheme ......................................................................................58 
Ta
ble 5:  Part 2 Dose Escalation Scheme ......................................................................................59 
Ta
ble 6:  ZEN003694-Related Dose Adjustment and Toxicity Man
agement Guidelines .............66 
Table 7:  Part 1 Inhibitors and Inducers of
 Relevant Drug-metabolizing Enzymes ......................70 
Table 8:  Part 2 Inhibitors and Inducers of Relev
ant Drug-metabolizing Enzymes ......................72 
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238162] OF APPENDICES 
Appendix 1:  ECOG Performance Status..................................................................................... 120 
Appendix 2:  NC
I CTCAE Version 4.03 Adverse Event Severity Grading ................................ 121 
Appendix 3:  Prostate Cancer Clinical Trials Working Group 2 Criteria ....................................122  
Appendix 4:  XTANDI  Package Insert  ................................ ..................................................... 126 
Appendix 5:  Z
YTIGA® Package Insert ..................................................................................... 147 
Appendix 6:  Investigator Agreement Page .................................................................................170 
 
 
 
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 11 of 170 1. SYNOPSIS 
TITLE:  A Phase 1b Safety and Tolerability Study of ZEN003694  in Combination with 
Enzalutamide  or Abiraterone in Patients with Metastatic Castration -Resistant Prostate Cancer  
PROTOCOL NUMBER:  ZEN003694 -002 
STUDY PHASE:  Phase 1  
INVESTIGATIONAL DRUG:   ZEN003694  
OBJECTIVES:  
Part 1: ZEN003694 in combination with enzalutamide  
Primary 
 To determine the safety, tolerability and maximum tolerated dose (MTD) of ZEN003694 in 
combination with enzalutamide  or apalutamide  in patients with metastatic castration -resistant 
prostate cancer ( mCRPC) who have progressed during prior treatment with  enzalutamide or 
apalutamide  (Cohort DE -A) or  abiraterone  (Cohort DE -B) by [CONTACT_107282] 
2 (PCWG2) criteria 2007 (dose escalation)  
 To confirm the safety and tolerabilit y of the MTD and recommended Phase 2 dose (RP2D) of 
ZEN003694 in combination with enzalutamide in the following two cohorts of patients with 
mCRPC (dose confirmation):  
o Cohort DC-A:  Patients with prior progression on enzalutamide or apalutamide 
by [CONTACT_43877]2 criteria who are currently or will be receiving a stable dose of 
enzalutamide  
o Cohort DC-B:  Patients who are enzalutamide -naïve and apalutamide -naive with 
prior progression on abiraterone by [CONTACT_43877]2 criteria  
Secondary  
 To determine the pharmacokineti cs (PK) of ZEN003694 and the  PK of enzalutamide along 
with their primary  active metabolites when administered in combination  
 To evaluate the preliminary clinical activity of ZEN003694 in combin ation with enzalutamide 
as applicable:  
o PSA response rate by [CONTACT_43877]2 criteria  
o Radiographic response rate  by [CONTACT_43877]2 criteria  
o Median progression -free survival by [CONTACT_43877]2 criteria  
o Circulating tumor cell (CTC) response rate (dose confirmation only)  
Explorator y 
 To explore pharmacodynamics (PD), prognostic and/or predictive bi omarkers of ZEN003694 
in combination  with enzalutamide in whole blood, plasma and tumor samples in the dose 
escalation phase and/or dose confirmation phase as follows:  
o Possible relationship of baseline tumor abnormalities (such as mutations, 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 12 of 170 translocation s, messenger ribonucleic acid [ mRNA], protein expression  and 
localization ), in circulating tumor DNA (ctDNA), circulating tumor cells 
(CTC) and tumor biopsies  and/or on-treatment changes with any observed 
antitumor activity  
 To explore the effects of ZEN003694 on immuno -oncology markers in tumor tissue and 
peripheral blood mononuclear cells   
Part 2: ZEN003694 in combination with abiraterone  
Primary 
 To determine the safety, tolerability and recommended Phase 2 dose (RP2D)  of ZEN003694 in 
combination with abiraterone in patients with metastatic castration -resistant prostate cancer 
(mCRPC)  who have progressed during prior treatment with abiraterone (Cohort DE -C) or  
enzalutamide or apalutamide (Cohort DE -D) by [CONTACT_885093] r Working Group 2 (PCWG2) 
criteria 2007 (Dose Escalation)  
 To confirm the safety and tolerability of the recommended Phase 2 dose (RP2D) of 
ZEN003694 in combination with abiraterone in the  following two cohorts of patients with 
mCRPC (dose confirmation):  
o Cohort DC-C:  Patients currently receiving abiraterone  who have experienced 
progression by [CONTACT_43877]2 criteria  
o Cohort DC-D:  Patients who are abiraterone -naïve with prior progression on 
enzalutamide or apalutamide  by [CONTACT_43877]2 criteria  
Secondary  
 To determine the pharmacokinetics ( PK) of ZEN003694 and the PK of abiraterone along with 
their primary active metabolites when administered in combination  
 To evaluate the preliminary clinical activity of ZEN003694 in combin ation with abiraterone  as 
applicable:  
o PSA response rate by [CONTACT_43877]2 criteria  
o Radiographic response rate  by [CONTACT_43877]2 criteria  
o Median progression -free survival by [CONTACT_43877]2 criteria  
o Circulating tumor cell (CTC) response rate (dose confirmation only)  
Explorator y 
 To explore pharmacodynamics (PD), prognostic  and/or predictive biomarkers of ZEN003694 
in combination with abiraterone  in whole blood, plasma and tumor samples in the dose 
escalation phase and/or dose confirmation phase as follows:  
o Possible relationship of baseline tumor abnormalities (such as muta tions, 
translocations, messenger ribonucleic acid [mRNA] , protein expression  and 
localization ), in circulating tumor DNA (ctDNA), circulating tumor cells 
(CTC) and tumor biopsies  and/or on -treatment changes with any observed 
antitumor activity  
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 13 of 170 STUDY DESIGN:  
This is an open label, non -randomized, Phase 1 dose escalation/dose confirmation study of 
ZEN003694 in combination with enzalutamide  (Part 1) and abiraterone (Part 2)  in patients with 
mCRPC.  
Dose Escalation  
A standard 3+3 cohort design will be uti lized for each study Part .  Cohorts of up to 6 patients will 
be enrolled at each dose level, and each patient will participate in only one cohort.  Each cycle will 
be 28 days in duration.    
 
Part 1, ZEN003694 in combination with enzalutamide:  
For patients who have progressed  on abiraterone  (Cohort DE -B), enzalutamide will be administered 
orally as a single agent daily for 14 days prior to the initiation of the combination therapy (Lead -in) 
to reach enzalutamide steady -state concentration (C ss) during Cycl e 1. After the Lead -in, if 
applicable , ZEN003694 will be administered orally in combination with daily enzalutamide for 28-
day cycle s. Patients who are progressing on enzalutamide  or apalutamide  (Cohort DE -A, Sub-Arm 
A1) and currently receiving a stable dose of enzalutamide will continue to receive enzalutamide  in 
combination with ZEN003694, if eligibility criteria are met.   For patients who have progressed on 
enzalutamide  or apalutamide  (Cohort DE -A, Sub-Arm A2 ) but are  not currently taking 
enzalutamide  or apalutamide or are currently taking apalutamide , enzalutamide will be administered 
orally as a single agent daily for 14 days prior to the initiation of the combination therapy (Lead -in) 
to reach enzalutamide steady -state concentration (C ss) during Cycle 1 .  
 
Part 2, ZEN003694 in combination with abiraterone:  
For patients who have progressed on enzalutamide  or apalutamide  (Cohort DE -D), abiraterone  will 
be administered orally as a single agent daily for 14 days prior to  the initiation of the combination 
therapy (Lead -in) to reach abiraterone  steady-state concentration (C ss) during Cycle 1 . After the 
Lead-in, if applicable , ZEN003694 will be administered orally in combination with daily 
abiraterone  for 28-day cycles.  Patients who are progressing on abiraterone (Cohort DE -C, Sub-Arm 
C1) and currently receiving a stable dose of abiraterone will continue to receive abiraterone in 
combination with ZEN003694, if eligibility criteria are met.   For patients who have progressed on  
abiraterone (Cohort DE -C, Sub-Arm C2) but are not currently taking abiraterone, abiraterone  will 
be administered orally as a single agent daily for 14 days prior to the initiation of the combination 
therapy (Lead -in) to reach abiraterone steady-state conc entration (C ss) during Cycle 1 .  
 
Part 1 and Part 2 : 
After the Lead -in, if applicable , ZEN003694 will be administered orally in combination with daily 
enzalutamide (Part 1) or abiraterone (Part 2) for 28-day cycles.  The first patient at each dose level 
will be treated  with ZEN003694  for one week before the second patient at the same dose level  is 
allowed to  receive their first dose of ZEN003694 .  Patients at each dose level will be treated (for 28 
days on ZEN003694 ) and observed through the end of the first cycle before treatment of patients at 
the next higher dose level can begin.  If alternative dosing regimens are explored, the one week 
delay of enrollment between the first and subsequent patients may be waived b y the Cohort Review 
Committee (CRC) as long as the daily exposure is known to be tolerated.  
 
ZEN003694 -related adverse events (AEs) for determination of DLTs will be assessed for each 
patient during the [ADDRESS_1238163] of his/her  ability assess the relatedness of 
an AE observed as attributable to either enzalutamide  (Part 1) or abiraterone (Part 2)  or ZEN003694 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 14 of 170 alone, or if unable to do so, as attributable to the combination of enzalutamide  (Part 1) or 
abiraterone (Part 2)  and ZEN003694.   
Dose escalation will continue after all patients enrolled within a cohort have completed the 28 -day 
Cycle 1 DLT observation period with either 0 of 3  patients, or no more than 1 out of 6  patients in a 
cohort experiencing a DLT , with the proviso t hat dose escalation to MTD may be waived in Part 2 .  
Dose escalation decisions will be made based on clinical safety and (when available ) PK data 
(maximum or peak concentration [C max] and area under the curve [ AUC]) after review by [CONTACT_10186], 
consisting of a ll Investigators and the Zenith Medical Monitor.  If a DLT is observed in 1 of 
3 patients in a cohort and confirmed by [CONTACT_10186], 3  additional patients will be enrolled into that 
cohort.  If 1 of 6 patients in a cohort experiences a DLT, then dose escalation  may continue in the 
next cohort or the MTD of the combination can be declared.  If ≥ 2 of 3 – [ADDRESS_1238164] been enrolled at the previous dose 
level, that cohort will be expanded to 6  patients to confirm the MTD.  Should the MTD of the 
combination be exceeded at Dose Level 1, a cohort may be explored with a reduced dose of 
ZEN003694 or enzalutamide at the discretion of the CRC. Cohort management is summarized 
below. 
Number of Patients with  
Dose-limiting Toxicity  Action 
1 of 1 Add 5 more patients  
0 of 3 Proceed to next dose level  
1 of 3 Add 3 more patients  
1 of 6 Proceed to next dose level 
≥ 2 of 3 or ≥ 2 of 6  Add 3 more patients in the next lower dose level if only 
3 patients were treated in the next lower dose.  If 6  patients 
were treated at the next lower dose level and no more than 
one patient had DLT, then the next lower dose is the 
MTD. 
 
Part 1: Enrollment in Part 1 of the study with ZEN003694 in combination with enzalutamide 
will commence with 36  mg as the starting dose for ZEN003694 and 160 mg dose of enzalutamide  
(or at a lower stable dose for patients in DE -A or DC-A).   The dose of enzalutamide will be held 
constant throughout Cycle 1 of  Dose Escalation . After Cycle 1, e nzalutamide toxicity may be 
managed per the XTANDI® Package Insert.  Dose escalation will proceed per the schema below 
unless intervening toxicity is o bserved.  
 
Dose Level  ZEN003694 (mg)  Fold Increase from  
Prior Dose Level  
1 36 -- 
2 48 1.33 
3 60 1.25 
4 72 1.20 
5 96 1.33 
Additional levels may be explored at the discretion of the CRC  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 15 of 170 Part 2: Enrollment in Part 2 of the  study with ZEN003694 in combination with abiraterone  
will commence with 72 mg as the starting dose for ZEN003694 and 1000 mg dose of abiraterone 
once daily .   The dose of abiraterone 1000 mg will be held constant throughout Cycle 1 of Dose 
Escalation . After Cycle 1, abiraterone toxicity may be managed per the ZYTIGA® Package Insert.  
Dose escalation /de-escalation  will proceed per the schema below unless intervening toxicity is 
observed.  
 
Dose Level  ZEN003694 (mg)  * Fold Increase from  
Prior Dose Level  
-1 48 0.67 
1 72 -- 
2 96 1.33 
* Dose de -escalation from 72 mg is allowed  by [CONTACT_9084] .  Additional dose levels may 
be explored based on safety and at the discretion of the CRC , with the proviso that 
dose escalation to MTD may be waived in Part 2.  
Part 1 and Part 2 : Dose escalation increments between cohorts will be determined by [CONTACT_885094] (e.g., C max and AUC) based on the following schema:   
 Dose escalation up to 2 -fold is allowed in Dose Level 2 and 3 unless one drug-related 
Grade 2 event is observed in Dose Level 1 and 2, respectively  
 Subsequent dose escalation up to 1.5 -fold is allowed until a DLT is observed  
 Subsequent dose escalation up to 1.33 -fold is allowed until MTD is established , or, in 
Part 2, if MTD is waived and RP2D is declared  
All dose escalations will be guided by  [CONTACT_885095] (e.g., C max and AUC)  from both 
ZEN003694 -[ADDRESS_1238165] to the combined AUC 0-24 of 
ZEN003694 and its active metabolite ZEN003791.   
   
 
Intermediate doses and/or alternative dosing schedules may be evaluated to best determine the  
MTD and/or RP2D of ZEN0036 94 in combination with enzalutamide (Part 1) and abiraterone (Part 
2) based on evaluation of clinical safety and available PK data (e.g., C max and AUC) and upon 
agreement of the CRC members.  No intra -patient dose escalation is allowed during the first three 
cycles of therapy.  If a patient has not experienced any Grade [ADDRESS_1238166] dose currently declared tolerable by [CONTACT_885096] -patient dose escalation(s) will be determined on a cycle -by-cycle basis at 
the discretion of the Investigator and with approval from the CRC.   
Teleconferences with membe rs of the CRC will be held during the dose escalation phase to discuss 
any suspected DLTs that have occurred in patients within each cohort.  The frequency of the 
teleconference calls will be determined by [CONTACT_885097], data review, frequency of DLT 
notifications, discussions with investigational sites and other factors.  Approximately one week after 
the last patient in a dose cohort completes Cycle 1 and prior to escalating to the next dose level (or 
de-escalating), the CRC will review toxicities  and available PK (e.g., C max and AUC)  from the 
current cohort of the study during a teleconference.   

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238167] 28 days of treatment (i.e., Cycle 1) in the dose 
escalation phase.   Toxicity will be graded and recorded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events  (NCI CTCAE ), Version 4.03.  A DLT is defined 
as a clinically significant AE or laboratory abnormality that is considered possibly, probably or 
definitely related to ZEN003694 and which meets any of the following criteria:  
 Grade 3 or greater non -hematologic clinical toxicity with the exception of Grade  3 nausea 
or Grade 3/4 vomiting and diarrhea persisting less than 72 hours in the absence of maximal 
medical therapy  
 Grade 4 neutropenia lasting more than 5 days 
 Grade 3 or greater febrile neutropenia (temperature ≥ 38.5ºC)  
 Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with clinically significant 
bleeding, or any requirem ent for platelet transfusion  
 Any other Grade 3 or 4 laboratory abnormality th at requires hospi[INVESTIGATOR_059]  
 An ALT > 3x ULN with concomitant total bilirubin > 2x ULN  
 Any ZEN003694 -related toxicity  that results in more than 25% of missed doses during 
Cycle 1 of treatment  
 In the situation where toxicity requires withholding ZEN003694 following the receipt of at 
least 75% of scheduled dosing during Cycle 1: Failure to begin Cycle [ADDRESS_1238168] discontinue dosing with ZEN003694; patients must complete 
the Safety Follow -up visit prior to discontinuation from the study.    
Determination of evaluability will be made during the first 28 days of  ZEN003694  treatment (i.e., 
Cycle 1) in the dose escalation phase.  Patients meeting one or more of the following  will be 
considered unevaluable and will be replaced:  
 Patients who miss more than 25% of ZEN003694 and/or enzalutamide or abiraterone doses 
or fail to begin Cycle 2 within 1 week of the scheduled start date for reasons other than  
ZEN003694 -related toxicity 
 Patients who  require enzalutamide or abiraterone dose hold or modification  in Cycle 1 , 
including during the 14 -day Lead -in period  for reaso ns other than ZEN003694 -related 
toxicity.     
 Part 1 only:  If a patient is unable to tolerate enzalutamide for any reason at dose of [ADDRESS_1238169] dose of ZEN003694, then the patient should not 
receive ZEN003694, and be withdrawn from the study and replaced.  
 Part 2 only:  If a patient is unable to tolerate for any reason abiraterone at dose of [ADDRESS_1238170] dose of ZEN003694, then the patient 
should not receive ZEN003694, and b e withdrawn from the study and replaced  
Definition of the Maximum Tolerated Dose  
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238171] dose level of ZEN003694 in combination with enzalutamide  
(Part 1) or abiraterone ( Part 2; if MTD is determined ) at which no  more than [ADDRESS_1238172] cycle of therapy. MTD may be declared independently for any 
given dosing regimen, i.e., the respective MTDs for once daily dosing, twice daily dosing, and any 
alternative dosing regimen(s) need not be at the same dose.  
Definition of the Recommended Phase 2 Dose  
The RP2D is defined as the dose level of ZEN003694 in combinatio n with enzalutamide  (Part 1) or 
abiraterone (Part 2)  recommended for further clinical study.  In Part 1 of this study, t he RP2D may 
be the same as the MTD or modified from the MTD based on assessment of  overall exposure, safety 
experience in Cycle 2 and beyond, PD and clinical benefit data .  In Part 2 of this study, the MTD 
establishment may be waived and the RP2D will then be based on assessment of overall exposure, 
safety experience in Cycle 2 and beyond, PD and clinical benefit data ; alternatively,  it may be based 
on the MTD  established. The RP2D of ZEN003694 in combination with enzalutamide (Part 1) or 
abiraterone (Part 2) will be determined in the dose confirmation phase of the study.  RP2D may be 
declared independently for any given Part of the study  or dosing regimen, i.e., the respective 
RP2Ds for once daily dosing, twice daily dosing, an d any alternative dosing regimen(s) need not be 
at the same dose.  
Dose Confirmation  
Part 1 only:  Once the MTD of ZEN003694 in combination with enzalutamide has been determined 
in the dose escalation portion of Part 1 of the study, up to 20 patients who me et the 
inclusion/exclusion criteria for Cohort DC-A and up to 20 patients who meet the 
inclusion/exclusion criteria for Cohort DC-B of the dose confirmation phase will be enrolled for 
further evaluation of safety, PK, PD and preliminary clinical activity.   
Enzalutamide -naive and apalutamide -naïve patients in Cohort DC-B will be administered 
enzalutamide (160 mg) orally once daily for 14 days prior to the initiation of the combination 
therapy (Lead -in) to reach enzalutamide C ss during Cycle 1.  After the Lead -in, ZEN003694 will be 
administered orally in combination with daily enzalutamide for 28-day cycle s.  Patients in Cohort 
DC-A who are currently receiving  a stable dose of  enzalutamide  (Sub-arm A1) will continue to 
receive en zalutamide and will not participate in the Lead -in. Patients in Cohort DC -A who are not 
currently receiving enzalutamide or apalutamide or are currently taking apalutamide (Sub-arm A2) 
will be administered enzalutamide orally once daily for 14 days  prior to the initiation of the 
combination therapy (Lead -in) to reach enzalutamide C ss.  After the Lead -in, ZEN003694 will be 
administered orally in combination with daily enzalutamide for 28-day cycles .   
Part 2 only:  Once the CRC has determined a recommended phase 2 dose of ZEN003694 in 
combination with abiraterone in the dose escalation portion of Part 2 of the study, up to 20 patients 
who meet the inclusion/exclusion criteria for Cohort DC-C and up to 20 patients who meet the 
inclusion/exclusion criteria for  Cohort DC-D of the dose confirmation phase will be enrolled for 
further evaluation of safety, PK, PD and preliminary clinical activity.  
Abiraterone -naïve patients in Cohort DC -D will be administered abiraterone (1000 mg once daily) 
orally for 14 days pri or to the initiation of the combination therapy (Lead -in) to reach abiraterone 
Css during Cycle 1.  After the Lead -in, ZEN003694 will be administered orally in combination with 
daily abiraterone for 28 -day cycles.  Patients in Cohort DC -C who are currently  receiving a stable 
dose of abiraterone (Sub-arm C1) will continue to receive abiraterone when enrolled in the dose 
confirmation phase of the study and will not participate in the Lead -in.  Patients in Cohort DC -C 
who are not currently receiving abiraterto ne (Sub-Arm C2) will be administered abiraterone orally 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 18 of 170 once daily for 14 days prior to the initiation of the combination therapy (Lead -in) to reach 
abiraterone C ss.  After the Lead -in, ZEN003694 will be administered orally in combination with 
daily abiraterone for 28-day cycles.   
Part 1 and Part 2 : When the 6th patient in each cohort in the dose confirmation phase has 
completed one cycle of therapy, or earlier if clinically indicated, the CRC will review the safety 
data.  If  ≥ [ADDRESS_1238173] experienced  drug-related SAEs or DLT -equivalent events, the CRC may 
recommend a modification in the dose or regimen of ZEN003694 in combination with enzalutamide 
for the dose confirmation phase.  
NUMBER OF SITES:  
Up to 10 sites in the [LOCATION_002]  may participate in this study.  
NUMBER OF PATIENTS:  
Part 1: Up to 80 evaluable patients will be enrolled in the study; approximately  40 patients will be 
enrolled in the dose escalation phase and up to 40  patients will be enrolled in the dose confirmation  
phase. 
Part 2: Up to 55 evaluable patients will be enrolled in the study; approximately  15 patients will be 
enrolled in the dose escalation phase and up to 40  patients will be enrolled in the dose confirmation 
phase. 
ESTIMATED STUDY DURATION:  
The study duration including the enrollment period and follow -up for both the dose escalation and 
dose confirmation phases is approximately 36 months  for Part 1 and 24 months for Part 2 , 
depending upon total enrollment.   
ELIGIBILITY CRITERIA:  
Part 1:, ZEN003694 in combination with enzalutamide  
Part [ADDRESS_1238174] meet the following inclusion criteria to be eligible for the study.  
Part 1 All Patients  
1. Males age ≥ 18 years  
2. Metastatic, castrate resistant, h istologically confirmed  prostate cancer; surgically castrated 
or continuous medical castration for ≥  8 weeks prior to screening  
3. Serum testosterone < 50 ng/dL determined within [ADDRESS_1238175] administration of study 
drug 
4. Eastern Cooperative Oncology Group (ECOG) performance sta tus of 0 or 1  
5. Adequate laboratory parameters at Screening including:  
a. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L 
b. Platelet count ≥ 100,000/mm3 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 19 of 170 c. Aspartate aminotransferase  (AST) or alanine aminotransferase  (ALT) ≤ 2.[ADDRESS_1238176] (≤ [ADDRESS_1238177] if liver metastases ar e present)  
d. Total bilirubin ≤ 1. [ADDRESS_1238178]  
e. Serum creatinine ≤ 1.[ADDRESS_1238179] or calculated (Cockcroft -Gault formula) or 
measured creatinine clearance ≥ 60 mL/min  
f. Prothrombin time  (PT), international normalized ratio  (INR) and partial 
thromboplastin time  (PTT) < 1.[ADDRESS_1238180] study drug administration  
8. Ability to swallow capsules and comply with study procedures  
9. Ability to und erstand and willingness to sign informed consent form prior to initiation of 
any study procedures  
Part 1 Dose Escalation  only  
10. Cohort DE -A: Prior progression on  enzalutamide  or apalutamide  at any time by [CONTACT_43877]2 
criteria and is or will be receiving a stable dose of enzalutamide (defined as a dose that has 
not changed for at least 2 weeks prior to Cycle 1 Day 1 and is not expected to change on 
study).  Patients may or may  not have experienced prior progression on abiraterone.  
11. Cohort DE -B: Enzalutamide -naïve and apalutamide -naïve patients following prior 
progression on  abiraterone by [CONTACT_43877]2 criteria .   
Part 1 Dose Confirmation  only 
12. Cohort DC-A:  Prior progression on  enzalutamide  or apalutamide  at any time by [CONTACT_43877]2 
criteria and is or will be receiving a stable dose of enzalutamide (defined as a dose that has 
not changed for at least 2 weeks prior to Cycle 1 Day 1 and is not expected to change on 
study).  Patients may or may  not have experienced prior progression on abiraterone.  
13. Cohort DC-B:  Enzalutamide -naïve and apalutamide -naïve patients following prior 
progression on abiraterone by [CONTACT_43877]2 criteria . 
Part [ADDRESS_1238181] previously received an investigational BET inhibitor (including previous participation 
in this study or Study ZEN003694 -001)  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238182] received  prior systemic anti -cancer therapy (i ncluding abiraterone) or investigational 
therapy within [ADDRESS_1238183] 
administration of study drug  
4. Failure to recover to Grade 1 or lower toxicity related to prior systemic therapy (excluding 
alopecia and neuropathy) prior to study entry  
5. Radiation therapy within [ADDRESS_1238184] administration of study 
drug (enzalutamide in DE-B and DC -B or ZEN003694 in DE-A and DC -A) 
7. Have received prior chemotherapy in the metastatic castration -resistant setting (prior 
chemotherapy in the hormone -sensitive setting is allowed provided last dose was at least 
6 months prior to study entry)  
8. Have received prior investigati onal anti-androgen therapy  
9. Currently receiving medications known to be strong inhibitors of cytochrome ( CYP)2C8, 
strong inducers (except enzalutamide  or apalutamide ) or inhibitors of CYP3A4 and 
substrates of CYP1A2, CYP3A4, CYP2C9 and CYP2C19 with a narrow  therapeutic 
window.  Strong inducers, inhibitors and substrates must be discontinued at least [ADDRESS_1238185] administration of study drug.  
10. Not a candidate for enzalutamide treatment, in the opi[INVESTIGATOR_689]  
11. Left ventricular ejection  fraction less than the lower of 50% or the lower limit of 
institution’s normal range  
12. QTcF interval > 450 msec  
13. Known impaired cardiac function or clinically significant cardiac disease such as 
uncontrolled supraventricular arrhythmia, ventricular arrhythmi a requiring therapy, or 
congestive heart failure (N ew York Heart Association  functional class III or IV)  
14. Myocardial infarction or unstable angina within [ADDRESS_1238186] administration of 
study drug  
15. Other clinically significant co -morbidities, such as uncontrolled pulmonary disease, active 
central nervous system disease, active, uncontrolled bacterial, viral, or fungal infection(s) 
requiring systemic therapy, or any other condition that could compromise safety or the 
patient’s participation in t he study 
16. Other known active cancer requiring therapy at time of study entry  
17. Historically positive (screening tests not required) for human immunodeficiency virus 
(HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections.  HBV 
positivity defined by [CONTACT_23977] B surface antigen (HBsAg).  HCV positivity defined 
as positive HCV viral load  
18. Major surgery other than diagnostic surgery, dental surgery or stenting within [ADDRESS_1238187] administration of study drug  
19. History of congenital or other deficiency in platelet function, any known inherent or 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 21 of 170 acquired coagulopathy , or therapeutic anticoagulation with warfarin or api[INVESTIGATOR_3822] (low -dose 
warfarin for port patency or prophylactic anti -platelet agents are allowed)  
20. Concurrent participation in another clinical investigational  treatment  trial 
21. Any other reason that in the opi[INVESTIGATOR_885065] g participation or following the study schedule  
Part 2 Only, ZEN003694 in combination with abiraterone:  
Part [ADDRESS_1238188] meet the following inclusion criteria to be eligible for the study.  
Part 2 All Patients  
1. Males age ≥ 18 years  
2. Metastatic, castrate resistant, h istologically confirmed  prostate cancer; surgically castrated 
or continuous medical castration for ≥  8 weeks prior to screening  
3. Serum testosterone < 50 ng/dL determined within [ADDRESS_1238189] administration of study 
drug 
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1  
5. Adequate labora tory parameters at Screening including:  
a. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L 
b. Platelet count ≥ 100,000/mm3 
c. Aspartate aminotransferase  (AST) or alanine aminotransferase  (ALT) ≤ 2. [ADDRESS_1238190] (≤ [ADDRESS_1238191] if liver metastases are present)  
d. Total bilirubin ≤ 1.[ADDRESS_1238192]  
e. Serum creatinine ≤ 1.[ADDRESS_1238193] or calculated (Cockcroft -Gault formula) or 
measured creatinine clearance ≥ 60 mL/min  
f. Prothrombin time  (PT), international normalized ratio  (INR) and partial 
thromboplastin time  (PTT) < 1.[ADDRESS_1238194] study drug administration  
8. Ability to swallow capsules and comply with study procedures  
9. Ability to understand and willing ness to sign informed consent form prior to initiation of 
any study procedures  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 22 of 170 Part 2 Dose Escalation  only  
10. Cohort DE -C: Prior progression on  abiraterone  at any time by [CONTACT_43877]2 criteria and is or 
will be receiving a stable dose of abiraterone (defined as a dose that has not changed for at 
least 2 weeks prior to Cycle 1 Day 1 and is not expected to change on study ).  Patients may 
or may not have experienced prior progression on enzalutamide  or apalutamide .  
11. Cohort DE -D: Abiraterone -naïve patients  following prior progression on  enzalutamide or 
apalutamide by [CONTACT_43877]2 criteria .   
Part 2 Dose Confirmation  only 
12. Cohort DC -C:  Prior progression on  abiraterone  at any time by [CONTACT_43877]2 criteria and is or 
will be receiving a stable dose of abiraterone (defined as  a dose that has not changed for at 
least 2 weeks prior to Cycle 1 Day 1 and is not expected to change on study ).  Patients may 
or may not have experienced prior progression on enzalutamide or apalutamide . 
13. Cohort DC -D:  Abiraterone -naïve patients following  prior progression on  enzalutamide  or 
apalutamide by [CONTACT_43877]2 criteria .   
Part [ADDRESS_1238195] previously received an investigational BET inhibitor (including previous participation 
in this study or Study ZEN003694 -001)  
2. Have received  prior systemic anti -cancer therapy or investigational therapy within [ADDRESS_1238196] administration of  study drug. 
(Patients progressing on enzalutamide or apalutamide require a 2 week wash -out prior to 
start of abiraterone Cycle 1 Lead -in where applicable)  
3. Failure to recover to Grade 1 or lower toxicity relate d to prior systemic therapy (excluding 
alopecia and neuropathy) prior to study entry  
4. Radiation therapy within [ADDRESS_1238197] administration of study 
drug (abiraterone in DE -D and DC -D or ZEN003694 in DE -C and DC-C) 
6. Have received prior chemotherapy in the metastatic castration -resistant setting (prior 
chemotherapy in the hormone -sensitive setting is allowed provided last dose was at least 
6 months prior to  study entry)  
7. Have received prior investigational anti -androgen therapy  
8. Currently receiving medications known to be substrates of CYP1A2  or CYP2D6  with a 
narrow therapeutic window.  Major substrates must be discontinued at least [ADDRESS_1238198] a dministration of study drug.  
9. Not a candidate for abiraterone  treatment, in the opi[INVESTIGATOR_689]  
10. Left ventricular ejection fraction less than the lower of 50% or the lower limit of 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 23 of 170 institution’s normal range  
11. QTcF interval > 450 msec  
12. Known impair ed cardiac function or clinically significant cardiac disease such as 
uncontrolled supraventricular arrhythmia, ventricular arrhythmia requiring therapy, or 
congestive heart failure (N ew York Heart Association  functional class III or IV)  
13. Myocardial infarction or unstable angina within [ADDRESS_1238199] administration of 
study drug  
14. Other clinically significant co -morbidities, such as uncontrolled pulmonary disease, active 
central nervous system disease, active, uncontrolled bacterial, viral,  or fungal infection(s) 
requiring systemic therapy, or any other condition that could compromise safety or the 
patient’s participation in the study  
15. Other known active cancer requiring therapy at time of study entry  
16. Historically positive (screening tests no t required) for human immunodeficiency virus 
(HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections.  HBV 
positivity defined by [CONTACT_23977] B surface antigen (HBsAg).  HCV positivity defined 
as positive HCV viral load  
17. Major surgery other than diagnostic surgery, dental surgery or stenting within [ADDRESS_1238200] administration of study drug  
18. History of congenital or other deficiency in platelet function, any known inherent or 
acquired coagulopathy , or therapeutic anticoagulation with warfarin or api[INVESTIGATOR_3822] (low-dose 
warfarin for port patency or pr ophylactic anti -platelet agent s are allowed)  
19. Concurrent participation in another clinical investigational treatment trial  
20. Any other reason that in the opi[INVESTIGATOR_885066] g participation or following the study schedule  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 24 of 170 DOSE, REGIMEN AND ROUTE OF ADMINISTRATION:  
ZEN003694  
ZEN003694 is a novel, potent BET bromodomain inhibitor currently under clinical investigati on.  
ZEN003694  will be supplied in capsules  of two different dosage strengths:  12 mg and 48 mg.   
Part 1: The starting dose for this study is 36 mg daily.  Dosing in initial cohorts will commence with 
ZEN003694 administered once daily ZEN003694 in combination with enzalutamide (160 mg  or at 
a lower stable dose for patients in DE -A or DC-A).  Alternative dosing regimens (i.e., twice daily 
dosing, on/off schedules) may be explored in separate dose cohorts based on CRC safety review 
and approval.  
Part 2: The starting dose for this study is 72 mg daily.  Dosing in initial cohorts will commence with 
ZEN003694 administered once daily ZEN003694 in combination with abiraterone (1000 mg once 
daily) orally.  Alternative dosing regimens (i.e., twice daily dosin g, on/off schedules) may be 
explored in separate dose cohorts based on CRC safety review and approval.  
Both Part 1 and Part 2 : ZEN003694 will be administered orally in 28 -day cycles and should be 
ingested with a full (8 -ounce) glass of water at least 1 hour before eating or 2 hours after eating 
(fasting). 
Part 1: Enzalutamide  
Enzalutamide is an androgen receptor inhibitor indicated for the treatment of patients with mCRPC.  
Enzalutamide 160 mg (four 40  mg capsules) will be administered orally once daily according to the 
XTANDI® Package Insert  without food in 28-day cycles  for all enzalutamide -naïve patients (DE -B 
and DC-B cohorts) .  For patients in DE -A and DC -A cohorts, enzalutamide will be administered at 
the dose level previously determined to be stable and that has not changed for at least two weeks 
prior to starting Cycle 1  Day 1 combination study treatment or restarting enzalutamide treatment in 
the Lead-in phase.  In Dose Escalation, t he dose of enzalutamide will be held constant throughout 
Cycle 1 of the study. After Cycle 1, the dose of enzalutamide  may be modified for toxicity per the 
XTANDI® Package Insert.  
Patients may continue receiving ZEN003694 in combination with enzalutamide until disease 
progression by [CONTACT_43877]2 criteria, unacceptable toxicity, requirement for non -protocol therapy or 
patient withdrawal from study.  Patients with PSA -only progression may remain on study until 
clinical and/or radiographic evidence of progression by [CONTACT_43877]2 criteria.  
Part 2: Abiraterone  
Abiraterone  is an androgen synthesis inhibitor indicated for the treatment of patients with mCRPC.  
Abiraterone 1000  mg (four 250 mg capsules) will be administered orally once daily according to the 
ZYTIGA® Package Insert  without food in 28-day cycles .  In Dose Escalation, t he dose of 
abiraterone  will be held constant at 1000 mg throughout Cycle 1 of the study. After Cycle 1, the 
dose of abiraterone may be modified for toxicity per the ZYTIGA® Package Insert.  
Patients may continue receiving ZEN003694 in combination with abiraterone  until disease 
progression by [CONTACT_43877]2 criteria, unacceptable toxicity, requirement for non -protocol therapy or 
patient withdrawal from study.  Patients with PSA -only progression may remain on study until 
clinical and/or radiographic evidence of progression b y PCWG2 criteria.  
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 25 of 170 STUDY ASSESSMENTS:  
Safety 
Safety will be assessed by [CONTACT_22244], weight, ECOG performance status, vital 
signs, clinical laboratory assessments  (hematology, serum chemistries,  serum troponin, coagulation 
tests and urinalysis) , 12-lead electrocardiogram (ECG) and monitoring of AEs (see Schedule of 
Events).  
Pharmacokinetics  
Part 1: Plasma samples will be collected to assess the PK properties of ZEN003694 and the 
metabolite ZEN003791, and enzalutamide  and the metaboli te des-methyl enzalutamide.  Urine 
samples may also be collected at the direction of Zenith in the Dose Confirmation phase  to assess 
ZEN003694 and its metabolite s, including ZEN003791.   Plasma and urine  concentrations of 
ZEN003694, the metabolite ZEN00379 1, enzalutamide  and des-methyl enzalutamide  will be 
determined by a validated liquid chromatography -tandem mass spectrometry ( LC-MS/MS) 
bioanalytical  method.  Samples will be collected as indicated in the Schedule of Events.  
Part 2: Plasma samples will be c ollected to assess the PK properties of ZEN003694 and the 
metabolite ZEN003791, and abiraterone .  Plasma concentrations of ZEN003694, the metabolite 
ZEN00379 1, and abiraterone  will be determined by a validated liquid chromatography -tandem mass 
spectrometry  (LC-MS/MS) bioanalytical  method.  Samples will be collected as indicated in the 
Schedule of Events.  
Pharmacodynamics  
Blood samples will be drawn for analyses of BET inhibitor gene expression profile , cell-free DNA 
and circulating tumor DNA,  CTCs and exploratory biomarkers  (dose confirmation only)  as 
indicated in the Schedule of Events.   Blood samples for analyses of immuno -oncology biomarkers 
will also be drawn at selected clinical sites.   Tumor tissue will be obtained for histological and 
immunohistochemical analyses, expression of  V-Myc avian myelocytomatosis viral oncogene 
homolog (MYC), glucocorticoid receptor ( GR) and androgen receptor ( AR), and RNA  sequencing 
(and DNA sequencing if adequate tumor tissue is available)  analysis to identi fy somatic mutations, 
alternative splicing, fusions and alterations in gene expression.  Tumor tissue will be obtained  as 
indicated in the Schedule of Events.  
Response  
Whole body radionuclide imaging (T ech-99) and cross -sectional imaging of the 
chest/abdom en/pelvis should be performed in accordance with institutional standards.  Use of 
intravenous contrast is required unless contraindicated.  Magnetic resonance imaging (MRI) may be 
substituted for computed tomography (CT) per the Investigator’s discretion.  Disease status should 
be assessed using the PCWG2 criteria as indicated in the Schedule of Events.  
Blood samples will be drawn to measure PSA levels as indicated in the Schedule of Events.  
Whole blood samples will be drawn for enumeration of CTCs as indicated in the Schedule of 
Events. 
 
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 26 of 170 STATISTICAL METHODS:  
The primary statistical analysis of the data will be descriptive in nature.  For continuous variables 
this means calculation of the number of observations, mean, standard deviation, median, minimum, 
and maximum.  Categorical variables will be summarized by [CONTACT_885098].  
For ordinal -scaled variables, a combination of the above may be employed as appropriate:  
frequency and percentage of observations within a category  and means and standard deviations of 
the scores of the categories.  For categorical and ordinal variables, percentages will be calculated 
based on non -missing data.  
Based on the characteristics of the study design and lack of a concurrent control arm, for mal testing 
of treatment effects (i.e., inferential statistics) will not be performed.  However, some measures will 
be summarized by [CONTACT_885099] 95% confidence intervals.  
Sample Size Determination  
A conventional algorithm (3+3 p atients per dose level) will be used to identify the MTD, escalating 
on [ADDRESS_1238201] 2 of 3 or 2 of 6 patients experiencing a DLT.  With this design, there is a 71% 
chance of escalation if the true but unknown rate of DLT is 20%, and less than 50% chance of 
escalation if the true but unknown rate of DLT is higher than 30 %. 
Part 1: Approximately 40 patients may be enrolled in the dose escalation phase of the study.  Up to 
40 patients in the dose confirmation phase  may be enrolled at the MTD or RP2D.  The sample size 
is sufficient to support preliminary safety and pharmaco logic assessments.  
Part 2: Approximately 15 patients may be enrolled in the dose escalation phase of the study.  Up to 
40 patients in the dose confirmation phase  may be enrolled at the MTD or RP2D.  The sample size 
is sufficient to support preliminary safety and pharmacologic assessments.  
Analysis Populations  
The following populations will be analyzed by [CONTACT_9524]:  
Safety population:  Patients who receive at least one  dose of ZEN003694.  
DLT population:  Patients who experience a DLT as defined by [CONTACT_3181].  Patients who 
experience a DLT within the first cycle of treatment and drop out of the study will be considered 
evaluable for DLT and will not be replaced.  
 Part 1 only: No dose modification of enzalutamide (160 mg) is permitted during Cycle 1 , 
including the 14 -day Lead -in period; patients requiring dose modification during Cycle [ADDRESS_1238202] cycle will be considered 
unevaluable and will be replaced.  
 Part 2 only: No dose modification of abiraterone (1000 mg) is permitted during Cycle 1, 
including the 14-day Lead-in period; patients requiring dose modification during Cycle [ADDRESS_1238203] cycle will be considered 
unevaluable a nd will be replaced.  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 27 of 170 Statistical Analyses  
Prior to the analysis of the final study data, a detailed statistical analysis plan (SAP) will be written.  
Detailed information regarding analysis datasets, summarization of the data and analyses will be 
provided in the SAP.   
ZEN003694- 002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 28 of 170 Table 1:  PART 1 ONLY:  ZEN003694 + Enzalutamide  
Schedule of Events – Dose E
scalation (DE) and Dose Confirmation (DC) 
 Screening  
(Within 28 
Days of C1D -14 
for DE-B and 
DC-B or C1D 1 
for DE-A and 
DC-A) Cycle 1 
(Days -14 through -1) Cycle 1 
(Days 1 – 28) Cycle 2 
(Days 1 – 28) Cycle [ADDRESS_1238204] 
(Days 1 – 28) Unscheduled 
Visit v End of 
Treatment  
w Safety 
Follow-up 
(30 Days 
after 
End of 
Treatment)x 
Medical, Surgical, Malignancy 
History, Prior Cancer 
Treatments, Demographics  X        
Informed Consent  X        
Physical Examination, Weight, 
Height, ECOG P erformance 
Status, Vital Signs a X  Days 1, 8, 15, 22  Days 1, 15  Days 1 X X X 
Hematology b X DE-B and DC-B: 
*Day -14 
DE-A and DC -A 
Sub-arm A2^ Days 1*, 8, 15, 
22 Days 1, 8, 15, 22  Days 1, 15  X X X 
Coagulation Tests c X DE-B and DC-B: 
*Day -14 
DE-A and DC -A 
Sub-arm A2^ Days 1*, 15 Day 1 Day 1 X   
Serum Chemistries d X DE-B and DC-B: 
*Day -14 
DE-A and DC -A 
Sub-arm A2^ Days 1*, 8, 15, 
22 Days 1, 8, 15, 22  Days 1, 15  X X X 
Troponin e   Days 1, 15  Day 1 Day 1  X  
Serum Prostate-specific Antigen  X DE-B and DC-B: 
*Day -14 
DE-A and DC -A 
Sub-arm A2^  
Day 1* Day 1 Day 1  X X 
Urinalysis f X DE-B and DC -B: 
*Day -14 
DE-A and DC-A  
Sub-arm A2^ Day 1* Day 1 Day 1 X X X 
Serum Testosterone  X  Day 1 Day 1 Day 1  X X 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 29 of 170  Screening  
(Within 28 
Days of C1D -14 
for DE-B and 
DC-B or C1D 1 
for DE-A and 
DC-A) Cycle 1 
(Days -14 through -1) Cycle 1 
(Days 1 – 28) Cycle 2 
(Days 1 – 28) Cycle [ADDRESS_1238205] 
(Days 1 – 28) Unscheduled 
Visit v End of 
Treatment  
w Safety 
Follow-up 
(30 Days 
after 
End of 
Treatment)x 
Echocardiogram or Multigated 
Acquisition Scan g X        
Triplicate 12-Lead 
Electrocardiogram  h X  Days 1, [ADDRESS_1238206] i X i X X i 
Qualitative Exploration of Visual 
Symptoms i X X Days 1, 8, 15, 22  Days 1, 15  Days 1  X X 
Fresh Tumor and Archival 
Tumor Tissue  Collection 
(Optional for DE, Mandatory for 
DC for Patients with Accessible 
Tumors) X j    X k  X l  
Pharmacokinetics m   Days 1, 2, 15 Day 1     
BET Inhibitor Gene Expression 
Profile n   Days 1, 2       
Circulating Tumor Cells (CTCs) 
for 
Pharmacodynamic/Correlative 
Evaluation  o  DE-B and DC-B: 
Day -14 
DE-A and DC -A 
Sub-arm A2^ Day 1  Day 1 o  
 
 X  
CTCs for Enumeration/Response 
Analysis p  DE-B and DC-B: 
Day -14 
DE-A and DC -A 
Sub-arm A2^ Day 1  Day 1 p  X  
Exploratory PD Biomarkers (DC 
Only) q  DC-B: 
Day -14 
DC-A 
Sub-arm A2^ Day 1 Day 1   X  
Exploratory Immuno -Oncology 
Biomarkers r (DE Only, select 
sites only)  Xr  Days 1 r, 8, 22      
ZEN003694  Administration s   Days 1 through 28 of each cycle     
Enzalutamide Administration t  DE-B and DC-B:  
Days -14 through -1 Days 1 through 28 of each cycle     
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 30 of 170  Screening  
(Within 28 
Days of C1D -14 
for DE-B and 
DC-B or C1D 1 
for DE-A and 
DC-A) Cycle 1 
(Days -14 through -1) Cycle 1 
(Days 1 – 28) Cycle 2 
(Days 1 – 28) Cycle [ADDRESS_1238207] 
(Days 1 – 28) Unscheduled 
Visit v End of 
Treatment  
w Safety 
Follow-up 
(30 Days 
after 
End of 
Treatment)x 
DE-A and DC -A 
Sub-arm A2^ 
Adverse Events  DE-B and DC-B: 
Day -14 
DE-A and DC -A 
Sub-arm A2^ Days 1, 8, 15, 22  Days 1, 15  Day 1 X X X 
Prior/Concomitant Medications  X DE-B and DC-B: 
Day -14 
DE-A and DC -A  
Sub-arm A2^ Days 1, 8, 15, 22  Days 1, 15  Day 1 X X X 
Tumor Assessment u X    X u X X  
Exploratory BET Inhibitor  Blood 
Signature (DC only) y   Day 1 Day 1 X y  X  
Urinalysis for Renal Clearance  
(DC Only)  z   Day 15      
Exploratory cfDNA and ctDNAaa  DE-B and DC -B 
Day -14 
DE-A and DC -A  
Sub-arm A2^ Day 1  Day 1  X  
Cycle 1 Day -14 Enzalutamide Lead-in should begin -14 days ± 1 day from Cycle 1 Day 1. All other scheduled clinic attendance should occur within ± 3 days of the specified 
dates at all visits unless otherwise specified .  Imaging for tumor assessments may be scheduled up to 7 days prior to the scheduled clinic visit day.  
* For patients requiring enzalutamide Lead-in, perform laboratory tests at Cycle 1 Day -14 only if Screening visit tests were performed more than 7 days prior to the Cycle 1 Day -
14 visit. For patients that do not require enzalutamide Lead-in, perform laboratory tests at Cycle 1 Day 1 only if Screening visit tests were performed more than 7 days prior to the 
Cyc
le 1 Day 1 visit. 
^ Only for patients in DE-A or DC-A who are not currently taking enzalutamide or are currently taking apalutamide, enzalutamide is to be (re )started with a 14 day Lead-in and 
Visit C1D-14 shall be conducted for applicable patients (DE-A and DC-A Sub-arm A2)  
All assessments and tests/samples should be obtained pre-dose unless specified otherwise , and are to be performed even if dosing is not required (i.e., due to an on/off 
schedule) on the specified study visit day.  Note:  The visits in Cycle 2, on Days [ADDRESS_1238208], on Day 15, will only include blood draws for safet y 
laboratory testing and may be drawn after the patient has taken his dose (if dosing is required on that day). 
Footnotes:  
a Complete physical examination to be performed at the Screening visit and a symptom-directed physical examination thereafter.   Height to be measured at the Screening Visit 
only. Vital signs: body temperature, blood pressure and heart rate.  
b Hem
atology: complete blood count (CBC) with differential and absolute neutrophil count (ANC) . Day [ADDRESS_1238209] as long as platelets are stable and there are no other laboratory concerns in the opi[INVESTIGATOR_689].   
c Coagulation tests:  prothrombin time (PT) or international normalized ratio (INR) and partial thromboplastin time (PTT)  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 31 of 170 d Serum chemistry:  albumin, alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase, amylase, bicarbonate, total bilirubin, blood urea nitrogen 
(BUN), total calcium, chloride, creatinine, glucose, lactate dehydrogenase (LDH), lipase, sodium, potassium, phosphorus and magnesium.  Note:  Serum testosterone will be 
collected at screening , Day [ADDRESS_1238210] as 
long as platelets are stable and t
here are no other laboratory concerns in the opi[INVESTIGATOR_689].  
e  Troponin: serum samples will be drawn for analyses of troponin T and/or I proteins, based on local laboratory procedure. For any individual patient, the same method will be 
used at each timepoint. 
f Urinalysis: dipstick with micro-analysis if clinically indicated.  
g  Cardiac echocardiogram or multigated acquisition (MUGA) scan for left ventricular ejection fraction   
h Triplicate 12-lead electrocardiogram (ECG) to be performed as follows for each Part.  For DE, DC-A and DC-B: Cycle 1 Day 1: pre-dose and 1 hour (±15 min) post-ZEN003694 
and
 enzalutamide dose
s; Cycle 1 Day 15: pre-dose and 1 hour (±15 min) post-ZEN003694 and enzalutamide doses; Cycle 2 Day 1: pre-ZEN003694 and enzalutamide doses; Cycle 
[ADDRESS_1238211] (C5D1, C7D1, etc.):  pre-ZEN003694 and enzalutamide doses. 
i Ophthalmology assessments will be performed at Screening, C2D1, C6D1 (and every sixth cycle onward) and at the End of Treatment (±7 days at each visit).  Screening 
ophthalmology assessments are to be performed prior to C1D1 and after all entry criteria have been assessed and the subject is approved for enrollment in the study.  If 
abnormalities are detected or there are visual disturbances noted at the End of Treatment, ophthalmology assessments are to be performed at the Safety Follow-Up visit.  At any 
time during the study should a clinically meaningful change in visual symptoms occur, unscheduled assessments are to be performed.  Ophthalmology assessments will include:  
Ophthalmic history, Snellen best corrected visual acuity (including refraction, if needed), color vision testing (using standard HRR pseudoisochromatic plates), pupi[INVESTIGATOR_115726], 
confrontational visual field testing, intraocular pressure (using Goldmann tonometry or TonoPen tonometry), external eye and ocular motility exam and slit lamp biomicroscopy, 
indirect ophthalmoscopy, OCT optic nerve and macula tests, fundus photography, and other exams as clinically indicated. Completion of the Qualitative Exploration of Visual 
Symptoms form (provided by [CONTACT_1034]) is required at every clinic visit.       
j Fre
sh tumor sample collections are optional and encouraged at Screening during the DE phase.  Fresh tumor samples are mandatory at Screening during the DC phase for patients 
with accessible lesions.  During each biopsy procedure, 2-4 tumor tissue cores (optimally 4 cores) should be obtained.  For those patients in DE-A or DC-A who are not currently 
taking enzalutamide and require 14 day Lead-in , the screening fresh tumor biopsy can be collected from time of consent through Cycle 1 Day -1, preferably during the 14 day 
enzalutamide Lead-in. Archival tumor samples (initial diagnostic tissue or from prostatectomy or other resected tissue), if available and with the patient’s consent, will be collected 
during the Screening period through the end of Cycle [ADDRESS_1238212]. 
k Fresh tumor sample collections at Cycle 3 Day 1 (± 15 days) during the DE phase are encouraged yet optional. Fresh tumor sample collections at Cycle 3 Day 1 (± 15 days) 
during the DC phase are mandatory if the tumor is accessible .  During each biopsy procedure, 2-4 tumor tissue cores (optimally 4 cores) should be obtained. 
l An op
tional biopsy will be taken at the time of disease progression by [CONTACT_107282] 2 (PCWG2) criteria for patients i n DE or DC phases of the study . 
Whenever possible, this biopsy should be performed while the patient is still receiving ZEN003694 and enzalutamide, and 2 to 4 hours following administration of ZEN003694 
and enzalutamide on 
the day of biopsy.  
m Blood (plasma) for pharmacokinetic (PK) profile of ZEN003694 and enzalutamide and their active metabolites will be collected in DE, DC-A and DC-B as specified below: 
 C1D1:  pre-ZEN003964 and enzalutamide doses 
 C1D1:  15 min (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 hours (±30 min) post-ZEN003694 and 
enzalutamide doses 
 C1D2:  pre-ZEN003694 and enzalutamide doses  
 C1D15:  pre-ZEN003964 and enzalutamide doses 
 C1D15:  15 min (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 hours (±30 min) post-ZEN003694 and 
enzalutamide doses 
 C2D1:  pre-ZEN003964 and enzalutamide doses 
 If enzalutamide dose is reduced in DE any time after Cycle 1 or in DC at any time, PK samples are to be collected 28 days ±7 days following dose modification: pre-
ZEN003964 and enzalutamide doses, and 15 min (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 hours 
(±30 min) post-ZEN003694 and enzalutamide doses 
n Blood samples (whole blood) for BET inhibitor gene expression profile: 
 C1D1:  pre-ZEN003694 and enzalutamide doses 
 C1D1:  2 hours (±15 min), 4 hours (±15 min), and 6 hour (±15 min) post-ZEN003694 and enzalutamide doses 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 32 of 170  C1D2:  pre-ZEN003694 and enzalutamide doses 
 Unscheduled blood samples (whole blood) for BET inhibitor gene expression profile at pre-dose, 2 hours (±15 min), 4 hours (±15 min), and/or 6 hour (±15 min) post-
ZEN003694 and enzalutamide doses may also be drawn at later time-points, upon direction by [CONTACT_885100] 
o Blood samples (whole blood) for CTCs for PD/correlative evaluation: 
 C1D-14:  pre-enzalutamide dose (for all patients requiring enzalutamide Lead-in ) 
 C1D1:  pre-ZEN003694 an
d enzalutamide doses 
 C3D1:  pre-ZEN003694 and enzalutamide doses 
 Every third cycle D1 (C6D1, C9D1, etc.):  pre-ZEN003694 and enzalutamide doses 
 At disease progression and at the time of PSA or radiographic response 
p Blood samples (whole bloo
d) for CTCs for enumeration/response analysis: 
 C1D-14:  pre-enzalutamide dose (for all patients requiring enzalutamide Lead-in ) 
 C1D1:  pre-ZEN003694 and enzalutamide doses 
 C3D1:  pre-ZEN003694 and enzalutamide doses 
 Every third cycle D1 (C6D1, C9D1, etc.):  pre-ZEN003694 and enzalutamide doses 
 At disease progression and at the time of PSA or radiographic response 
q Blood samples (plasma) for exploratory PD assessments (DC-A and DC-B ): 
 C1D-14:  pre-enzalutamide dose (for all patients requiring enzalutamide Lead-in )  
 C1D1:  pre-ZEN003694 an
d enzalutamide doses  
 C2D1:  pre-ZEN003694 and enzalutamide doses  
 At study treatment discontinuation 
r Blood samples (whole blood) for immuno-oncology biomarker assessments ( DE Only , at selected clinical sites only)   
 Scre
ening (Prior to the first dose of enzalutamide for the Day -14 L ead-in for all patients requiring enzalutamide L ead-in.  Prior to ZEN003694 dosing on C1D1 of DE-A 
or DC-A for patients who do not require enzalutamide Lead-in .)   
 C1D1:  For all patients requiring enzalutamide L ead-in, pre-ZEN003694 and pre-enzalutamide dosing 
 C1D8: 
 pre-ZEN003694 and pre-enzalutamide dosing 
 C1D22:  pre-ZEN003694 and pre-enzalutamide dosing 
s ZEN003694 should be taken at the same time as enzalutamide starting on C1D1. 
t Enzalutamide  will be given as a single agent for 14 days (C1D -14 through -1) prior to the initiation of the combination therapy on C1D1 (Lead-in).  The Lead-in period occurs 
only for Cycle 1 in DE-B and DC-B phases, and for those patients in DE-A or DC-A who are not currently taking enzalutamide and require the 14 day Lead-in .  Enzalutamide 
should
 be taken once daily starting on C1D- 14. 
u Tumor assessment to include whole body radionuclide imaging (Te ch-99) + cross-sectional imaging of the chest/abdomen/pelvis.  Use of IV contrast is required unless contra-
indicated.   Magnetic resonance imaging (MRI) may be substituted for computed tomography (CT) per Investigator’s discretion.   Tumor assessment are to be performed during the 
Screening period, Cycle [ADDRESS_1238213] (C6D1, C9D1, etc.).   Imaging may be scheduled up to 7 days prior to the scheduled clinic visit day. 
v Ph
ysical examination, vital signs, hematology, coagulation tests, serum chemistry, urinalysis, ECG , tumor assessments, and/or other assessments may be performed as clinically 
indicated duri ng any unscheduled visit 
w At the End of Treatment if a subject’s dose was held and treatment was not resumed after a two week period, the scheduling of the EOT visit from the date of last study drug is 
extended from 7 days to 14 days (±3 days). 
x The Safety Follow-Up Visit should be completed 30 days (±3 days) after the End of Treatment visit or prior to the subject beginning a new anti-cancer treatment, whichever 
occurs first.  If the subject begins a new anti-cancer treatment within 7 days following the End of Treatment visit, the Safety Follow-Up visit is not required. 
y Blood samples (whole blood) for  Exploratory BET inhibitor blood signature (DC-A and DC-B ): 
 C1D1: pre-ZEN003694 and enzalutamide doses 
 C1D1: 4 hours (±15 min) post-ZEN003694 and enzalutamide doses 
 C2D1: pre-ZEN003694 and enzalutamide doses 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 33 of 170  C3D1: pre-ZEN003694 and enzalutamide doses  
 Every [ADDRESS_1238214] (C6D1, C9D1, etc.): pre-ZEN003694 and enzalutamide doses 
 End of Treatment Visit 
z Urine samples for renal clearance of ZEN003694 and its metabolites for up to 8 hours may be collected at C1D15 upon direction from Zenith (DC Only) 
aa Blood samples (whole blood) for exploratory cfDNA and ctDNA assessments 
 C1D-14 pre- enzalutamide dose ( DE-B and DC-B and DE-A or DC-A Sub-Arm A2: all patients requiring the enzalutamide Lead-in ) 
 C1D1 pre-ZEN003694 and enzalutamide doses 
 C3D1 pre-ZEN003694 and enzalutamide doses 
 End of Treatment Visit 
 In selected patients who have shown evidence of response or progression, an unscheduled pre-dose sample may be collected during the course of the response based 
upon agreement between the Sponsor and Investigator 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 34 of 170 Table 2:  PART 2 ONLY:  ZEN003694 + Abiraterone  
Schedule of Events – Dose E
scalation (DE) and Dose Confirmation (DC) 
 Screening  
(Within 28 
Days of C1D -14 
for DE-B and 
DC-B or C1D1 
for DE-A and 
DC-A) Cycle 1 
(Days -14 through -1) Cycle 1 
(Days 1 – 28) Cycle 2 
(Days 1 – 28) Cycle [ADDRESS_1238215] 
(Days 1 – 28) Unscheduled 
Visit v End of 
Treatment  
w Safety 
Follow-up 
(30 Days 
after 
End of 
Treatment)x 
Medical, Surgical, Malignancy 
History, Prior Cancer 
Treatments, Demographics  X        
Informed Consent  X        
Physical Examination, Weight, 
Height, ECOG P erformance 
Status, Vital Signs a X  Days 1, 8, 15, 22  Days 1, 15  Days 1 X X X 
Hematology b X DE-D and DC -D: 
*Day -14 
DE-C and DC -C 
Sub-arm C2^ Days 1*, 8, 15, 
22 Days 1, 8, 15, 22  Days 1, 15  X X X 
Coagulation Tests c X DE-D and DC -D: 
*Day -14 
DE-C and DC -C 
Sub-arm C2^ Days 1*, 15 Day 1 Day 1 X   
Serum Chemistries d X DE-D and DC -D: 
*Day -14 
DE-C and DC -C 
Sub-arm C2^ Days 1*, 8, 15, 
22 Days 1, 8, 15, 22  Days 1, 15  X X X 
Troponin e   Days 1, 15  Day 1 Day 1  X  
Serum Prostate-specific Antigen  X DE-D and DC -D: 
*Day -14 
DE-C and DC -C 
Sub-arm C2^  
Day 1* Day 1 Day 1  X X 
Urinalysis f X DE-D and DC -D: 
*Day -14 
DE-C and DC -C 
Sub-arm C2^ Day 1* Day 1 Day 1 X X X 
Serum Testosterone  X  Day 1 Day 1 Day 1  X X 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 35 of 170  Screening  
(Within 28 
Days of C1D -14 
for DE-B and 
DC-B or C1D1 
for DE-A and 
DC-A) Cycle 1 
(Days -14 through -1) Cycle 1 
(Days 1 – 28) Cycle 2 
(Days 1 – 28) Cycle [ADDRESS_1238216] 
(Days 1 – 28) Unscheduled 
Visit v End of 
Treatment  
w Safety 
Follow-up 
(30 Days 
after 
End of 
Treatment)x 
Echocardiogram or Multigated 
Acquisition Scan g X        
Triplicate 12 -Lead 
Electrocardiogram  h X  Days 1, 15 Day 1 Day 1 h X   
Ophthalmology Assessmentsi X i     X i   
Qualitative Exploration of Visual 
Symptoms i  X Day 1 Day 1   X  
Fresh Tumor and Archival 
Tumor Tissue  Collection 
(Optional for DE, Mandatory for 
DC for Patients with Accessible 
Tumors) X j    X k  X l  
Pharmacokinetics m   Days 1, 2, 15 Day 1     
BET Inhibitor Gene Expression 
Profile n   Days 1, 2       
Circulating Tumor Cells (CTCs) 
for 
Pharmacodynamic/Correlative 
Evaluation  o  DE-D and DC -D: 
Day -14 
DE-C and DC -C 
Sub-arm C2^ Day 1  Day 1 o  
 
 X  
CTCs for Enumeration/Response 
Analysis p  DE-D and DC -D: 
Day -14 
DE-C and DC -C 
Sub-arm C2^ Day 1  Day 1 p  X  
Exploratory PD Biomarkers (DC 
Only) q  DC-D: 
Day -14 
DC-C 
Sub-arm C2^ Day 1 Day 1   X  
ZEN003694  Administration s   Days 1 through 28 of each cycle     
Abiraterone  Administration t  DE-D and DC -D:  
Days -14 through  -1 
DE-C and DC -C 
Sub-arm C2^ Days 1 through 28 of each cycle     
Adverse Events   DE-D and DC -D: 
Day -14 Days 1, 8, 15, 22  Days 1, 15  Day 1 X X X 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 36 of 170  Screening  
(Within 28 
Days of C1D -14 
for DE-B and 
DC-B or C1D1 
for DE-A and 
DC-A) Cycle 1 
(Days -14 through -1) Cycle 1 
(Days 1 – 28) Cycle 2 
(Days 1 – 28) Cycle [ADDRESS_1238217] 
(Days 1 – 28) Unscheduled 
Visit v End of 
Treatment  
w Safety 
Follow-up 
(30 Days 
after 
End of 
Treatment)x 
DE-C and DC-C 
Sub-arm C2^ 
Prior/Concomitant Medications  X DE-D and DC -D: 
Day -14 
DE-C and DC -C 
Sub-arm C2^ Days 1, 8, 15, 22  Days 1, 15  Day 1 X X X 
Tumor Assessment u X    X u X X  
Exploratory BET Inhibitor Blood 
Signature (DC only) y   Day 1 Day 1 X y  X  
Exploratory cfDNA and ctDNAaa  DE-D and DC -D 
Day -14 
DE-C and DC -C 
Sub-arm C2^ Day 1  Day 1  X  
 
Cycle 1 Day -14 Abiraterone Lead-in should begin -14 days ± 1 day from Cycle 1 Day 1. All other scheduled clinic attendance should occur within ± 3 days of the specified dates 
at all visits unless otherwise 
specified.  Imaging for tumor assessments may be scheduled up to 7 days prior to the scheduled clinic visit day.  
* For patients requiring abiraterone Lead-in, perform laboratory tests at Cycle 1 Day -14 only if Screening visit tests were performed more than 7 days prior to the Cycle 1 Day -14 
visit. For patients that do not require abiraterone Lead-in, perform laboratory tests at Cycle 1 Day 1 only if Screening visit tests were performed more than 7 days prior to the Cycle 
1 Day 1 visit. 
^ Only for patients in DE-C or DC-C who are not currently taking abiraterone , abiraterone is to be re-started with a 14 day Lead-in and Visit C1D-14 shall be conducted for 
applicable patients (DE-C or DC-C Sub-arm C2)  
All assessments and tests/samples should be obtained pre-dose unless specified otherwise , and are to be performed even if dosing is not required (i.e., due to an on/off 
schedule) on the specified study visit day.  Note:  The visits in Cycle 2, on Days [ADDRESS_1238218], on Day 15, will only include blood draws for safety 
laboratory testing and may be drawn after the patient has taken his dose (if dosing is required on that day). 
Footnotes:  
a Complete physical examination to be performed at the Screening visit and a symptom-directed physical examination thereafter.   Height to be measured at the Screening Visit 
only. Vital signs: body temperature, blood pressure and heart rate.  
b Hem
atology: complete blood count (CBC) with differential and absolute neutrophil count (ANC) . Day [ADDRESS_1238219] as long as platelets are stable and there are no other laboratory concerns in the opi[INVESTIGATOR_689].  
c Coagulation tests:  prothrombin time (PT) or international normalized ratio (INR) and partial thromboplastin time (PTT)  
d Serum chemistry:  albumin, alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase, amylase, bicarbonate, total bilirubin, blood urea nitrogen 
(BUN), total calcium, chloride, creatinine, glucose, lactate dehydrogenase (LDH), lipase, sodium, potassium, phosphorus and magnesium.  Note:  Serum testosterone will be 
collected at screening, Day [ADDRESS_1238220] as 
long as platelets are stable and t
here are no other laboratory concerns in the opi[INVESTIGATOR_689].  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 37 of 170 e  Troponin: serum samples will be drawn for analyses of troponin T and/or I proteins, based on local laboratory procedure. For any individual patient, the same method will be 
used at each timepoint. 
f Urinalysis: dipstick with micro-analysis if clinically indicated.  
g  Cardiac echocardiogram or multigated acquisition (MUGA) scan for left ventricular ejection fraction   
h Triplicate 12-lead electrocardiogram (ECG) to be performed as follows for each Part.  For DE, DC-C and DC-D: Cycle 1 Day 1: pre-dose and 1 hour (±15 min) post-ZEN003694 
and abiraterone doses; Cycle 1 Day 15: pre-dose and 1 hour (±15 min) post-ZEN003694 and abiraterone doses; Cycle 2 Day 1: pre-ZEN003694 and abiraterone doses; Cycle [ADDRESS_1238221] (C5D1, C7D1, etc.):  pre-ZEN003694 and abiraterone doses. 
i Ophthalmology assessments will be performed at Screening prior to C1D1 and after all entry criteria have been assessed and the subject is approved for enrollment in the study. 
At any time during the study should a clinically meaningful change in visual symptoms occur, repeat assessments are to be performed and may be recorded as an Unscheduled 
Visit. Ophthalmology assessments will include: Ophthalmic history, Snellen best corrected visual acuity (including refraction, if needed), color vision testing (using standard HRR 
pseudoisochromatic plates), pupi[INVESTIGATOR_115726], OCT optic nerve and macula tests, fundus photography, and other exams as clinically indicated. The Visual Symptoms form (provided 
by [CONTACT_1034]) is to be administered by [CONTACT_885101]-dose on Cycle 1 Day-14, Cycle 1 Day 1, Cycle 2 Day 1 and at the EOT visit.        
j Fresh tumor sample collections are optional and encouraged at Screening during the DE phase.  Fresh tumor samples are mandatory at Screening during the DC phase for patients 
with accessible lesions.  During each biopsy procedure, 2-4 tumor tissue cores (optimally 4 cores) should be obtained.  For those patients in DE-C or DC-C who are not currently 
taking abiraterone and require 14 day Lead-in , the screening fresh tumor biopsy can be collected from time of consent through Cycle 1 Day -1, preferably during the 14 day 
abiraterone Lead-in. Archival tumor samples (initial diagnostic tissue or from prostatectomy or other resected tissue), if available and with the patient’s consent, will be collected 
during the Screening period through the end of Cycle [ADDRESS_1238222]. 
k Fresh tumor sample collections at Cycle 3 Day 1 (± 15 days) during the DE phase are encouraged yet optional. Fresh tumor sample collections at Cycle 3 Day 1 (± 15 days) 
during the DC phase are mandatory if the tumor is accessible .  During each biopsy procedure, 2-4 tumor tissue cores (optimally 4 cores) should be obtained. 
l An op
tional biopsy will be taken at the time of disease progression by [CONTACT_107282] 2 (PCWG2) criteria for patients in the DE phase or DC phase of the study . 
Whenever possible, this biopsy should be performed while the patient is still receiving ZEN003694 and abiraterone, and 2 to 4 hours following administration of ZEN003694 and 
abiraterone on the day of biopsy.  
m Blood (plasma) for pharmacokinetic (PK) profile of ZEN003694 and abiraterone and their active metabolites will be collected in DE, DC-C and DC-D as specified below: 
 C1D1:  pre-ZEN003964 and abiraterone doses 
 C1D1:  15 min (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 hours (±30 min) post-ZEN003694 and 
abiraterone doses 
 C1D2:  pre-ZEN003694 and abiraterone doses  
 C1D15:  pre-ZEN003964 and abiraterone doses 
 C1D15:  15 min (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 hours (±30 min) post-ZEN003694 and 
abiraterone doses 
 C2D1:  pre-ZEN003964 and abiraterone doses 
 If abiraterone dose is reduced in DE any time after Cycle 1 or in DC at any time, optional PK samples are to be collected at the discretion of the sponsor following dose 
modification: pre-ZEN003964 and abiraterone doses, and 15 min (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) 
and 8 hours (±30 min) post-ZEN003694 and abiraterone doses 
n Blood samples (whole blood) for BET inhibitor gene expression profile: 
 C1D1:  pre-ZEN003694 and abiraterone doses 
 C1D1:  2 hours (±15 min), 4 hours (±15 min), and 6 hour (±15 min) post-ZEN003694 and abiraterone doses 
 C1D2:  pre-ZEN003694 and abiraterone doses 
 Unscheduled blood samples (whole blood) for BET inhibitor gene expression profile at pre-dose, 2 hours (±15 min), 4 hours (±15 min), and/or 6 hour (±15 min) post-
ZEN003694 and abiraterone doses may also be drawn at later time-points, upon direction by [CONTACT_705967] 
o Blood samples (whole blood) for CTCs for PD/correlative evaluation: 
 C1D-14:  pre-abiraterone dose ( for all patients requirin g abiraterone Lead-in ) 
 C1D1:  pre-ZEN003694 and abiraterone doses 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 38 of 170  C3D1:  pre-ZEN003694 and abiraterone doses 
 Every third cycle D1 (C6D1, C9D1, etc.):  pre-ZEN003694 and abiraterone doses 
 At disease progression and at the time of PSA or radiographic response 
p Blood samples (whole blo
od) for CTCs for enumeration/response analysis: 
 C1D-14:  pre-abiraterone dose ( for all patients requiring abiraterone Lead-in ) 
 C1D1:  pre-ZEN003694 and abiraterone doses 
 C3D1:  pre-ZEN003694 and abiraterone doses 
 Every third cycle D1 (C6D1, C9D1, etc.):  pre-ZEN003694 and abiraterone doses 
 At disease progression and at the time of PSA or radiographic response 
q Blood samples (plasma) f
or exploratory PD assessments (DC only ): 
 C1D-14:  pre-abiraterone dose (for all patients requiring abiraterone Lead-in )  
 C1D1:  pre-ZEN003694 an
d abiraterone doses  
 C2D1:  pre-ZEN003694 and abiraterone doses  
 At study treatment discontinuation 
s ZEN003694 should be taken at the same time as abiraterone starting on C1D1. 
t Abiraterone   will be given as a single agent for 14 days (C1D -14 through -1) prior to the initiation of the combination therapy on C1D1 (Lead-in).  The Lead-in period occurs 
only for Cycle 1 in DE-D and DC-D phases, and for those patients in DE-C or DC-C who are not currently taking abiraterone and require the 14 day Lead-in .  Abiraterone should 
be taken once daily starting on C1D-14. 
u Tumor assessment to include whole body radionuclide imaging (Tech-99) + cross-sectional imaging of the chest/abdomen/pelvis.  Use of IV contrast is required unless contra-
indicated.  Magnetic resonance imaging (MRI) may be substituted for computed tomography (CT) per Investigator’s discretion.  Tumor assessment are to be performed during the 
Screening period, Cycle [ADDRESS_1238223] (C6D1, C9D1, etc.).  Imaging may be scheduled up to 7 days prior to the scheduled clinic visit day. 
v Physical examination, vital signs, hematology, coagulation tests, serum chemistry, urinalysis, ECG, tumor assessments, and/or other assessments may be performed as clinically 
indicated during any unscheduled visit 
w At the End of Treatment if a subject’s dose was held and treatment was not resumed after a two week period, the scheduling of the EOT visit from the date of last study drug is 
extended from 7 days to 14 days (±3 days). 
x The Safety Follow-Up Visit should be completed 30 days (±3 days) after the End of Treatment visit or prior to the subject beginning a new anti-cancer treatment, whichever 
occurs first.  If the subject begins a new anti-cancer treatment within 7 days following the End of Treatment visit, the Safety Follow-Up visit is not required. 
y Blood samples (whole blood) for  Exploratory BET inhibitor blood signature ( DC-C and DC-D ): 
 C1D1: pre-ZEN003694 and abiraterone doses 
 C1D1: 4 hours (±15 min) post-ZEN003694 and abiraterone doses 
 C2D1: pre-ZEN003694 and abiraterone doses 
 C3D1: pre-ZEN003694 and abiraterone doses  
 Every [ADDRESS_1238224] (C6D1, C9D1, etc.): pre-ZEN003694 and abiraterone doses 
 End of Treatment Visit 
aa Blood samples (whole blood) for exploratory cfDNA and ctDNA assessments 
 C1D-14 pre- abiraterone dose (DE-D and DC-D and DE-C or DC-C Sub-arm C2:  all patients requiring abiraterone Lead-in ) 
 C1D1 pre-ZEN003694 and abiraterone doses 
 C3D1 pre-ZEN003694 and abiraterone doses 
 End of Treatment Visit 
 In selected patients who have shown evidence of response or progression, an unscheduled pre-dose sample may be collected during the course of the response based 
upon agreement between the Sponsor and Investigator 
 
ZEN003694- 002 Clinical Study Protocol  Versio n:  Final 
Amendment 10  05 November 2018 
 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 39 of 170 
 
 
 
 
 2. BACKGROUND  
2.1 BET Inhibitors in Cancer 
The bromodomain and extra terminal domain (BET) proteins comprise four closely related 
bromodomain -containing proteins (BRD2, BRD3, BRD4, and BRDT) that are a subset of the 
larger family of [ADDRESS_1238225] due to their potential to target the 
expression of oncogenes i ncluding V -Myc avian myelocytomatosis viral oncogene h omolog 
(MYC), B-cell lymphoma 2 ( BCL-2) and B-cell l ymphoma 2 -like 1 (BCL2L1)  as well as for 
their involvement in mediating drug resistance  (Dawson, Kouzarides, & Huntly, 2012 ; 
Dawson et al., 2011 ; Goodell & Godley, 2013 ; Neff & Armstrong, 2013 ; Shi & Vakoc, 2014 ; 
Zuber et al., 2011 ).  Expression of multiple oncogenes is also driven by [CONTACT_442856]4 recruitment at 
super-enhancers, providing a rationale for the activity of BET inhibitors (BETi) beyond the 
MYC family ( Hnisz et al., 2013 ; Loven et al., 2013 ).  All of the BETi currently in clinical trials 
target all members of the BET family, although the anti-proliferative activity of BETi in cancer 
cells may be mediated, in large part, through inhibition of BRD4 ( Filippakopoulos & Knapp, 
2014). 
In vit
ro cell line analyses have shown that targeting BET proteins leads to inhibition of tumor 
growth in multiple cancer types, including both solid tumors and hematological malignancies 
through cell cycle arrest, and induction of senescence and apoptosis. 
2.2 Rationale and Mechanism for BET Inhibitors in Met astatic Castration-
resistant Prostate Cancer   
Metastatic castration-resistant prostate cancer (mCRPC)  is characterized by [CONTACT_885102] (AR) to drive cancer proliferation, tumor invasion, and 
metastasis  (Wyatt & Gleave, 2015 ).  Initial therapi[INVESTIGATOR_885067], followed by [CONTACT_202831]-deprivation therapy (ADT).  In many instances, 
further progression and metastases of the cancer is observed, hence the term metastatic castration 
resistant prostate cancer.  First line standard of care therapi[INVESTIGATOR_885068], androgen synthesis inhibitors such as the cytochrome steroid 17-alpha-
hydroxylase/17,20 lyase  (CYP17A1) inhibitor abiraterone and in some cases chemotherapy.  
However, recent studies have shown that patients become resistant to these first line treatments 
over time and require additional drug therapy ( Wyatt & Gleave, 2015 ).  Currently, there is no 
standard of care for second line mCRPC as the efficacy of AR modulators or chemotherapy in 
the second line setting is moderate.   Furthermore, it has been suggested that the resistance 
mechanism
s of abiraterone and enzalutamide overlap   (Azad, Volik, et al., 2015 ; Bianchini et 
al., 2014; Loriot et al., 2013 ; Noonan et al., 2013 ; Schrader et al., 2014 ). 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 40 of 170 
 
 
 
 
 Mechanisms of resistance to enzalutamide and abiraterone include alternative splicing of the AR 
resulting in the loss of the ligand binding domain and constitutively active androgen signaling 
(Nakazawa, Antonarakis, & Luo, 2014 ), up-regulation of alternate pathways such as 
gluco
corticoid receptor (GR) ( Arora et al., 2013 ; Isikbay et al., 2014 ), nuclear factor kappa-
light-chain-enhancer of activated B cells ( NF-κB) (Jin et al., 2013 ; Nadiminty et al., 2013 ), or 
MYC sig
naling pathways ( Lamb, Massie, & Neal, 2014 ; Nadiminty et al., 2013 ; Zeng et al., 
2015), as well as neuroendocrine differentiation ( Aggarwal, Zhang, Small, & Armstrong, 
2014; Beltran et al., 2014 ; Dang e t al., 2015 ).  Several of these resistance mechanisms, have 
either been shown to be regulated by [CONTACT_885103] (MYC expression: 
(Gao et al., 2013 ) AR splice variants: (S. C. Chan et al., 2015 ); GR: (Shah et al., 2015 ) or in 
other cancers, NF-κB: (Ceribelli et al., 2014 ; Gallagher et al., 2014 ; Zou et al., 2014 )), 
suggesting that BETi could be beneficial for patients with mCRPC that are resistant to 
enzalutamide and abiraterone.  In particular, the androgen receptor splice variant 7 ( AR-V7)  was 
recently suggested to be involved in the resistance to enzalutamide and abiraterone 
(Antonarakis et al., 2014 ), and cell lines expressing these variants are sensitive to ZEN003694 
and other BETi in culture and in xenografts ( Asangani et al., 2014 ; S. C. Chan et al., 2015 ; 
Gao et al., 2013 ; Wyce et al., 2013 ).  One of the proposed mechanisms of action of the BETi is 
to pre
vent the BET proteins from interacting with the N-terminus of the AR and activating 
downstream androgen signaling pathways  (Asangani et al., 2014 ).  This mechanism would also 
explain how the activity of ZEN003694 would not be abrogated by [CONTACT_885104], as the 
N-terminus is still intact.  Also, BETi prevent binding of the AR to their downstream effectors, 
including the E26 transformation-specific ( ETS) family of proteins (e.g., ETV1 and ERG), well 
known oncogenic drivers in prostate adenoca
rcinoma and neuroendocrine prostate cancer ( Gasi 
Tandefelt, Boormans, Hermans, & Trapman, 2014 ; Lotan et al., 2011 ; Williamson et al., 
2011), thus providing several possible mechanisms whereby [CONTACT_885105] c
ancers of different etiologies. 
BETi are also postulated to be good combination agents due to their novel involvement in the 
transcriptional up-regulation of several key oncogenic pathways ( Hnisz et al., 2013 ).  In 
mCRPC, the combination of BETi with enzalutamide could further abrogate AR signaling and 
inhibit tumor progression.   Several clinical studies have reported that enzalutamide treatment of 
post-abiraterone patients elicits a poor to moderate response rate ( Azad, Eigl, Murray, 
Kollmannsberger, & Chi, 2015 ; Bianchini et al., 2014 ; Loriot et al., 2013 ; Noonan et al., 
2013; Schrader et al., 2014 ), supporting the evaluation of BETi such as ZEN003694 in post-
abiraterone patients, either as a single agent, or in combination with enzalutamide.  
Recent preclinical studies have
 suggested that SPOP mutant CRPC might be less sensitive to 
BETi, mainly due to the upregulation of the BET proteins, which are natural substrates of the 
SPOP ubiquitin ligase (Dai et al., 2017 ; Janouskova et al., 2017 ; P. Zhang et al., 2017 ).  
Howeve
r, SPOP is also involved in DNA damage repair (D. Zhang et al., 2014 ), and SPOP 
mutati
ons were found to activate AR and PI3K/mTOR signaling (Blattner et al., 2017 ) and lead 
to genomic instability (Boysen et al., 2015 ).  Therefore, it remains to be determined if this 
ZEN003694-002 Clinical Study Protocol Version:  Final 
Amendment 10 05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 41 of 170 altered sensitivity is also found in the clinic, and more importantly, if combination with either 
enzalutamide or abiraterone could be beneficial in that patient population. 
2.3 ZEN003694 
ZEN003694 is a structurally
 novel, orally bioavailable small molecule that epi[INVESTIGATOR_885069]-terminal domain (BET) inhibition.  
   
  ZEN003694 was discovered and developed by [CONTACT_885106][INVESTIGATOR_885060]. and has 
broad potential as an anti-proliferative agent i
n solid tumors and hematologic malignancies.  
2.4 Nonclinical Data  
For full information regarding ZEN003694, refer to the Investigator’s Brochure. 
ZEN003694 and 
its major active metabolite, ZEN003791, bind BET bromodomains and 
selectively inhibit the BET family member BRD4 binding to  super-enhancers in chromatin, in 
turn inhibiting expression of BRD4-dependent genes MYC and BCL-[ADDRESS_1238226] low potential for 
off-target pharmacologic effects.  
ZEN003694 showed potent cell growth inhi
bition in multiple solid tumor and hematological 
cancer cell lines as a single agent, and displayed synergy or additivity when combined with 
different anti-cancer agents.   In castration-resistant prostate cancer (CRPC) cell lines that were 
insensitive to enzalutamide, ZEN003694 showed potent activity as a single agent and synergy in 
combination with enzalutamide in a cell line with mild sensitivity to enzalutamide.   
In vivo preclinical data demons
trated that ZEN003694 dose-dependently inhibited tumor growth 
and MYC gene expression in C
RPC (VCaP and 22Rv1) cell line-derived subcutaneous mouse 
xenografts. ZEN003694 was well tole
rated at the dose range tested (up to 100 mg/kg  
[QD]
) and robustly inhibited the  expression of MYC in xenograft tumors. ZEN003694 was also 
evaluate
d in combination with enzalutamide in these xenograft mouse models.  VCaP cells are 
sensitive while 22Rv1 are 
resistant to enzalutamide treatment.  
In the 22Rv1 xenograft model, ZEN003694 exhibited robust tumor growth inhibition (TGI), 
which was significantly more effica
cious than that of enzalutamide.  The combination was well 
tolerated and based on the administered doses (mg/kg), there was no improvement in efficacy 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238227] adverse effects observed in the toxicology studies were considered likely to be mechanism-
based or sequelae; all significant adverse effects were considered to be discernable by [CONTACT_722255], physical examination, and/or standard laboratory analyses and medically 
manageable.  ZEN003694 did not inhibit hERG in patch-clamp assays and did not have an effect 
on the standard 10-lead electrocardiogr
aphic evaluations in the GLP compliant toxicology study 
in monkey.  ZEN003694 did not have any functional effect in respi[INVESTIGATOR_885070] (CNS) assessments at any dose level in the GLP-complaint toxicology studies.  
Furthermore, ZEN003694 was negative in the Ames mutagenicity study.  
Based on the nonclinical profile, results from animal toxicology studies and the structural 
compound, theoretical risks of human exposure to ZEN003694 include the following: 
 Anorexia and weight loss 
 Na
usea and other gastrointestinal symptoms 
 M
yelosuppression (with consequences of anemia, neutropenia and/or thrombocytopenia) 
 S
usceptibility to infection 
 B
leeding 
 Abe
rrations in clinical chemistry parameters 
Other 
drugs with similar mechanism of action, to the extent they have been studied in the clinic, 
have been associated with adverse events of diarrhea, nausea, vomiting, anorexia, rash, asthenia, 
thrombocytopenia, neutropenia, anemia, dysgeusia, fever, hyperglycemia, mucositis, 
coagulopathy, hemorrhage and aberrations of clinical chemistry parameters ( Thieblemont et al., 
2014). 
2.5 Clinical Data  
B
ased on data collected through the end of December 2017, the combined Phase 1 clinical data 
(44 patients) reported to date across 
both studies (this study and the ZEN003694-001 Single 
Agent Study) have identified the following a
dverse drug reactions (drug related and occurring in 
> 2 patients): visual impairment (typi[INVESTIGATOR_897] a transitory perception of brighter lights and/or light 
flashes, with or without visual color tinges, and with no functional consequences), nausea, 
fatigue, decreased appetite, vomiting, creatinine increase, platelet decrease, diarrhea, 
dehydration, decreased weight, dizziness, dysgeusia, and thrombocytopenia. These ZEN003694-
related adverse events (AEs) were generally Grade 1 or 2 in severity, were managed clinically, 
did not result in long-term sequelae, and resolved in the absence of drug exposure. 
 
 
 
 
   

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238228] with the AR to modulate AR signaling.  BETi were shown to induce apoptotic activity, 
and inhibit cell proliferation and tumor growth of different CRPC models ( Asangani et al., 
2014; C. H. Chan et al., 2015 ; Cho e t al., 2014 ; Gao et al., 2013 ; Wyce et al., 2013 ).  
Furthermore, recent studies have shown that the BET proteins are directly involved in resistance 
mechanisms to ARSI ( Shah et al., 2017 ) 
ZEN003694 inhibits proliferation in se
veral prostate cancer cell lines as well as in cell lines 
resistant to the ARSIs enzalutamide and abiraterone.  ZEN003694 also inhibits AR signaling in 
cells expressing high ratios of the AR-V7 (22Rv1) splice variant compared to the full-length AR, 
which lack the androgen binding domain and results in constitutive activation of AR signaling. 
Pre-clinical in vitro data also show that ZEN003694 synergizes with enzalutamide in inhibiting 
cell growth of a CRPC cell line and synergizes with abiraterone to inhibit the proliferation of a 
different CRPC cell line. 
In vivo preclinical data de
monstrate that ZEN003694 dose-dependently inhibited tumor growth 
in CRPC (VCaP and 22Rv1) cell line-derived subcutaneous mouse xenografts.  ZEN003694 was 
well tolerated at the dose range
 tested (up to 100 mg/kg q.d.) and robustly inhibited th e 
expression of MYC in xenograft tumors.  ZEN003694 was also evaluated as a single agent and 
in combination with enzalutamide in the CRPC (VCaP and 22R v1) xenograft mouse models.  
VCaP ce
lls are sensitive while 22R v1 are resistant to enzalutamide treatm ent.  In the VCaP 
xenograft model, Z EN003694 showed robust dose -dependent efficacy and was equivalent to the 
efficacy of enzalutamide.  In the 22R v1 xenograft model, ZEN003694 had robust efficacy and 
was more e
fficacious than enzalutamide.  
In the 22Rv1 model, the combination treatment of ZEN003694 and enzalutamide was evaluated 
at limited dose range combinations. 
 The combination was well tolerated and based on TGI 
normalized to the combination exposures of ZEN003694 and the active metabolite ZEN003791 
showed an additive effect at the evaluated concentrations. 
The in vivo models evaluated are limited in their capabilities to assess the combined effect of 
ARSIs and ZEN003694 as they do not necessarily represent the study populations:  
(1) enzalutamide-naïve patients that have progressed on abiraterone (or vice-versa) and (2) 
patie
nts taking an ARSI and progressing by [CONTACT_43877]2 criteria.  Despi[INVESTIGATOR_885071], the data show that ZEN003694 is active in a model that is resistant to enzalutamide and 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238229] that ZEN003694 inhibits persistant AR signaling even in cases 
associated with resistance to ARSI therapi[INVESTIGATOR_014], and inhibits tumor growth in prostate cancer in 
vivo models that are either resistant or se
nsitive to enzalutamide.  These data provide a rationale 
for studying ZEN003694 in combination with either enzalutamide or abiraterone in mCRPC 
patients who are likely to benefit from treatment.   
2.7 Dosing Rationale  
The safe starting dose of Z
EN003694 was determined in concordance with the International 
Conference on Harmonization  (ICH) S9 Guidance.   Zenith has calculated the starting dose for 
ZEN003694 in the Phase 1 single agent study, ZEN003694 -001, from the toxicology studies, that 
were 
dosed on a mg/kg basis, to derive a flat dose (48 mg) for the initial starting dose of 
ZEN003694 i n this first -in-human (FIH) Phase 1 study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 1: The starting dos
e of ZEN003694 in this combination treatment study, ZEN003694-002, 
is there
fore being selected as 36mg/d ay  
 The dose of enzalutamide will be held constant at 160 mg/d ay 
through Cycle 1 of  the study in Dose Escalation. Furthermore, since enzalutamide is a CYP3A4 
inducer and ZEN003694 is a substrate of C
YP3A4, the plasma concentration of ZEN003694 
dosed in combination with enzalutamide 
is expected to be lower than single agent administration 
at equivalent doses of ZEN003694. The dose of 36 mg/d ay is expected to produce tolerable 
exposure while being close to the therapeutic range. Finally no overlappi[INVESTIGATOR_885072]003694 in combination with enzalutamide further justifying the starting dose. 
Part 2:  
Based on the safety and PK/PD data from the ongoing investigation of Part 1 of the current 

=(1&OLQLFDO6WXG\3URWRFRO 9HUVLRQ)LQDO
$PHQGPHQW  1RYHPEHU
=HQLWK(SLJHQHWLFV/WG &RQILGHQWLDO 3DJHRI

VWXG\=(1LQFRPELQDWLRQZLWKHQ]DOXWDPLGHDUHDVRQDEOH =(1GRVHWRLQLWLDWH
WKLV FRPELQDWLRQ WULDO LV  PJ 4'  IRU =(1 LQ FRPELQDWLRQ  ZLWK  PJ 4'
DELUDWHURQH WKHGRVHRIPJ4'LQ3DUWZDVWROHUDWHGLQWKHFXUUHQWFRPELQDWLRQVWXG\ ZLWKRQH'/7RIJUDGH
QDXVHDRXWRIVL[SDWLHQWV'RVLQJDWPJ4'KDVDOVREHHQ WROHUDWHGE\DFRKRUWRIWKUHH
SDWLHQWVLQ3DUW=(1SOXVHQ]DOXWDPLGHDQGDGRVHRI PJ4'LVEHLQJLQYHVWLJDWHG
DWWKHWLPHRIWKLVDPHQGPHQW 





$ELUDWHURQHLVQRWD&<3$LQGXFHUDQG
LVQRWH[SHFWHGWRLQGXFHDKLJKHUUDWLRRIWKH=(1DFWLY HPHWDEROLWHWRSDUHQWLQ3DUWRI
WKLVVWXG\EXWLQWKHVHWWLQJRIDQWLFLSDWRU\PDQDJHPHQWRIDG YHUVHJDVWURLQWHVWLQDOHIIHFWVLWLV
H[SHFWHGWKDWPJRI=(1ZLOOEHWROHUDWHGLQFRPELQDWL RQZLWKPJDELUDWHURQH 

,QFDVHRI'/7VDQGFOLQLFDOO\VLJQLILFDQW$(VGRVHKROGVDQG UHGXFWLRQVDUHDOORZHGZKHUH
DSSOLFDEOHE\WKLVSURWRFRO3URDFWLYHPDQDJHPHQWRIQXWULWLRQ K\GUDWLRQDQGDQWLHPHWLFVZLOO
DOVR EH LPSOHPHQWHG LQ 3DUW  RI WKLV VWXG\ DQG SKDUPDFRNLQHWL F PRQLWRULQJ ZLOO DOORZ
PDQDJHPHQWRIV\VWHPLFH[SRVXUHZLWKLQNQRZQWROHUDWHGOHYHOV 

7KHFRUUHODWLRQRI'/7HYHQWVZL WKSDWLHQWH[SRVXUHDW&\FOH 'D\DQG&\FOH'D\DFURVV
ERWKPRQRWKHUDS\DQGFRPELQD WLRQWKHUDS\VWXGLHVLVVKRZQLQWK HILJXUHEHORZ


ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 47 of 170 
 
 
 
 
 The data show that DLT events occurred in patients with exposures (ZEN003694 + ZEN003791) 
greater than approximately 7500 ng*h/ml. The data also show that the PK  interaction with 
enzalutamide  has been minimal and the exposures of ZEN003694 + ZEN003791 were not 
significantly impacted by [CONTACT_171313]. The average exposure at the 72 mg dose in the single 
agent and the combination with enzalut
amide study is 5250 ng*h/ml and less than 7500 ng*h/ml, 
and also less than the Day 1 average AUC0-24 of 7048 ng*h/ml reported at the 96mg dose. 
Therefore, starting at a dose of [ADDRESS_1238230] the exposure of ZEN003694 based on its CYP 
profile.  
Integrated data on PK and safety to date supports the use of 72 mg as the starting dose for the 
ZEN003694 + abiraterone combination 
study.  Given that the maximum tolerated human dose of 
ZEN003694 as monotherapy and in combination with enzalutamide will both be determined 
before dose-escalation starts in Part 2 of this trial, dose-escalation of ZEN003694 in combination 
with abiraterone may not be sought in Part 2. 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 48 of 170 
 
 
 
 
 3. OBJECTIVES  
3.1 PART 1 OBJECTIVES: ZEN003694 in combination with enzalutamide 
3.1.1 Part 1: Primary 
 To determine the safety, tolerability and maximum tolerated dose (MTD) of 
ZEN00
[ADDRESS_1238231] 
progressed during prior treatment with enzalutamide or apalutamide (Cohort DE-A) 
or with abiraterone (Cohort DE-B) 
by [CONTACT_107282] 2 (PCWG2) 
criteria 2007 ( Scher et al., 2008 ) ( dose escalation) 
 To confirm the safety and tolerability of the MTD and recommended Phase 2 dose 
(RP2D)
 of ZEN003694 in combination with enzalutamide in the following two 
cohorts of patients with mCRPC (dose confirmation): 
o Cohort DC-A:  Patients with prior progression on enzalutamide or apalutamide 
by [CONTACT_43877]2 criteria who are currently or will be receiving a stable dose of 
enzalutamide  
o Cohort DC-B:  Patients who are enzalutamide-naïve with prior progression on 
abiraterone by [CONTACT_43877]2 criteria 
3.1.2 Part 1: Secondary 
 To determine the PK of ZEN003694 and the PK of enzalutamide along with their 
primary active metabolites when administered in combination  
 To evaluate the preliminary clinical activity of ZEN003694 in combination with 
enz
alutamide as applicable:  
o PSA response rate by [CONTACT_43877]2 criteria 
o Radiographic response rate by [CONTACT_43877]2 criteria 
o Media
n progression-free survival by [CONTACT_43877]2 criteria 
o C
irculating tumor cell (CTC) response rate  
3.1.3 P
art 1: Exploratory 
 To explore pharmacodynamics (PD), prognostic and/or predictive biomarkers of 
ZEN00
3694 in combination with enzalutamide in whole blood, plasma and tumor 
sample
s in the dose escalation phase and/or dose confirmation phase as follows:  
o  Possible relationship of baseline tumor abnormalities (such as mutations, 
translocati
ons, mRNA, protein expression and localization), in circulating tumor 
DNA (ctDNA), circulating tumor 
cells (CTC) and tumor biopsies and/or on-
treatment changes with any observed antitumor activity 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 49 of 170 
 
 
 
 
  To explore the effects of ZEN003694 on immuno-oncology markers in tumor tissue 
and peripheral blood mononuclear cells 
3.2 PART 2 OBJECTIVES: ZEN003694 in combination with abiraterone  
3.2.1 Part 2: Primary 
 To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of 
ZEN003694 in combination with abiraterone in patients with metastatic castration-
resistant prostate cancer (mCRPC) who have progressed during prior treatment with 
abiraterone (Cohort DE-C) or  enzalutamide or apalutamide (Cohort DE-D) by 
[CONTACT_107282] 2  criteria 2007 ( Scher et al., 2008 ) (dose 
escalation) 
 To confirm the safety and tolerability of the recommended Phase 2 dose (RP2D) of 
ZEN00
3694 in combination with abiraterone in the following two cohorts of 
patients with mCRPC (dose confirmation): 
o Cohort DC-C:  Patients currently receiving abiraterone who have experienced 
progression by [CONTACT_43877]2 criteria  
o Cohort DC-D:  Patients who are abiraterone-naïve with prior progression on 
enzalutamide or apalutamide by [CONTACT_43877]2 criteria  
3.2.2 Part 2: Secondary 
 To determine the PK of  ZEN003694 and the PK of abiraterone along with their 
primary active metabolites when administered in combination  
 To evaluate the preliminary clinical activity of ZEN003694 in combination with 
abira
terone as applicable:  
o PSA response rate by [CONTACT_43877]2 criteria 
o R
adiographic response rate by [CONTACT_43877]2 criteria 
o Media
n progression-free survival by [CONTACT_43877]2 criteria 
o C
irculating tumor cell (CTC) response rate  
3.2.3 P
art 2: Exploratory 
 To explore pharmacodynamics (PD), prognostic and/or predictive biomarkers of 
ZEN003694 in combination with abiraterone in whole blood, plasma and tumor 
samples in the dose escalation phase and/or dose confirmation phase as follows:  
o Possible relationship of baseline tumor abnormalities (such as mutations, 
translocations, mRNA, protein expression and localization), in circulating tumor 
DNA (ctDNA), circulating tumor 
cells (CTC) and tumor biopsies and/or on-
treatment changes with any observed antitumor activity 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 50 of 170 
 
 
 
 
 4. PATIENT S ELECTION 
4.1 Part 1: ZEN003694 in combination with enzalutamide  
4.1.1 Part 1: Inclusion Criteria 
Patients must meet all of the following inclusion criteria to be eligible for the study.  
Part 1 All Patients  
1. Males age ≥ 18 years 
2. Meta
static, castrate resistant histologically confirmed prostate cancer; surgically 
ca
strated or continuous medical castration for ≥ 8 weeks prior to screening 
3. Serum testosterone < 50 ng/dL determined within [ADDRESS_1238232] administration of 
study
 drug 
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 
5. A
dequate laboratory parameters at Screening including: 
a. Absolute
 neutrophil count (ANC) ≥ 1.5 × 109/L 
b. Platelet count ≥ 100,000/mm3 
c. Asparta
te aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.[ADDRESS_1238233] 
(≤ [ADDRESS_1238234] if liver metastases are present) 
d. Total bilirubin ≤ 1.[ADDRESS_1238235]  
e. Serum creatinine ≤ 1.[ADDRESS_1238236] or calculated (Cockcroft-Gault formula) or measured 
creatinine clearance ≥ 60 mL/min 
f. Prothrombin time ( PT), international normalized ratio (INR) and partial 
thromboplastin time (PTT) < 1.[ADDRESS_1238237] study drug administration 
8. Ability to swallow capsules and comply with study procedures  
9. Ability to understand and willingness to sign informed consent form prior to initiation of 
any study procedures 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 51 of 170 
 
 
 
 
  
Part 1 Dose Escalation  
10. Cohort DE-A: Prior progression on enzalutamide or apalutamide at any time by [CONTACT_43877]2 
criteria and is or will be receiving a stable dose of enzalutamide (defined as a dose that 
has not changed for at least 2 weeks prior to Cycle 1 Day 1 and is not expected to 
change on study).  Patients may or may not have experienced prior progression on 
abiraterone. 
11. Cohort DE-B: Enzalutamide-naïve and apalutamide-naïve patients following prior 
progression on abiraterone by [CONTACT_43877]2 criteria  
Part 1 Dose Confirmation 
12. Cohort DC-A:  Prior progression on enzalutamide or apalutamide at any time by [CONTACT_43877]2 
criteria and is or will be receiving a stable dose of enzalutamide (defined as a dose that 
has not changed for at least 2 weeks prior to Cycle 1 Day 1 and is not expected to change 
on study).  Patients may or may not have experienced prior progression on abiraterone.  
13. Cohort DC-B:  Enzalutamide-naïve patients and apalutamide-naïve following prior 
progression on abiraterone by [CONTACT_43877]2 criteria . 
4.1.2 Part 1: Exclusion Criteria 
Patients who meet any of the following exclusion criteria will not be eligible to participate in the 
study. 
Part [ADDRESS_1238238] previously received an investigational BET inhibitor (including previous 
participation in this study or Study ZEN003694-001 )  
3. Have received  prior  systemic anti -cancer therapy  (including abiraterone)  or 
investigational therapy within [ADDRESS_1238239] administration of study drug   
4. Failure to recover to Grade 1 or lower toxicity related to prior systemic therapy 
(ex
cluding alopecia and neuropathy) prior to study entry  
5. Radiation therapy within [ADDRESS_1238240] administration of 
study drug (enzalutamide in DE-B and DC-B or ZEN003694 in DE-A and DC-A)  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238241] received prior chemotherapy in the metastatic castration-resistant setting (prior 
chemotherapy in the hormone-sensitive setting is allowed provided last dose was at least 
6 months prior to study entry) 
8. Have received prior investigational anti-androgen therapy 
9. C
urrently receiving medications known to be strong inhibitors of CYP2C8, strong 
inducers
 (except enzalutamide or apalutamide) o r inhibitors of CYP3A4 and substrates of 
CYP1A2, CYP3A4, CYP2C9 and CYP2C19 with 
a narrow therapeutic window. See 
Section 6.8.1.  Strong inducers, inhibitors and substrates must be discontinued at least [ADDRESS_1238242] administration of study drug.  
10. Not a candidate for enzalutamide treatment, in the opi[INVESTIGATOR_689] 
11. Left ventricular ejection fraction less than the lower of 50% or the lower limit of 
institution’s normal range 
12. QTcF interval > 450 msec 
13. Known impaired cardiac function or clinically significant cardiac disease such as 
uncontrolled supraventricular arrhythmia, ventricular arrhythmia requiring therapy, or 
congestive heart failure ([LOCATION_001] Heart Association functional class III or IV)  
14. Myocardial infarction or unsta
ble angina within [ADDRESS_1238243] administration 
of study drug 
15. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, 
active CNS disease, active, uncontrolled bacterial, viral, or fungal infection(s) requiring 
systemic therapy, or any other condition that could compromise safety or the patient’s 
participation in the study 
16. Other known active cancer requiring therapy at time of study entry 
17. Historically positive (screening tests not required) for human immunodeficiency virus 
(HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections.  
HBV positivity defined by [CONTACT_23977] B surface antigen (H BsAg).  HCV positivity 
defined as positive HCV viral load.   
18. Major surgery other than diagnostic 
surgery, dental surgery or stenting within [ADDRESS_1238244] administration of study drug 
19. History of congenital or other deficiency in platelet function, any known inherent or 
acquired coagulopathy, or therapeutic anticoagulation with warfarin or api[INVESTIGATOR_3822] (low-
dose warfarin for port patency or prophylactic anti-platelet agents are allowed) 
20. Concurrent participation in another clinical investigation al treatment trial 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 53 of 170 
 
 
 
 
 21. Any other reason that in the opi[INVESTIGATOR_885073] 
4.2 Part 2: ZEN003694 in combination with abiraterone  
4.2.1 Part 2: Inclusion Criteria 
Patients must meet all of the following inclusion criteria to be eligible for the study.  
Part 2 All Patients 
1. Males age ≥ 18 years 
2. Meta
static, castrate resistant, histologically confirmed prostate cancer; surgically 
ca
strated or continuous medical castration for ≥ 8 weeks prior to screening 
3. Serum testosterone < 50 ng/dL determined within [ADDRESS_1238245] administration of 
study
 drug 
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 
5. Ade
quate laboratory parameters at Screening including: 
a. Absolute
 neutrophil count (ANC) ≥ 1.5 × 109/L 
b. Platelet count ≥ 100,000/mm3 
c. Asparta
te aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.[ADDRESS_1238246] (≤ [ADDRESS_1238247] if liver metastases are present) 
d. Total bilirubin ≤ 1.[ADDRESS_1238248]  
e. Se
rum creatinine ≤ 1.[ADDRESS_1238249] or calculated (Cockcroft-Gault formula) or 
measured creatinine clearance ≥ 60 mL/min 
f. Prothrombin time (PT), international normalized ratio (INR) and partial 
thromboplastin time (PTT) < 1.[ADDRESS_1238250] study drug administration 
8. Ability to swallow capsules and comply with study procedures  
9. Ability to understand and willingness to sign informed consent form prior to initiation of 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 54 of 170 
 
 
 
 
 any study procedures 
Part 2 Dose Escalation  
10. Cohort DE-C: Prior progression on abiraterone at any time by [CONTACT_43877]2 criteria and is or 
will be receiving a stable dose of abiraterone (defined as a dose that has not changed for 
at least 2 weeks prior to Cycle 1 Day 1 and is not expected to change on study).  Patients 
may or may not have experienced prior progression on enzalutamide or apalutamide.  
11. Cohort DE-D: Abiraterone-naïve patients 
following prior progression on enzalutamide 
or apalutamide by [CONTACT_43877]2 criteria.   
Part 2 Dose Confirmation 
12. Cohort DC-C:  Prior progression on abiraterone at any time by [CONTACT_43877]2 criteria and is or 
will be receiving a stable dose of abiraterone (defined as a dose that has not changed for 
at least 2 weeks prior to Cycle 1 Day 1 and is not expected to change on study).  Patients 
may or may not have experienced prior progression on enzalutamide or apalutamide. 
13. Cohort DC-D:  Abiraterone-naïve patients following prior progression on enzalutamideor 
apalutamide by [CONTACT_43877]2 criteria.   
4.2.2 Part 2: Exclusion Criteria 
Patients who meet any of the following exclusion criteria will not be eligible to participate in the 
study. 
Part [ADDRESS_1238251] previously received an investigational BET inhibitor (including previous 
participa
tion in this study or Study ZEN003694-001 )  
2. Have received prior systemic anti -ca ncer therapy or investigational therapy within 
[ADDRESS_1238252] administration of study 
drug. (Patients progressing on enzalutamide or apalutamide requi re a 2 week wash -out 
prior to start of abiraterone Cycle 1 Lead -in where applicable)  
3. Failure to recover to Grade 1 or lower toxicity related to prior systemic therapy 
(ex
cluding alopecia and neuropathy) prior to study entry  
4. Radiation therapy within [ADDRESS_1238253] administration of 
study drug (abiraterone in DE-D and DC-D or ZEN003694 in DE-C and DC- C) 
6. Have received prior chemotherapy in the metastatic castration-resistant setting (prior 
chemotherapy in the hormone-sensitive setting is allowed provided last dose was at least 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 55 of 170 
 
 
 
 
 6 months prior to study entry) 
7. Have received prior investigational anti-androgen therapy 
8. C
urrently receiving medications known to be substrates of CYP1A2 or CYP2D6 with a 
narr
ow therapeutic window.  Major substrates must be discontinued at least [ADDRESS_1238254] administration of study drug.  
9. Not a candidate for abiraterone treatment, in the opi[INVESTIGATOR_689] 
10. L
eft ventricular ejection fraction less than the lower of 50% or the lower limit of 
institution’s normal range 
11. QTcF interval > 450 msec 
12. Known impaired cardiac function or clinically significant cardiac disease such as 
uncontrolled supraventricular arrhythmia, ventricular arrhythmia requiring therapy, or 
congestive heart failure ([LOCATION_001] Heart Association functional class III or IV)  
13. Myocardial infarction or unstable angina within [ADDRESS_1238255] administration 
of study drug 
14. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, 
active central nervous system disease, active, uncontrolled bacterial, viral, or fungal 
infection(s) requiring systemic therapy, or any other condition that could compromise 
safety or the patient’s participation in the study 
15. Other known active cancer requiring therapy at time of study entry 
16. Historically positive (screening tests not required) for human immunodeficiency virus 
(HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections.  
HBV positivity defined by [CONTACT_23977] B surface antigen (HBsAg).  HCV positivity 
defined as positive HCV viral load 
17. Major surgery other than diagnostic surgery, dental surgery or stenting within [ADDRESS_1238256] administration of study drug 
18. History of congenital or other deficiency in platelet function, any known inherent or 
acquired coagulopathy, or therapeutic anticoagulation with warfarin or api[INVESTIGATOR_3822] (low-
dose warfarin for port patency or prophylactic anti-platelet agents are allowed) 
19. Concurrent participation in another clinical investigational treatment trial 
20. Any other reason that in the opi[INVESTIGATOR_885074]003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 56 of 170 
 
 
 
 
 5. STUDY PLAN  
5.1 Study Design 
This is an open label, non-randomized, Phase 1 dose escalation/dose confirmation study of 
ZEN003694 in combination with enzalutamide (Part 1) or abiraterone (Part 2) in patients with 
mCRPC.  
5.1.[ADDRESS_1238257] 3+3 cohort design will be utilized for each study Part.  Cohorts of up to 6 patients 
will be enrolled at each dose level, and each patient will participate in only one cohort.  Each 
cycle will be 28 days in duration.   
 
Part 1, Z
EN003694 in combination with enzalutamide: 
For patients who have progressed on abiraterone, (Cohort DE- B) enzalutamide will be 
administered orally as a single agent daily for 14 days prior to the initiation of the combination 
therapy (Lead-in) to reach enzalutamide steady-state concentration (Css) during Cycle 1.  After 
the Lead-in, if applicable, ZEN003694 will be administered orally in combination with daily 
enzalutamide for 28-day cycles. Patients who are progressing on enzalutamide or apalutamide 
(Cohort DE-A, Sub-arm A1) and who a
re currently receiving a stable dose of enzalutamide will 
continue to receive enzalutamide in combination with ZEN003694, if eligibility criteria are met. 
Patients in Cohort DE-A who are not currently receiving enzalutamide or apalutamide or are 
currently taking apalutamide (Sub-arm A2) will be administered enzalutamide orally once daily 
for 14 days prior to the initiation of the combination therapy (Lead-in) to reach enzalutamide C ss 
during Cycle 1.   
 
Part 2, ZEN003694 in combination with abiraterone: 
For patients who have progressed on 
enzalutamide or apalutamide (Cohort DE-D), abiraterone 
will be administered orally as a single agent daily for 14 days prior to the initiation of the 
combination therapy (Lead-in) to reach abiraterone steady-state concentration (C ss) during Cycle 
1. After the Lead-in, if applicable, ZEN003694 will be administered orally in combination with 
daily abiraterone for 28-day cycles. Patients who are progressing on abiraterone (Cohort DE-C, 
Sub-arm C1 ) and currently receiving a stable dose of abiraterone will continue to receive 
abiraterone in combination with ZEN003694, if eligibility criteria are met.  For patients who 
have progressed on abiraterone (Cohort DE-C, Sub-Arm C2) but are not currently taking 
abiraterone, abiraterone will be administered orally as a single agent daily for 14 days prior to 
the initiation of the combination therapy (Lead-in) to reach abiraterone steady-state 
concentration (C ss) during Cycle 1.  
 
Part 1 and Part 2: 
After the Lead-in, ZEN003694 will be administered orally in combination with daily 
enzalutamide (Part 1) or abira
terone (Part 2) for 28-day cycles.  The first patient at each dose 
level will be treated with ZEN003694 for one week before the second patient at the same dose 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238258] dose of ZEN003694.  Patients at each dose level will be 
treated (for 28 days) and observed through the end of the first cycle before treatment of patients 
at the next higher dose level can begin.  In unusual circumstances, (e.g., if there is 1 slot 
remaining to fill a cohort and 2 prospec
tive enrollees are being screened and qualify 
simultaneously) the sponsor may allow an extra subject to enter a cohort, although the same rules 
for determining MTD will apply. 
 
ZEN003694-related adverse events (AEs) for determination of DLTs will be assessed for each 
patient during the [ADDRESS_1238259] common AEs for enzalutamide and abiraterone 
are well-known (see Appen
dix 4 for XTANDI  Package Insert and Appen dix 5 for ZYTIGA® 
Package Insert
).  As such, the Investigator should to the best of his/her ability assess the 
relatedness of an AE observed as 
attributable to either enzalutamide (Part 1) or abiraterone (Part 
2) or ZEN003694 alone, or if unable to do so, as attributable to the combination of enzalutamide 
(Part 1) or abiraterone (Part 2) and ZEN003694.   
Dose escalation will continue a
fter all patients enrolled within a cohort have completed the 
28-day Cycle 1 DLT observation period with either 0 of 3 patients, or no more than 1 out of 
6 patients in a cohort experiencing a DLT, with the proviso that dose escalation to MTD may be 
waived in 
Part 2.  Dose escalation decisions will be made based on clinical safety and (when 
available) PK data (maximum or peak concentration [C max] and AUC) after review by [CONTACT_885107] (CRC), consisting of all Investigators and the Zenith Medical Monitor.  If a 
DLT is observed in 1 of 3 patients in a cohort and confirmed by [CONTACT_10186], 3 additional patients 
will be enrolled into that cohort.  
If 1 of 6 patients in a cohort experiences a DLT, then dose 
escalation may continue in the next cohort or the MTD of the combination can be declared.  If 
≥ 2 of 3 – [ADDRESS_1238260] 
been enrolled at the previous 
dose level, that cohort will be expanded to 6 patients to confirm the 
MTD.  Should the MTD of the combination be exceeded at Dose Level 1, a cohort may be 
explored with a reduced dose of ZEN003694 or enzalutamide (Part 1) or abiraterone (Part 2) at 
the discretion of the CRC.  Cohort management is summarized in Table 3. 
Table 3:  Dose-limiting Toxicity and 
Cohort Management  
Number of Patients with 
Dose-limiting Toxicity  Action 
1 of 1 Add 5 more patients 
0 of 3 Proceed to next dose  level 
1 of 3 Add 3 more patients 
1 of 6 Proceed to next dose level  
≥ 2 of 3 or ≥ 2 of 6  Add 3 more patients in the next lower dose level if 
only 3 patients were treated in the next lower dose.  If 
6 patients were treated at the next lower dose level and 
no more than one patient had DLT, then the next lower 
ZEN003694-002 Clinical Study Protocol Version:  Final 
Amendment 10 05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 58 of 170 dose is the MTD . 
Part 1: Enzalutamide is a strong inducer of CYP3A4.  Treatment with enzalutamide reduces the 
Cmax and AUC of the sensitive CYP3A4 substrate midazolam approximately 7- and 4-fold, 
respectively.  ZEN003694 is also a CYP3A4 substrate and therefore the levels of ZEN003694 
may be substantially lower when administrated to patients treated with enzalutamide due to 
increased clearance of ZEN003694 compared to ZEN003694 treatment alone.  Enrollment in this 
study with ZEN003694 in combination with enzalutamide will  commence with 36 mg as the 
starting dose for ZEN003694 and 160 mg 
dose of enzalutamide (or at a lower stable dose for 
patients in DE-A or DC- A).   The dose of enzalutamide will be held constant through Cycle 1 of 
the Dose 
Escalation. After Cycle 1, the dose of enzalutamide may be modified for toxicity per 
the XTANDI® Package Insert. Due to the possible higher clearance of ZEN003694 during co-
administration with enzalutamide, higher doses of ZEN003694 may be needed to achieve 
sufficient ZEN003694 exposure with the combination treatment than with ZEN003694 alone.  If 
enzalutamide dose is reduced at any time after Cycle 1, PK samples are to be obtained 28 Days 
(±7 Days) following dose modification. Dose escalation of ZEN003694 in this study will 
proceed as follows in Table 4 unless intervening toxicity is observed. 
Table 4:  Part 1 Dose Escalation Scheme
 
Dose Level  ZEN003694 (mg)  Fold Increase from  
Prior Dose Level  
1 36 -- 
2 48 1.33 
3 60 1.25 
4 72 1.20 
5 96 1.33* 
Additional levels may be explored at the discretion of the CRC  
Part 2:  
  
 
 
Enrollment in this study with ZEN003694 in combination with 
abiraterone will therefore commence with 72 mg QD as the starting dose for ZEN003694 and 
1000 mg dose of abiraterone once.   The dose of abiraterone will be held constant at 1000 mg 
through Cycle 1 of the Dose Escal
ation. After Cycle 1, the dose of abiraterone may be modified 
for toxicity per the ZYTIGA® Package Insert. Dose escalation/de-escalation of ZEN003694 in
this study will proceed as follows in T
able 5 unless intervening toxicity is observed. 

ZEN003694-002 Clinical Study Protocol Version:  Final 
Amendment 10 05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 59 of 170 Table 5:  Part 2 Dose Escalation Scheme 
Dose Level  ZEN003694 (mg)  * Fold Increase from  
Prior Dose Level  
-1 48 0.67 
1 72 -- 
2 96 1.33 
* Dose de -escalation from 72 mg is allowed  by [CONTACT_9084] .  Additional dose levels may be
explored based on safety and at the discretion of the CRC , with the proviso that dose
escalation to MTD may be waived in Part 2.
Part 1 and Part 2:  
Dose escalation increments between cohorts will be determined by [CONTACT_885108] (e.g., C max and AUC) based on the following schema:  
Dose e
scalation up to 2-fold is allowed in Dose Level 2 and 3 unless one drug-related
Grade 2 event is observed in Dose Level 1 and 2, respectively
Subsequent dose escalation up to 1.5-fold is allowed until a DLT is obse
rved
Subsequent dose escalation up to 1.33-fold is allowed until MTD is established, or, in
Part 2, if MTD is waived and RP2D is declared
All dose e
scalations will be
 guided by [CONTACT_885095] (e.g., C max and AUC) from both 
ZEN003694-[ADDRESS_1238261] to the combined AUC 0-24 of 
ZEN003694 and its active metabolite 
ZEN003791.   
   
 
Intermediate doses and/or alternative dosing schedules may be evaluated to best determine the 
MTD and/or RP2D of ZEN003694 in combination with enzalutamide (Part 1) or abiraterone 
(Part 2) based on evaluation of 
clinical safety and available PK data (e.g., C max and AUC) and 
upon agreement of the CRC members.   No intra-patient dose escalation is allowed during the 
first thre
e cycles of therapy.  If a patient has not experienced any Grade [ADDRESS_1238262] dose currently declared tolerable by [CONTACT_885109]-patient dose escalation(s) will be determined on a cycle-
by-cycle basis at the discretion of the Investigator and with approval from the CRC.   
5.1.[ADDRESS_1238263] 28 days of treatment (i.e., Cycle 1) in the 
dose escalation phase.  Toxicity will be graded and recorded according to National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03 (see 
Appendix 2).  A DLT is defined a
s a clinically significant AE or laboratory abnormality that is 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 60 of 170 
 
 
 
 
 considered possibly, probably or definitely related to ZEN003694 and which meets any of the 
following criteria: 
 Grade 3 or great
er non-hematologic clinical toxicity with the exception of Grade 3 
nausea or Grade 3/4 vomiting a
nd diarrhea persisting less than 72 hours in the absence 
of maximal medical therapy  
 Gra
de 4 neutropenia lasting more than 5 da
ys 
 Grade 3 or greater febrile
 neutropenia (temperature ≥ 38.5ºC) 
 Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with clinically significant 
bleeding, or any requirement for platelet transfusion 
 Any other Grade 3 or 4 laboratory abnormality that requires hospi[INVESTIGATOR_059] 
 An ALT > 3x ULN with concomitant total bilirubin > 2x ULN 
 Any ZEN003694-related toxicity that results in more than 25% of missed doses during 
Cycle 1 of treatment  
 In the situation where toxicity requires withholding ZEN003694 following the receipt 
of at least 75% of scheduled dosing during Cycle 1: Failure to begin Cycle [ADDRESS_1238264] discontinue dosing with ZEN003694; patients must 
complete the Safety Follow-up visit prior to discontinuation from the study.   
Determination of evaluabilit
y will be made during the first 28 days of ZEN003694 treatment 
(i.e., Cycle 1) in the dose escalation phase. Patients meeting one or more of the following will be 
considered unevaluable and will be replaced: 
 Patients who miss more than 25% of ZEN003694 and/or enzalutamide or abiraterone 
doses 
or fail to begin Cycle 2 within 1 week of the scheduled start date for reasons other 
than ZEN003694-related toxicity 
 Patients who require enzalutamide or abiraterone dose hold or modification in Cycle 1 , 
including during the 14-day Lead-in period for reasons other than ZEN003694-related 
toxicity 
 Part 1 only : If a patient is 
unable to tolerate enzalutamide for any reason at dose of [ADDRESS_1238265] dose of ZEN003694, then the patient should 
not receive ZEN003694, and be withdrawn from the study and replaced  
 Part 2 only:  I f a patient is unable to tolerate for any reason abiraterone at dose of [ADDRESS_1238266] dose of ZEN003694, then the 
patient should not receive ZEN003694, and be withdrawn from the study and replaced 
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238267] dose level of ZEN003694 in combination with enzalutamide 
(Part 1) and abiraterone (Part 2; if MTD is determined ) at which no more than [ADDRESS_1238268] cycle of therapy. MTD may be declared independently for 
any given dosing regimen, i.e., the respective MTDs for once daily dosing, twice daily dosing, 
and any alternative dosing regimen(s) need not be at the same dose. 
5.1.4 Definition of the Recommended Phase 2 Dose 
The RP2D is defined as the dose level of ZEN003694 in combination with enzalutamide (Part 1) 
and abiraterone (Part 2) recommended for further clinical study.  In Part of this study the RP2D 
may be the same as the MTD or modified from the MTD based on assessments of overall 
exposure, safety experience in Cycle 2 and beyond, PD and clinical benefit data.  In Part 2 of this 
study the determination of an MTD may be waived and the RP2D may be declared based on 
assessment of overall exposure, safety experience , PD and clinical benefit data.  The RP2D of 
ZEN003694 in combination with enzalutamide (Part 1) or a
biraterone (Part 2) will be determined 
in the dose confirmation phase of the stud
y. RP2D may be declared independently for any given 
Part or dosing regimen, i.e., the respective RP2Ds for once daily dosing, twice daily dosing, and 
any alternative dosing regimen(s) need not be at the same dose. 
5.1.5 Dose Confirmation  
Part 1, ZEN003694 in combination with enzalutamide:  Once the MTD of ZEN003694 in 
combination with enzalutamide has been determined in the dose escalation portion of Part 1 of 
the study, up to 20 patients who meet the inclusion/exclusion criteria for Cohort A and up to 20 
patients who meet the inclusion/exclusion criteria for Cohort B of the dose confirmation phase 
will be enrolled for further evaluation of safety, PK, PD and preliminary clinical activity.   
Enzalutamide-naïve and apalutamide-naïve patients in Cohort DC-B will be administered 
enzalutamide (160 mg) orally once daily for 14 days prior to the initiation of the combination 
therapy (Lead-in) to reac
h enzalutamide C ss during Cycle 1.  After the Lead-in, ZEN003694 will 
be administered orally in combination with daily enzalutamide for 28-day cycles.  Patients in 
Cohort DC-A who are currently receiving a
 stable dose of enzalutamide   will continue to receive 
enzalutamide and will not participate in the Lead-in. Patients in Cohort DC-A who are not 
currently receiving enz
alutamide or apalutamide or are currently taking apalutamide will be 
administered enzalutamide orally once daily for 14 days prior to the initiation of the combination 
therapy (Lead-in) to reach enzalutamide C ss during Cycle 1.  After the Lead-in, ZEN003694 will 
be administered orally in combination with daily enzalutamide for 28-day cycles.   
Part 2, ZEN003694 in combination with abiraterone:  Once the CRC has determined a 
recommended phase 2 dose (RP2D) of ZEN003694 in combination with abiraterone in the dose 
escalation portion of Part 2 of the study, up to 20 patients who meet the inclusion/exclusion 
criteria for Cohort DC-C and up to 20 patients who meet the inclusion/exclusion criteria for 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 62 of 170 
 
 
 
 
 Cohort DC-D of the dose confirmation phase will be enrolled for further evaluation of safety, 
PK, PD and preliminary clinical activity.  
 Cohort DC-D: Abiraterone-naïve patients in Cohort DC-D will be administered 
abira
terone (1000 mg once daily) orally for 14 days prior to the initiation of the 
combination therapy (Lead-in) to reach abiraterone C ss during Cycle 1.  After the Lead-
in, ZEN003694 will be administered orally in combination with daily for 28-day cycles.   
 Cohort DC-C: Patients in Cohort DC-C are currently receiving a stable dose of 
abira
terone (as part of the study entry criteria for this cohort) and will continue to receive 
abiraterone when enrolled in the dose confirmation phase of the study and will not 
participate in the Lead-in. 
Part 1 and Part 2:  When the 6th patient in each cohort in the dose confirmation phase has 
completed one cycle of therapy, or earlier if clinically indicated, the CRC will review the safety 
data.  If  ≥ [ADDRESS_1238269] experienced drug-related SAEs or DLT-equivalent events, the CRC 
may 
recommend a modification in the dose or regimen of ZEN003694 in combination with 
enzalutamide (Part 1) or abiraterone (Part 2) for the dose confirmation phase. 
5.2 Safety Review 
Safety will be assessed 
by [CONTACT_22244], weight, ECOG performance status, 
vital signs, clinical laboratory assessments including serum troponin, 12-lead electrocardiogram 
(ECG) and monitoring of AEs (see Schedule of Events Table 1 & Table 2).  AEs will be graded 
using NCI CTCAE Version 4.03 (see Appendix 2 ).  Teleconferences with members of the CRC 
will be held during the dose escalation phase to discuss any suspected DLTs that have occurred 
in patients within each cohort.  The frequency of the teleconference calls will be determined by 
[CONTACT_885097], data review, frequency of DLT notifications, discussions with 
investigational sites and other factors.  Approximately one week after the last patient in a dose 
cohort completes Cycle 1 and prior to escalating to the next dose level (or de-escalating), the 
CRC will review toxicities and available PK (e.g., C max and AUC) from the current cohort of the 
study
 during a teleconference.    
The CRC‘s responsibilities during the course
 of the study include: 
 Review all relevant safety findings and confirm all DLTs  
 R
eview and approve all intra-patient dose escalation(s)  
 Determine all cohort dose escalation and de-escalation decisions during the dose 
escalation phase 
 Recommend alternative dose and regimen as appropriate  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 63 of 170 
 
 
 
 
  Determine the MTD and RP2D ; and, in Part 2, determine whether MTD should be 
determined or, alternatively, that the RP2D may be declared without establishing MTD 
per the protocol definition (Section 5.1.3) 
 Recommend the dose(s) and regimen(s) to extend into the dose confirmation phase 
 C
onsider any relevant safety data from Study ZE N003694-001 
 Further monitor safety during the dose confirmation phase, including review of the safety 
data
 after the sixth patient completes Cycle 1  
5.3 Num
ber of Sites and Patients 
Part 1: Up to 80 evaluable patients will be enrolled in the study at up to 10 sites in the United 
States.  Approximately 40 pati
ents will be enrolled in the dose escalation phase and up to 40 
patients will be enrolled in the dose c
onfirmation phase. 
Part 2: Up to 55 evaluable pati
ents will be enrolled in the study at up to 10 sites in the United 
States.  Approximately 15 pati
ents will be enrolled in the dose escalation phase and up to 40 
patients will be enrolled in the dose confir
mation phase. 
5.4 Study Duration 
The study duration by P
art including the enrollment period and follow-up for both the dose 
escalation and dose confirmation phases is approximately 36 months, depending upon total 
enrollment.  Patients may continue receiving ZEN003694 in combination with enzalutamide 
(Part 1) or abiraterone (Part 2) until disease progression by [CONTACT_43877]2 criteria, unacceptable 
toxicity, requirement for non-protocol therapy or patient withdrawal from study.  Patients with 
PSA-only progression may remain on study until clinical and/or radiographic evidence of 
progression by [CONTACT_43877]2 criteria. 
5.5 Premature Study Termination or Suspension of Enrollment 
Zenith has the right to terminate the participation of an individual study site, study Part, or the 
entire study, at any time, 
for any reason.  Reasons for terminating the study include, but are not 
limited to, the following: 
 The incidence or severity of AEs in this or other studies indicates a potential health 
haz
ard to patients 
 Patient enrollment is unsatisfactory 
 Data records are inaccurate or incomplete 
 The Investigator does not adhere to the protocol or applicable regulatory guidelines in 
conduc
ting the study 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 64 of 170 
 
 
 
 
  A decision on the part of Zenith to suspend or discontinue testing, evaluation or 
development of ZEN003694 
In addition, Zenith may suspend enrollment in the study at any time for any reason. 
All Investigators and appropriate Reg
ulatory Authorities will be promptly notified upon early 
termination of the study.  In addition, Investigators and Regulatory Authorities will be promptly 
notified if enrollment is terminated or suspended for any reason. 
6. STUDY DRUG AND CONCOMITANT TREATMENT 
6.1 ZEN003694 
ZEN003694 is a novel, potent BET inhibitor currently under clinical investigation.  It is provided 
in two dosage strengths:  12 mg and 48 mg.  ZEN003694 will be administered orally in 28-day 
cycles and should be ingested with a full 
(8-ounce) glass of water at least 1 hour before eating or 
2 hours after eating (fasti
ng).  Each capsule should be swallowed whole.  Patients should be 
advised not to chew, dissolve, or open the
 capsules. Patients should also be advised to minimize 
their exposure to sunlight. 
6.2 Enzalutamide 
Enzalutami
de is an androgen receptor inhibitor indicated for the treatment of patients with 
mCRPC.  Enzalutamide 160 mg (four 40 mg capsules) will be administered orally once daily 
according to the XTANDI® Pac
kage Insert without food in 28-day cycles through Cycle 1 in 
Dose Escalation for all enzaluta
mide-naïve patients (DE-B and DC-B cohorts).  For patients in 
DE-A and DC-A cohorts, enzalutamide will be administered at the dose level previously 
determined to be stable and that has not changed for at least two weeks prior to starting Cycle 1 
Day 1 combination study treatment or restarting enzalutamide treatment in the Lead-in phase .  
After Cycle 1 of Dose Escalation or any time in Dose Confirmation, the dose of enzalutamide 
may be modified for toxicity per the XTANDI® Package Insert.  Each capsule should be 
swallowed whole.  Patients should be advised not to chew, dissolve, or open the capsules. 
6.3 Abiraterone  
Abira
terone is an androgen synthesis inhibitor indicated for the treatment of patients with 
mCRPC.  Abiraterone 1000 mg (four 250 mg capsules) will be administered orally once daily 
according to the ZYTIGA® Pa
ckage Insert without food in 28-day cycles. Prednisone 5 mg (one 
5 mg capsule) will be administered orally twice daily in 28-day cycles. In Dose Escalation, the 
dose of abiraterone will be held constant at 1000 mg throughout Cycle 1 of the study. After 
Cycle 1, the dose of abiraterone may be modified for toxicity per the ZYTIGA® Package Insert.  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238270] dose currently declared tolerable by [CONTACT_885110]-
patient dose escalation(s) will be determined on a cycle- by-cycle basis at the discretion of the 
Investigator and with approval from the CRC.  Patients who required a dose reduction due to 
toxicity at any time will not be allowed to re-escalate to a higher dose level.  
6.4.2 Managem
ent of ZEN003694-related Toxicity in the Dose Escalation and Dose 
Confirmation Phases  
Dose adjustment (hold or reduction) of ZEN003694 is allowed in the dose escalation phase of 
the study beyond Cycle 1 and will be based on the toxicities that are deemed possibly, probably 
or definitely related to ZEN003694.   Dose reductions of ZEN003694 during Cycle 1 will not be 
allowed however ZEN003694 doses may be held due to treatment-related toxicity.  If 
ZEN003694 treatment is withheld for toxicit
y attributed by [CONTACT_885111]003694 
alone, then enzalutamide dosing may continue unmodified.  For guidance regarding what 
ZEN003694-related toxicities qualify as a DLT in Cycle 1 of the dose escalation phase of the 
study, refer to Section 5.1.2 Definition of Dose Limiting Toxicity .   
Dose 
adjustment (hold or reduction) of ZEN003694 is allowed in the dose confirmation phase of 
the study at any time and will be based on the toxicities that are deemed possibly, probably or 
definitely related to ZEN003694.  If ZEN003694 treatment is withheld for toxicity attributed by 
[CONTACT_885111]003694 alone, then enzalutamide dosing may continue unmodified. 
Dose adjustment and toxicity management g
uidelines are summarized in  Table 6. 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 66 of 170 
 
 
 
 
 Table 6:  ZEN003694-Related Dose Adjustment and Toxicity Management Guidelines 
Event Hematologic & Non -hematologic Toxicity  
(Excluding Anemia)  
Grade 1  No change 
Grade 2 No change required; but a dose hold for Grade 2 laboratory toxicity or 
a laboratory trend of concern is allowed based on Investigator 
discretion.  
 
In cases where the dose is held, if toxicity or trend is reduced to a 
Grade 1 within 14 days,  treatment may resume at a dose level and 
regimen determined by [CONTACT_885112].  
Grade 3 Hold treatment.   
 
If toxicity resolves  to baseline  or Grade 1  within 14 days, treatment 
may resume at the  same dose level .  
 
If toxicity is reduced to Grade  2 within 14 days, treatment may 
resume at one dose level below or at a reduced frequency  (except in 
Cycle 1 of dose escalation)  with mutual agreement between the 
Investigator and Zenith .  
Grade 4 Hold treatment.   
 
If toxicity is resolved to Grade ≤ 2 within 14  days, treatment may 
resume at one dose level below or at a reduced frequency  (except in 
Cycle 1 of dose escalation)  with mutual agreement between the 
Investigator and Zenith.  
Dose interruption caused by [CONTACT_885113]003694- related toxicities lasting longer than 14 days 
(hematologic or non-hematologic toxicity) will result in study drug discontinuation unless there 
is objective evidence of benefit.   Any subject experiencing concomitant ALT elevation to > 3x 
ULN and bilirubin elevation to > 2x ULN will be permanently discontinued from dosing with 
ZEN003694.   
Only one re-challenge at the same dose level is allowed and two dose reductions and/or decrease 
in dosing frequency is allowed. 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 67 of 170 
 
 
 
 
 6.5 Part 1: Management of Enzalutamide-related  Toxicity in the Dose 
Escalation and Dose Confirmation Phases 
No dose adjustment (hold or reduction) of enzalutamide is allowed during Cycle 1 in the dose 
escalation phase of the study. For toxicities in dose escalation Cycle 1 that, in the opi[INVESTIGATOR_1070], could reasonably be a
ttributed to either study drug (eg, fatigue, nausea), the 
investigator should hold ZEN003694 first as a “therapeutic trial”, and only hold enzalutamide in 
addition if the trial hold of ZEN003694 is unsuccessful in managing toxicity. Holding 
enzalutamide in dose escalation Cycle [ADDRESS_1238271] unevaluable for DLT 
determination (5.1.2 Definition of Dose Limiting Toxicity), although the subject may continue in 
the trial if recommended by [CONTACT_885114].  
If a patient in Dose Escalati
on or Dose Confirmation Cohort B is unable to tolerate enzalutamid e 
for any reason at dose of [ADDRESS_1238272] dose of ZEN003694, 
then the patient should not receive ZEN003694, and be withdrawn from the study and replaced.  
Beyond Cycle 1 in the dose escalation phase and any time during the dose confirmation phase, 
enzalutamide toxicity may be managed per the XTANDI  Package Insert.   In the case that 
enzalutamide is held to manage enzalutamide-related toxicity, the Investigator should contact 
[CONTACT_885115]003694. If enzalutamide is held 
greater than [ADDRESS_1238273] withdraw from the study unless he is, in the Investigator's 
judgment, clearly benefitting from ZEN003694 treatment alone, in which case the Investigator 
must consult with Zenith reg arding continuing ZEN003694 monotherapy with possible 
modification of the dose. If enzalutamide dose is reduced at any time after Cycle 1 in Dose 
Escalation or any time in Dose Confirmation, PK samples are to be obtained 28 Days (±7 Days) 
following dose modification at the following 
time-points: pre-ZEN003964 and enzalutamide 
doses, and 15 minutes (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours 
(±15 min), 6 hours (±15 min) and 8 hours (±30 min) post-ZEN003694 and enzalutamide doses. 
Commonly reported adverse reac
tions with enzalutamide include asthenia/fatigue, back pain, 
decrease appetite, constipation, arthralgia, diarrhea, hot flush, upper respi[INVESTIGATOR_1092], 
peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension and 
dizziness/vertigo.  In patients who have p
reviously received docetaxel treatment, neutropenia and 
infections have been reported.  Falls and hypertension have also been reported.  Management of 
enzalutamide side effects are at the discretion of the Investigator.   Refer to XTANDI  Package 
Insert in Appendix 4 for further information. 
Warning and precautions with enzaluta
mide include :  
 Seizures in patients with mCRPC who previously received docetaxel.  
 Posterior reversible encephalopathy syndrome (PRES) in post approval reports.  PRES 
diagnosi
s should be confirmed by [CONTACT_885116]003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238274] discontinue the study. 
6.6   Part 2: Management of Abiraterone-related Toxicity in the Dose Escalation 
and Dose Confirmation Phases 
No dose adjustment (hold or reduction) of abiraterone is allowed during Cycle [ADDRESS_1238275] as a “therapeutic trial”, and only hold abiraterone in addition if the trial hold of 
ZEN003694 is unsuccessful in managing toxicity. Holding abiraterone in dose escalation Cycle [ADDRESS_1238276] unevaluable for
 DLT determination ( 5.1.2 Definition of Dose Limiting 
Toxicity
), although the subject may continue in the trial if recommended by [CONTACT_885117].  
If a patient in Dose Escalation 
or Dose Confirmation Cohort D is unable to tolerate abiraterone 
for any reason at dose of [ADDRESS_1238277] dose of ZEN003694, 
then the patient should not receive ZEN003694, and be
 withdrawn from the study and replaced.  
Beyond Cycle 1 in the dose escalation phase and any time during the dose confirmation phase, 
enzalutamide toxicity may be managed per the ZYTIGA  Package Insert.   
The most common adverse drug reactions (≥5%) reported in clinical studies were joint swelling 
or discomfort, hypokalemia, edema, muscle discomfort, hot flush, diarrhea, urinary tract 
infection, cough, hypertension, arrhythmia, urinary frequency, nocturia, dyspepsia, and upper 
respi[INVESTIGATOR_1092]. The most common adverse drug reactions that resulted in drug 
discontinuation were aspartate aminotransferase increased, alanine aminotransferase increased, 
urosepsis and cardiac failure (each in <1% of patients taking ZYTIGA).  Management of 
abiraterone side effects are at the discretion of the Investigator.  Refer to ZYTIGA  Package 
Insert in Appendix 5 for further information.  
 
Warning
 and precautions with abiraterone include:  
• Hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess  
• Adr
enocortical insufficiency  
• He
patotoxicity  
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238278] 1 hour before eating or 2 hours after eating (fasting).  Treatment 
compliance will be monitored by [CONTACT_885118]’s dosing diary and drug accountability 
recor
ds.  Study treatment administration data will be recorded in the patient’s medical record and 
on the Drug Administration electronic case report forms (e CRFs).   
6.8 Concomitant Medications and Therapi[INVESTIGATOR_014] 
6.8.1 Part 1 and
 Part 2: Prohibited Concomitant Medications and Therapi[INVESTIGATOR_885062]003694  
ZEN003694 is primarily metabolized by [CONTACT_097]3A4.  Therefore, strong inhibitors and inducers of 
CYP3A4 (except enzalutamide) must be excluded during ZEN003694 administration.   
 
 
 
 
Because of the known risk of QT/QTc 
prolongation from 5-hydroxytryptamine type 3 (5-HT3) 
receptor anti-emetics, 5-HT3 receptor antagonist antiemetic drugs should be used with 
Investigator discretion, if alternative drugs are not available.  Dolasetron should be avoided, as 
the prolongation of QTc may be greater with this drug based upon American Society of Clinical 
Oncology (ASCO) guidelines ( Basch et al., 2011 ). To date, ZEN003694 has shown no evidence 
of QT 
prolongation, suggesting that drugs such as 5-HT3 antagonists may be safely used 
concomitantly where indicated by [CONTACT_737]'s clinical judgment. 
During the study, other chemotherapy, immunotherapy, radiation (except, if ≤ 5 fractions for 
palliative care of solitary bone lesions), bone-targeting radionuclides, or surgery is also 
prohibited. Therapeutic anticoagulation with warfarin, api[INVESTIGATOR_3822], or other anti-factor agents is not 
permitted, but low-dose warfarin for maintenance of port patency or prophylactic anti-platelet 
agents are allowed. 
6.8.2 Part 1: Prohibited Concomitant M
edications and Therapi[INVESTIGATOR_885075] a substrate of CYP2C8 and therefore use of strong CYP2C8 inhibitors should be 
avoided because CYP2C8 inhibitors increase the plasma exposure of enzalutamide. 
Enzalutamide is also a moderate inducer of CYP2C9 and CYP2C19; thus enzalutamide may 
decrease plasma exposures of these drugs that are significant substrates of these enzymes. 
Refer to XTANDI  (enzalutamide) Package Insert in Appendix 4 for further information 
rega
rding potential drug-drug interactions. 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238279] is not comprehensive; 
when c
onsidering use of a medication that could be a potential CYP3A4 inhibitor or inducer, 
CYP1A2 substrate, CYP2C8 inhibitor or significant CYP3A4, CYP2C9 or CYP2C19 substrate, 
the Investigator should consult with Zenith. 
 
T
able 7:  Part 1 Inhibitors and Inducer
s of Relevant Drug-m etabolizing Enzymes Category  Inhibitors  
of CYP3A 4 
(May increase  
ZEN003694  
exposure)  Inducers  
of CYP3A 4 
(May decrease  
ZEN003694 
exposure)  Substrates  
of CYP1A2  
 
 
 
 AVOID boceprevir  
clarithromycin  
conivaptan  
grapefruit juice 
indinavir 
itraconazole  
ketoconazole  
lopi[INVESTIGATOR_054]/ritonavir  
mibefradil  
nefazodone  
nelfinavir  
posaconazole  
ritonavir  
saquinavir  
telaprevir  
telithromycin  
voriconazole  avasimibe 
rifampin 
St. John’s wort  
 ramelteon  
tizanidine  
theophylline  
Source:  http://wwwfda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/  
ucm093664h tm 
Sites are to consider the following potential drug interactions when enrolling patients: 
  
   
  
 Gemfibrozil inhibits CYP2C8 and may increase exposure to enzalutamide 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 71 of 170 
 
 
 
 
  The following are substrates of CYP3A4/CYP2C9/CYP2C19 and exposure to these drugs 
may be decreased by [CONTACT_171313]:  
o CYP3A4: alfentanil, astemizole, cyclosporine, dihydroergotamine, ergotamine, 
fentanyl, pi[INVESTIGATOR_3924], quinidine, sirolimus, tacrolimus, Cannabidiol (CBD) enriched 
products, midazolam, triazolam , lovastatin, simvastatin 
o CYP2C9: warfarin, phenytoin, celecoxib 
o C
YP2C19: S-mephenytoin 
 
Any
 CYP3A4 inhibitors, inducers and substrates, CYP2C8 inhibitors, and CYP3A4, CYP1A2, 
CYP2C9 and CYP2C19 substrates taken by
 [CONTACT_885119]’s chart and on the Concomitant Medications eCRF.  If Zenith’s 
approval is not obtained prior to administration of these medications, the patient may be 
withdrawn from the study by [CONTACT_705967]. 
6.8.3 Part 2: Prohibited Concomitant Medications and Therapi[INVESTIGATOR_885076]-metabolizing enzyme CYP2D6. In a CYP2D6 
drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were 
increa
sed 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone 
acetate 1,000 mg daily. Avoid coadministration of abiraterone acetate with substrates of 
CYP2D6 with a narrow therapeutic index (e.g., thioridazine). 
Abiraterone is a substrate of C
YP3A4, but in vivo the strong CYP3A4 inhibitor ketoconazole 
had no clinically meaningful impact on abiraterone exposure. The strong CYP3A4 inducer 
rifampi[INVESTIGATOR_885077]. Hence, strong CYP3A4 inducers should be 
avoided or used with caution as they may diminish the effectiveness of abiraterone. 
A list of inhibitors, inducers and substrates are listed in Table 8.  This list is not comprehensive; 
when consi
dering use of a medication the Investigator should consult with Zenith. 
 
 
 
 
 
 
 
 
 
 
 
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 72 of 170 
 
 
 
 
 Table 8:  Part 2 Inhibitors and Inducers of Relevant Drug-metabolizing Enzymes 
Category  Inhibitors  
of CYP3A 4 
(May increase  
ZEN003694  
exposure)  Inducers  
of CYP3A 4 
(May decrease  
abiraterone 
and/or 
ZEN003694 
exposure)  Substrates 
of CYP2D6 
(exposure 
may be 
increased by 
[CONTACT_143061])  Substrates  
of CYP1A2  
 
 
 
 AVOID boceprevir  
clarithromycin  
conivaptan  
grapefruit juice  
indinavir 
itraconazole  
ketoconazole  
lopi[INVESTIGATOR_054]/ritonavir  
mibefradil  
nefazodone  
nelfinavir  
posaconazole  
ritonavir  
saquinavir  
telaprevir  
telithromyc in 
voriconazole  avasimibe 
rifampin 
St. John’s wort  
 thioridazine  ramelteon  
tizanidine  
theophylline  
Source:  http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/  
ucm093664htm 
Any CYP3A4 inhibitors, inducers and substrates, CYP1A2 and CYP2D6 substrates taken by [CONTACT_885120]
d in the patient’s chart and on the 
Concomitant Medications eCRF.  If Zenith’s approval is not obtained prior to administration of 
these medications, the patient may be withdrawn from the study by [CONTACT_705967]. 
6.8.[ADDRESS_1238280] 2 weeks prior to the start of ZEN003694 dosing and will 
remain stable during ZEN003694 treatment.  
Unlike the reported experience with other BET Inhibitors, ZEN003694 treatment has not been 
associated with clinically important thrombocytopenia in the 75 patients treated with 
ZEN003694 to date. Therefore, the prophylactic use of anti-platelet agents (eg, low-dose aspi[INVESTIGATOR_248], 
clodiprogel) is permitted but should be carefully reassessed in any patient in whom 
thrombocytopenia occurs.  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238281] signs of GI intolerance. Patients should be provided ‘filled’ prescriptions for an 
anti-emetic, if possible, or ensure patients fill their prescriptions of an anti-emetic on the first day 
of dosing (C1D1). Patients are to be instructed to take the anti-emetic at first signs of nausea.  
Treatment with filgrastim or other colony stimulating factors will be permitted for Grade 3 or 
higher hematologic toxicity as per Package Insert, but may not be used prophylactically.  Patients 
should receive full supportive care, including hematopoietic growth factors based upon ASCO 
guidelines ( Smith et al., 2015 ), if clinically indicated.  
Trea
tment required for care of complications/adverse events arising from the cancer and/or 
treatment will be permitted.  
All concomitant medications must be recorded on 
the Concomitant Medications eCRF.  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 75 of 170 
 
 
 
 
 7.3 Abiraterone 
See ZYTIGA  Package Insert ( Appendix 5) for detailed information on abiraterone description, 
formula
tion, and storage conditions. 
7.[ADDRESS_1238282] be retained until final 
reconciliation or as indicated by [CONTACT_705967].  The study drug is to be administered/dispensed by [CONTACT_885121].  
Under no circumstances will the Investigator allow the study drug to be used other than as 
directed by [CONTACT_3181].  Although appropriate personnel may be designated to 
administer/dispense drug and maintain drug accountability records, the Investigator is ultimately 
responsible for all drug accountability. 
The Investigator or designee must maintain accurate records of the receipt, disposition and return 
of study drug.  Documentation of 
drug disposition/return should identify the patient receiving the 
study drug, the quantities (by [CONTACT_885122]) of study drug dispensed/returned and dates study 
drug were dispensed/returned/destroyed.    
This documentation is required in addition to drug 
acc
ountability information recorded on eCRFs.  A copy of the reconciled drug inventory record 
will be provided to Zenith or its designee, and the study site will retain the original record.  A 
written explanation must be provided for any discrepancies. 
Zenith representatives will authorize the return or destruction of all used, partially used, and 
unused bottles of study drug.  If the study site is capable of destroying study drug it may do so 
upon authorization by [CONTACT_705967].  Records will include date of destruction or return, and quantities 
destroyed or returned to Zenith or its designee.  Detailed instructions on study drug 
accountability will be provided in a study reference manual. 
Part 1 only:  Enzalutamide will be used by [CONTACT_885123].  Patients will record 
their daily administration of enzalutamide in an Enzalutamide Dosing Diary. Enzalutamide 
Dosing Diaries will be reviewed for 
subject compliance by [CONTACT_408811]. Detailed 
instructions regarding enzalutamide compliance will be provided in a study reference manual. 
Part 2 Only:  Abiraterone will be used by [CONTACT_885123].  Patients will record their 
daily administration of abiraterone in an Abiraterone Dosing Diary. Abiraterone Dosing Diaries 
will be reviewed for subject compliance by [CONTACT_408811]. Detailed instructions regarding 
abiraterone compliance will be provided in a study reference manual. Prednisone will be 
documented as a concomitant medication on the applicable log in patient source documentation. 
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 76 of 170 
 
 
 
 
 8. STUDY PROCEDURES AND ASSESSMENTS 
The Schedule of Events ( Table 1 & Table 2) is given as an aid to patient management.  This 
sec
tion describes evaluations to be performed before, during and after treatment.  Scheduled 
clinic attendance should occur within ± 3 days of the specified dates at all visits.  Where this is 
not possible because of extenuating circumstances (e.g., holidays, vacations), the reason should 
be noted in the patient’s chart.  
All AEs that occur anytime during the study and any concomitant medication use should be 
recorded on the CRFs.   Patients with Grade 2, 3 or 4 study drug-related toxicity should be 
followed as the Investigator deems clinically appropriate.  The duration and time to resolution of 
AEs should be evaluated and recorded in the patient’s chart and on the AE eCRF.   Additional 
evaluations may be performed as necessary.   
8.[ADDRESS_1238283] day of treatment (Cycle 1, 
Day -14 if enzalutamide or abiraterone Lead-in is required).  The informed consent form (ICF) 
must be sig
ned before screening procedures are performed (see Section 8.2.1).  
Scre
ening will include: 
 Collection of information on status of inclusion and exclusion criteria (see Section 8.2.2)  
 Complete medical history, including cancer history, prior PSA data, prior cancer-related 
surger
y and treatments, and demographic history (see Section 8.2.3) 
 Listing of all medications taken within 21 days of enrollment and any ongoing 
medica
tions 
 Physical examination including height (cm) and weight (kg) (see Sections 8.2.4 and 
8.2.5) 
 ECOG performance status (see Section 8.2.6 and Appendix 1) 
 Vital signs (temperature [Fº], blood pressure and heart rate) (see Section 8.2.7)  
 Hematology (see Section 8.2.8)  
 Coagulation tests (see Section 8.2.8)   
 Serum chemistries  (see Section 8.2.8): including serum testosterone 
 PSA  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 77 of 170 
 
 
 
 
  Urinalysis (see Section 8.2.8) 
 Echocardiogram or multigated acquisition (MUGA) scan (see Section 8.2.9) 

 Triplicate 12 -lead ECG (see Section 8.2.10) 
 Ophthalmology assessments (see Section  8.2.16)  To be performed prior to first dose of 
ZEN003694 and after all entry criteria have been satisfied and enrollment is approved  
 Part 1 Only: Qualitative Exploration of Visual Symptoms (see Section  8.2.16) 

 PD samples:  whole blood for exploratory immuno-oncology biomarkers (Only in Pa rt 1, 
DE Only ) (at selected clinical sites only; see Section 8.2.12): (Prior to the Day -14 L ead-
in for patients requiring enzalutamide Lead -in (Part 1) )   
 Fresh tumor biopsy samples (optional during dose escalation phase, mandatory during 
dose c
onfirmation phase). For those patients in DE-A or DC- A (Part 1) or DE-C or DC- C 
(Part 2) who are not currently taking enzalutamide (Part 1) or abiraterone (Part 2) and 
require the 14 day Lead- in, the screening fresh tumor biopsy samples can be collected 
from time of consent through Cycle 1 Day -1, preferably during the 14 day enzalutamide 
(Part 1) or abiraterone (Part 2) Lead- in. (see Section 8.2.12) 
 Tumor assessment  (see Section 8.2.15)  Imaging for tumor assessments may be scheduled 
up to 7 days prior to the scheduled clinic visit day. 
8.1.2 Cycle 
1 Lead-in for Dose Escalation & Dose Confirmation (required for 
Cohorts DE-B, DC-B, DE-D, DC-D; also required for patients requiring enzalutamide 
Lead-in (Part 1: Sub-arm A2) or abiraterone Lead-in (Part 2: Sub-arm C2) 
Day -14 (-14 days ± 1 day from Cycle 1 Day 1)  (Pre-enzalutamide Dose (Part 1) / Pre-
abirate
rone dose (Part 2)) 
 Hematology (if Screening visit tests were performed more than 7 days prior to this visit) 
 C
oagulation tests (if Screening visit tests were performed more than 7 days prior to this 
visit) 

 Serum chemistries  tests (if Screening visit tests were performed more than 7 days prior to 
this visit) 
 Urinalysis (if Screening visit tests were performed more than 7 days prior to this visit) 
 PSA tests (if Screening visit tests were performed more than 7 days prior to this visit) 
 Qualitative Exploration of Visual Symptoms (see Section  8.2.16 ) 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 78 of 170 
 
 
 
 
  PD samples:  whole blood for CTCs for enumeration and PD (DE and DC ), and plasma 
for ex
ploratory PD ( DC only) (see Section 8.2.12)   
 PD samples: whole blood for exploratory cfDNA and ctDNA  (For all patients requiring 
enzalutamide Lead -in (Part 1: DE-B and  DC-B and DE-A and DC -A Sub-arm A2) & 
for all patients requiring abiraterone Lead -in (Part 2: DE-D and DC -D and DE-C and 
DC-C Sub-arm C2) 
Day 
-14 (Enzalutamide (Part 1) or Abiraterone (Part 2) Dosing) 
 Part 1: Enzalutamide daily at least 1 hour before eating or 2 hours after eating 
 P
art 2: Abiraterone once daily at least 1 hour before eating or 2 hours after eating  
Day -
14 (Post-enzalutamide Dose (Part 1) or Post-abiraterone Dose (Part 2)) 
 AEs (see Section 8.2.13) 

 Concomitant medications (see Section 8.2.14) 
8.1.3 Cycle 1 Dose Escalation and Dose Confirmation  
Day 1 (Pre-dose) 
 Symptom-directed physical examination and weight 
 ECOG performance status 
 Vital signs (temperature [Fº], blood pressure and heart rate)  
 He
matology (Collect for all patients requiring Cycle [ADDRESS_1238284] if Screening visit tests were performed more than 7 days 
prior to this visit) 
 Coagulation tests (Collect for all patients requiring Cycle [ADDRESS_1238285] if Screening visit tests were performed more than 7 
days prior to this visit) 
 Serum chemistries  including serum testosterone (Collect for all patients requiring Cycle [ADDRESS_1238286] if Screening visit tests 
were performed more than 7 days prior to this visit) 
 Serum troponin level 
 PSA (Collect for all patients requiring Cycle [ADDRESS_1238287] if Screening visit tests were performed more than 7 days prior to 
this visit) 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 79 of 170 
 
 
 
 
  Urinalysis (Collect for all patients requiring Cycle [ADDRESS_1238288] if Screening visit tests were performed more than 7 days 
prior to this visit) 
 Triplicate 12 -lead ECG 
 PK sample for ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2) (see Section 
8.2.11)
 
 PD sample s:  whole blood for BET inhibitor gene expression profile ( DE and DC) , 
explora
tory BET inhibitor blood signature (DC  only), and for CTCs for enumeration and 
PD (DE and DC ); plasma  for exploratory PD ( DC only) 
 P
D samples:  whole blood for exploratory immuno-oncology biomarkers (at selected 
cli
nical sites only; see Section 8.2.12).  (Only in Part 1, DE only:   for all patients 
requiring enzalutamide Lead- in) 
 PD samples: whole blood for exploratory cfDNA and ctDNA  
 AEs (for all patients requiring Lead- in) 
 Qualitative Exploration of Visual Symptoms (see Section  8.2.16 ) 
 Concomitant medications  
Day 1 (Dosin
g) 
 Part 1: ZEN003694  and e nzalutamide  at least 1 hour before eating or 2 hours after eating 
 Part 2: Abiraterone once daily at least 1 hour before eating or 2 hours after eating 
Day 1 (P
ost-dose) 
 PK samples for ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2) 
o 15 
minutes (±5 min), 30 minutes (±5 min), 1 hour (±5 min), 2 hours (±10 min), 
4 hours (±15 min), 6 hours (±15 min) and 8 hours (±30 min) post-ZEN003694 and 
enzalutamide (Part 1) or abiraterone (Part 2) doses  
 PD samples :  whole blood for BET inhibitor gene expression (all patients) at 2 hours 
(±15 min), 4 hours (±15 mi
n), and 6 hours (±15 min)  and Exploratory 
BET inhibitor 
blood signature ( DC only) 4 hours (±15 min) post- ZEN003694 and enzalutamide (Part 
1) or abiraterone (Part 2)  doses  
 
 Triplicate 12-lead ECG:  1 hour (± 15 min) post-ZEN003694 and enzalutamide (Part 1) 
or abira
terone (Part 2) doses  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 80 of 170 
 
 
 
 
  AEs 
 Concomitant medications  
Day 2 (P
re-dose) 
 PK sample for ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2):  24 hours 
(±1 hour)
 after Cycle 1 Day 1 ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 
2) doses 
 PD sample:  whole  blood for BET inhibitor gene expression 24 hours (±1 hour ) after 
Day 1 ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2) doses 
Days 2 – 28 (Dosing as per dosing regimen – QD, BID, on/off schedule) 
 Part 1: ZEN003694 and enzalutamide daily at least 1 hour before eating or 2 hours after 
ea
ting 
 Part 2: Abiraterone once daily at least 1 hour before eating or 2 hours after eating 
Note:  Instruct patients not to take study drug and enzalutamide (Part 1) or abiraterone 
(Part 2) before their clinic visits on Days 8, 15 and 22. 
Note: All assessments and tests/samples described below are to be performed PRE-DOSE, 
unless specified otherwise, and are to be performed even if dosing is not required (ie., due 
to an on/off schedule) on the specified study visit day. 
Day 8 (Pre-dose) 
 Symptom-directed physical examination and weight 
 ECOG pe
rformance status 
 Vital signs (temperature [Fº], blood pressure and heart rate)  
 Hematology 
 Serum chemistries 
 PD sample:  whole blood for exploratory immuno-oncology biomarkers (at selected 
cli
nical sites only)  (Part 1 DE Only ) 
 AEs 
 Concomitant medications  
 Qua
litative Exploration of Visual Symptoms (see Section  8.2.16 )   
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 81 of 170 
 
 
 
 
 Day 15 (Pre-dose) 
 Symptom-directed physical examination and weight 
 ECOG pe
rformance status 
 Vital si
gns (temperature [Fº], blood pressure and heart rate)  
 He
matology  
 C
oagulation tests 
 Serum chemistries 
 Serum troponin level  
 Triplicate 12-lead ECG 
 PK sample for ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2) 
 AEs 
 Qualitative Exploration of Visual Symptoms (see Section  8.2.16 ) 
 Concomitant medications  
Day 15 (D
osing) 
 Part 1: ZEN003694  and e nzalutamide at least 1 hour before eating or 2 hours after eating 
 Part 2: Abiraterone once daily at least 1 hour before eating or 2 hours after eating  
Day 15 (P
ost-dose)  
 PK samples for ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2) 
o 15 
minutes (±5 min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours 
(±15 mi
n), 6 hours (±15 min) and 8 hours (±30 
min) post-ZEN003694 and 
enzalutamide (Part 1) or abiraterone (Part 2) doses 
 Triplicate 12-lead ECG:  1 hour (± 15 min) post-ZEN003694 and enzalutamide (Part 1) 
or a
biraterone (Part 2) doses  
 Part 1 only: Urine collection for renal clearance may be requested by [CONTACT_885124] [ADDRESS_1238289]-ZEN003694 and enzalutamide doses 
Day 22 (Pre-dose or in 
the morning if dosing is not required on this day due to an alternate 
dosing schedule) 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 82 of 170 
 
 
 
 
  Symptom-directed physical examination and weight 
 ECOG performance status 
 Vital si
gns (temperature [Fº], blood pressure and heart rate)  
 He
matology 
 S
erum chemistries 
 PD sample:  whole blood for exploratory immuno-oncology biomarkers (at selected 
cli
nical sites only) ( Part 1 DE Only ) 
 AEs 
 Concomitant medications  
 Qualitative Exploration of Visual Symptoms (see Section  8.2.16 )   
8.1.4 Cycle 2 
 
Part 1: From Cycle 2, Day [ADDRESS_1238290], if the enzalutamide dose is reduced, PK samples are to be 
obtained 28 Days (±7 Days) following modification at the following time-points: pre-
ZEN003964 and enzalutamide doses, and 15 minutes (±5 min), 30 min (±5 min), 1 hour (±5 
min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 hours (±30 min) post-
ZEN003694 and enzalutamide doses.    
Part 2: From Cycle 2, Day
 [ADDRESS_1238291], if the ZEN003694 or abiraterone doses are modified, 
optional PK samples are to be obtained at the discretion of the sponsor following modification at 
the following time-points: pre-ZEN003964 and abiraterone doses, and 15 minutes (±5 min), 30 
min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 
hours (±30 min) post-ZEN003694 and abiraterone doses.    
Part 1 and Part 2:  
Day 1 (Pre-dose) 
 S
ymptom-directed physical examination and weight 
 ECOG pe
rformance status 
 Vital signs (temperature [Fº], blood pressure and heart rate)  
 Hematology 
 Coagulation tests 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 83 of 170 
 
 
 
 
  Serum chemistries: including serum testosterone 
 Serum troponin level 
 PSA 

 Urinalysis 
 Tr
iplicate 12 -lead ECG 
 Part 1 only: Ophthalmology assessments (±7 days) (see Section  8.2.16)  
 PK sample for ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2) 
 P
D samples:  plasma for exploratory PD ( DC only ) 
 PD sample:  whole blood for Exploratory BET inhibitor blood signature ( DC only)  
 AEs 
 Qualitative Exploration of Visual Symptoms (see Section  8.2.16 ) 
 Concomitant medications 
Days 1 – 28 (D
osing as per dosing regimen – QD, BID, on/off schedule, etc.) 
 Part 1: ZEN003694 dosing and enzalutamide daily at least 1 hour before eating or 2 hours 
afte
r eating 
 Part 2: Abiraterone once daily at least 1 hour before eating or 2 hours after eating  
Note:  Instruct patients not to take study drug and enzalutamide (Part 1) or abiraterone 
(Part 2) before their clinic visit on Day 15. 
Note: All assessments and tests/samples described below are to be performed PRE-DOSE, 
unless specified otherwise, and are to be performed even if dosing is not required (i.e., due 
to an on/off schedule) on the specified study visit day. 
Day 8 (The Cycle 2, Day 8 visit w
ill only include blood draws for safety laboratory testing 
and may be drawn after the patient has taken his dose) 
 Hematology 
 Serum chemistries 
Day 15 (Pre-dose) 
 Symptom-directed physical examination and weight 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 84 of 170 
 
 
 
 
  ECOG performance status 
 Vital signs (temperature [Fº], blood pressure and heart rate)  
 He
matology 
 S
erum chemistries 
 AEs 
 P
art 1 Only: Qualitative Exploration of Visual Symptoms (see Section  8.2.16) 

 Concomitant medications  
Day 22
 (The Cycle 2, Day 22 visit will only include blood draws for safety laboratory 
testing and may be drawn after the patient has taken his dose) 
 Hematology 
 Serum chemistries 
8.1.[ADDRESS_1238292]  
Day 1 (Pre-dose) 
 Symptom-directed physical examination and weight 
 ECOG performance status 
 Vital signs (temperature [Fº], blood pressure and heart rate) Hematology (may be drawn 
after the patient has taken his dose) 
 Coagulation tests (may be drawn after the patient has taken his dose) 
 Serum chemistries: including serum testosterone (may be drawn after the patient has 
taken his 
dose) 
 Serum troponin level (may be drawn after the patient has taken his dose) 
 PSA (
may be drawn after the patient has taken his dose) 
 Urinalysis (may be drawn after the patient has taken his dose) 
 AEs 
 Part 1 Only: Qualitative Exploration of Visual Symptoms (see Section  8.2.16) 
 Concomitant medications  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 85 of 170 
 
 
 
 
  Cycle 3 Only: Fresh tumor biopsy samples (optional in DE, mandatory in DC) ± 15 days 
are to be performed on a ZEN003694 dosing day (see Section 8.2.12). The on-treatment 
biopsy 
should be collected 2-4 hours after ZEN003694 administration, if possible. 
 Cycle 3 Only: PD sa mples: whole blood for exploratory cfDNA and ctDNA  
Days 1 – 28 (Dosing as per dosing regimen – QD, BID, on/off schedule) 
 Part 1: ZEN003694 and enzalutamide at least 1 hour before eating or 2 hours after eating 
 P
art 2: Abiraterone once daily at least 1 hour before eating or 2 hours after eating  
Note:  Instruct patients not to take study drug and enzalutamide (Part 1) or abiraterone 
(Part 2) before their clinic visit on Day 1 of each cycle. 
Day 15 (For Cycles 3 and onwards, the Day 15 visit will only include blood draws for safety 
laboratory testing and may be drawn after the patient has taken his dose. Day 15 
hematology and/or serum chemistries can be waived at Investigator discretion starting in 
Cycle [ADDRESS_1238293] as long as platelets are stable and there are no other laboratory concerns in 
the opi[INVESTIGATOR_689].) 
 Hematology 
 S
erum chemistries 
8.1.[ADDRESS_1238294] (Cycles 5, 7, etc.) 
Day 1 (Pre-dose) 
 Triplicate 12-lead ECG 
8.1.[ADDRESS_1238295] (Cycles 6, 9, etc.) 
Day 1 (Pre-dose) 
 PD samples :  whole blood for CTCs for enumeration and PD.  Note:  Additional whole 
blood for CTCs for enumeration and 
PD to be obtained at the time of disease progression 
as well at the time of PSA or radiogr
aphic response. 
 PD sample:  whole blood for Exploratory BET inhibitor blood signature ( DC only)  
 Tumor a
ssessment  (see Section 8.2.15)  Imaging for tumor assessments may be scheduled 
up to 7 days prio
r to the scheduled clinic visit day. 
 Part 1 Only: Ophthalmology assessments:  At Cycle [ADDRESS_1238296] (±7 
day
s) (see Section 8.2.16) 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 86 of 170 
 
 
 
 
 8.1.8 Unscheduled Visits and Assessments 
Any of the following assessments and tests (as well as others) may be performed as clinically 
indicated or to assess PD/biomarker responses as agreed upon by [CONTACT_093]. Additionally, 
unscheduled assessments or sample collections may occur during a schedul ed visit as required. 
 Symptom-directed physical examination and weight 
 ECOG pe
rformance status 
 Vital si
gns (temperature [Fº], blood pressure and heart rate)  
 He
matology 
 C
oagulation tests 
 Serum chemistries 
 Urinalysis 
 Triplicate 12 -lead ECGAEs 
 Concomitant medications  
 Tumor assessment 
 Ophthalmology assessments 
8.1.9 E
nd of Treatment Visit  
The following assessments should be performed within one week (± 3 days) of discontinuation 
of ZEN003694 treatment:   If a subject’s dose was held and treatment was not resumed after a 
two week period, the scheduling of the EOT visit from the date of last study drug is extended to 
14 days ±3 days. 
 Symptom-directed physical examination and weight 
 ECOG pe
rformance status 
 Vital si
gns (temperature [Fº], blood pressure and heart rate)  
 He
matology 
 Serum chemistries: including serum testosterone 
 Serum troponin level 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 87 of 170 
 
 
 
 
  PSA 
 Urinalysis 
 P
D sample:  plasma for exploratory PD ( DC only) 
 PD sample:  whole blood for Exploratory BET inhibitor blood signature ( DC only)  
 P
D samples:  whole blood for CTCs for enumeration and PD at time of disease 
progre
ssion and time of PSA or radiographic response 
 PD samples: whole blood for exploratory cfDNA and ctDNA  
 P
art 1 Only: Ophthalmology assessments (±7 days) (see Section  8.2.16 ) 
 Qualitative Exploration of Visual Symptoms (see Section  8.2.16 )   
 AEs 
 C
oncomitant medications  
 F
resh tumor biopsy sample (optional during dose escalation and dose confirmation). The  
biopsies are to be collected at the time of disease progression, if possible .    The biopsy 
collected at the time of progression should be collected 2-4 hours after ZEN003694 
administration, if possible. 
 Tumor assessment  (if not performed within the last 3 months) 
8.1.[ADDRESS_1238297].  If a new cancer therapy is started within 7 days following the End of 
Treatment visit, the Safety Follow-up visit is not required.  The patient should return to the clinic 
for a final safety evaluation, including the following assessments:  
 Symptom-directed physical examination and weight 
 ECOG pe
rformance status 
 Vital si
gns (temperature [Fº], blood pressure and heart rate)  
 Hematology 
 Serum chemistries: including serum testosterone 
 Urinalysis 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 88 of 170 
 
 
 
 
  PSA 
 Part 1 Only: Ophthalmology assessments (see Section  8.2.16) (±7 days Collected at 
Safety Follow-up  only if EOT assessments were abnormal or if there were visual 
disturbances) 
 Part 1 Only: Qualitative Exploration of Visual Symptoms (see Section  8.2.16)     
 AEs
 
 C
oncomitant medications  
8.[ADDRESS_1238298] explain that the patient is not obliged to enter the study, and is free to withdraw 
from it at any time for any reason.  If new safety information becomes available and results in 
significant changes in risk/benefit assessment, the ICF should be reviewed and updated if 
necessary.   Under this circumstance, all patients, including those already being treated, should be 
given the new information, given a copy of the revised ICF, and allowed to re-evaluate their 
consent to continue in the study. 
A copy of the signed and dated ICF will be provided to the patient.  The Investigator will retain 
the original signed ICF. 
8.2.2 Inclusion/Exclusion Criteria 
Review the inclusion/exclusion criteria (see Section 4) at the Screening visit to ensure that the 
patient qualifies for the study.  The patient may be enrolled into the study if inclusion criteria ar e 
met and none of the exclusion criteria are met. 
8.2.3 Medical History and Demographics 
Obtain a
 complete medical history (significant past and ongoing conditions) including cancer 
history, prior PSA data, prior cancer treatments and surgeries, and demographic information at 
the Screening visit.  Previous history of allergies/ allergic reactions should also be captured on 
the Medical History eCRF. 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 89 of 170 
 
 
 
 
 8.2.4 Physical Examination/Symptom-directed Physical Examination 
Physical examination including ears/eyes/nose/throat/neck, respi[INVESTIGATOR_696], cardiovascular, 
gastrointestinal, musculoskeletal, central and peripheral nervous system, and dermatologic 
assessments will be performed at the Screening visit.  A symptom-directed physical examination, 
including evaluation of new symptoms and follow-up findings from previous physical 
examinations, should be performed at each study visit pre-ZEN003694 and enzalutamide (Part 1) 
or abiraterone (Part 2) dosing per the S
chedule of Events.  
8.2.5 Height and Weight 
Height (cm) should be rec
orded only at the Screening visit and weight (kg) measurements should 
be measured per the Schedule of Events.  
8.2.6 ECOG P
erformance Status 
ECOG performanc
e status will be assessed using the criteria described in Appendix 1.  
8.2.7 Vital Signs 
Vital signs include temperature (F
º), blood pressure and heart rate. 
8.2.8 Laboratory Parameters 
The following laborator
y parameters will be performed at the indicated time points in the 
Schedule of Events ( Table 1 & Table 2).  The Investigator must evaluate all results outside the 
reference range and
 determine the clinical significance (clinically significant or not clinically 
significant) of each result.   
 Hematology:  hemoglobin, hematocrit, red blood cell count, while blood cell count, 
neutrophil
s (absolute), lymphocytes (absolute), monocytes (absolute), eosinophils 
(absolute), basophil (absolute), mean corpuscular volume and platelet count  
 Coagulation tests: INR or PT and PTT 
 Serum chemistries:  albumin, ALT, AST, alkaline phosphatase, amylase, bicarbonate, 
tota
l bilirubin, blood urea nitrogen, calcium, chloride, creatinine, glucose, lactate 
dehydrogenase (LDH), lipase, sodium, potassium, phosphorus and magnesium.  Serum 
testosterone at Screening visit, Day 1 of each Cycle, EOT, and Safety Follow-up. 
 Serum troponin:  serum samples will be drawn for analyses of troponin T and/or I 
proteins, based on local laboratory procedure. For any individual patient, the same 
method will be used at each timepoint.  
 PSA 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 90 of 170 
 
 
 
 
  Urinalysis:  d ipstick with micro-analysis if clinically indicated 
Note: Day 15 safety labs (hematology and/or serum chemistries) can be waived at Investigator 
discretion starting in Cycle [ADDRESS_1238299] as long as platelets are stable and there are no other 
laboratory concerns in the opi[INVESTIGATOR_689]. 
8.2.9 Echocardiogram or MUGA 
Echocardio gram 
or MUGA scan with left ventricular ejection fraction will be obtained during 
the Scree
ning period. 
8.2.10 12-lead ECG 
Tripli
cate 12-lead ECGs will be obtained at the indicated time points in the protocol and 
Schedule of Events.  Note: The timing of post-dose ECG assessments in Cycle [ADDRESS_1238300] dose level.  This will enable a more accurate estimation of the 
time to 
maximum concentration (T max) of ZEN003694 from the PK data obtained from the 
patients in  Dose Levels 1 and 2. 
8.2.11 Phar
macokinetic Sampling 
Plasma samples will be collected to assess the PK properties of ZEN003694 and  the metabolite 
ZEN003791,  
PK analyses of plasma ZEN003694 and ZEN003791 will be performed at the following 
timepoints: 
 Pre-ZEN003694 and enzalutamide (Part 1) or abiraterone (Part 2) dose, 15 minutes (±5 
min), 30 minutes (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 
hours (±15 min) and 8 hours (±30 min) post
-ZEN003694 and enzalutamide (Part 1) or 
abiraterone (Part [ADDRESS_1238301]-dose in the Dose Confirmation phase at the direction of Zenith. 
Plasma and urine concentrations will be determined by a valida ted liquid chromatography-
tandem mass spectrometry (LC-MS/MS) bioanalytical method.  Samples will be collected as 
indicated in the Schedule of Events and the laboratory manual.  Exploratory analyses for other 
metabolites may be conducted by [CONTACT_885125]. 
Part 1: PK properties of enzalut
amide and the metabolite des-methyl enzalutamide will be 
assessed  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 91 of 170 
 
 
 
 
 PK analyses of plasma enzalutamide and des-methyl enzalutamide will be performed at the 
following timepoints: 
 Pre-enzalutamide and ZEN003694 dose, 1 hour (±5 min), 2 hours (±10 min), 4 hours 
(±15 min) and 8 hour
s (±30 min) post- ZEN003694 and enza
lutamide doses  
If enzalutamide dose is reduced
 at any time after Cycle 1, PK samples are to be obtained 28 Days 
(±7 Days) following modification: pre-Z
EN003964 and enzalutamide doses, and 15 minutes (±5 
min), 30 min (±5 min), 1 hour (±5 min), 2 hours (±10 min), 4 hours (±15 min), 6 hours (±15 
min) and 8 hours (±30 min) post-ZEN003694 and enzalutamide doses. 
 
Part 2: PK analyses of abiraterone will be performed at the following timepoints: 
 Pre-abiraterone and ZEN003694 dose, 15 minutes (±5 min), 30 minutes (±5 min), 1 hour 
(±5 min), 2 hours (
±10 min), 4 hours (±15 min), 6 hours (±15 min) and 8 hours (±30 min) 
post-ZEN003694 and abiraterone doses
  
Unscheduled plasma samples for PK ana
lysis may be requested by [CONTACT_885126]003694 
or abiraterone dose changes. 
8.2.12 Pharmacodynamic Sampling 
Blood samples will be drawn for analyses of CTCs (enumeration and PD), cell-free DNA and 
circulating tumor DNA, exploratory biomarkers and BET inhibitor gene expression profile as 
indicated in the Schedule of Events.  Tumor tissue will be obtained for histological and 
immunohistochemical analyses, expression of MYC, GR and AR, and RNA sequencing analysis 
to identify somatic mutations, alternati
ve splicing, fusions and alterations in gene expression.  
Tumor tissue will be obtained as indicated in the Schedule of Events.   Protocols for blood 
collection and processing whole blood, plasma and CTCs; tumor biopsy; tissue collection; and 
all sample storage and transportation will be provided in the study reference manual. 
 Whole Blood CTC:   Whole blood will be collected for the following analyses:  
CTC enumeration, AR-N/AR-C expression to assess AR splice variants.  
CTCs will
 be identified and quantified (“
enumerated”) on the basis of nuclear staining 
with 4,6-diamidino-2-phenylindole, anti-cytokeratin and anti-CD45 antibodies (which 
distinguishes CD45- epi[INVESTIGATOR_885078]45 leukocytes).  Slides will be prepared and 
analyzed for CTC enumeration and 5-plex AR-N/AR-C expression (dose confirmation 
phase only).  
One of
 the resistance mechanisms of ADT is the synthesis of constitutively active AR 
splice variants lacking the canonical ligand binding domain.  Since BETi are predicted to 
exert anti-tumor activity on both AR (native form) and ligand-independent AR splice 
variants, it is predicted that ZEN003694 would have anti-tumor activity in patients 
independent of AR splice isoforms.  Monitoring the 
AR variants will provide important 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 92 of 170 
 
 
 
 
 clinical data regarding the activity of BETi on mCRPC patients with AR variants  (Ware, 
Garcia-Blanco, Armstrong, & Dehm, 2014) .  Furthermore, an increase in the AR splice 
variants has been associated with re
sistance to enzalutamide and abiraterone 
(Antonarakis et al., 2014 ), which is the patient population selected for treatment with 
ZEN003694. 
 Plasma:  P lasma samples will be collected and banked for biomarker analysis.  Plasma 
sample
s will be analyzed for protein-based biomarkers using either the Myriad RBM 
OncoMAP (124 analytes) or the Somalogic Somascan (~1000 analytes).  The objective 
will be to find plasma-based biomarkers with potential correlation to tumor response, 
which will be further evaluated in Phase 2.  In addition, patients that show response 
(i.e., decrease tumor mass or CTCs) will be analyzed for metabolites and exosomes.  
Samples will be analyzed in batch upon completion of the dose confirmation phase.  
Plasma biomarkers correlating with AR versus AR splice variants may also be identified 
with this analysis. 
 Whole blood BETi gene expression analysis:  Whole blood will be collected.  In 
Cycle 1, RNA will be extracted from these tubes and expression of 6 BETi responsive 
gen
es, along with a housekeepi[INVESTIGATOR_885079] (cyclophilin), will be measured using 
quantitative polymerase chain reaction (qPCR).  Preclinical studies with normal and 
patient whole blood have shown that the expression of 5 of these genes (MYC, BCL2, 
chemokine (C-C motif) receptor 1[CCR1], interleukin [ADDRESS_1238302] [IL1RN], 
G protein-coupled receptor 183 [GPR183]) is inhibited in a BETi (ZEN003694) dose-
depende
nt manner, while a sixth ge
ne, histone gene cluster 1, H2BE histone family 
member E (HIST2H2BE), increases in a ZEN003694 dose-dependent manner.  
Monitoring 
the expression of these 
genes at baseline, 2, 4, [ADDRESS_1238303] been attained.  
 
 Exploratory whole blood cfDNA and ctDNA:  W hole blood will be collected from 
patients to isolate plasma and the buffy coat.  The plasma will be used to purify cfDNA 
and compare to DNA extracted from the buffy coat in order to identify circulating DNA 
that is derived from the tumors (ctDNA).  It will possibly allow a survey of the different 
mutations present in tumors across the body, monitor changes in the tumor cell 
population over the course of the trial, and possibly identify mechanisms of resistance to 
ZEN003694.  Changes in the percentage of ctDNA fraction and mutational spectrum of 
ctDNA over the course of the treatment will be monitored and compared to the biopsies 
obtained from the same patient to potentially establish correlations with the patient’s 
response, similarly to what has been recently published for ARSIs  ( Annala et al., 2018 ; 
Wyatt et al., 2017 ; Wyatt et al., 2016 ) and PARP inhibitors ( Goodall et al., 2017 ; 
Quigley et al., 2017 )). 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 93 of 170 
 
 
 
 
  Exploratory BETi blood signature:  [CONTACT_885148]-
points during the trial per the Table 1 & Table 2: Schedule of Events to measure changes 
in gene expression during 
the c
ourse of the study.  To measure gene expression, RNA 
will be extracted from the blood, a
nd all the RNA molecules will be sequenced by [CONTACT_16638]-
Seq to allow quantification of all the genes expressed in the sample.  By [CONTACT_885127], potential genes associated with response 
and/or resistance to ZEN003694 might be identified, and they are sometimes referred to 
as biomarkers.  These biomarkers could be further evaluated in future studies and used to 
predict r
esponses to ZEN003694, and/or select a treatment regimen using whole blood.  
 
 Tumor Biopsy:  Metastatic tumor biopsies will be taken with core needle or excisional 
biopsy.  Fine needle aspi[INVESTIGATOR_228052].  It is encouraged that 4 core samples be 
collected from a single site with
 a minimum of 2 core samples collected.  The biopsy 
sample will be split into two components, one formalin fixed for histological and 
immunohistoche
mical analyses, as well as possible DNA mutation analysis. The other 
component will be flash frozen for RNA isolation and sequencing.  In addition to the 
typi[INVESTIGATOR_885080], the expression and nuclear localization of AR, GR and MYC will be 
assessed by [CONTACT_9064].  For RNA sequencing analysis, paired end 
sequencing (100 bp, 45-50x106 rea
ds) will be used to identify somatic mutations, 
alternative splicing, fusions and alterations in gene expression.  An RNA aliquot will be 
taken from the frozen samples to detect the presence of the AR-V7 splice variant as well.   
In the dose confirmation phase, sampling accessible tumors is mandatory at baseline and 
during the course of treatment and optional at disease progression to help identify 
potential biomarkers for tumor 
response as well as tumor resistance. Archival tumor 
samples (initial diagnostic biopsy or biopsy at time of prostatectomy or other resected 
tissue), if available, will be collected during the Screening period through the end of 
Cycle [ADDRESS_1238304].  
 
 Immuno-Oncology samples :  At selected sites only in dose escalation of Part 1, whole 
blood will be collected for the following analyses:  T-cell receptor (TCR) sequencing in 
PBMCs and flow cytometry in PBMCs.   TCR sequencing will analyze both clonotype 
frequency and diversity of tumor-specific T-cell responses in the entire TCR repertoire.  
Flow cytometry will measure populations of T-helper subsets, cytotoxic and memory T-
cells, T-regs, B-cells, myeloid cell populations as well as LAG3, CTLA4 and PD-1 cell 
populations. In addition, PD-L1 and CD8 cells will be possibly evaluated by 
[CONTACT_885128].   
 
8.2.13 Adverse Events 
Adverse events will be collected as defined in Sections 10.1, 10.2 and 10.3. 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 94 of 170 
 
 
 
 
 8.2.14 Concomitant Medications 
All prior cancer-related treatment and procedures will be captured on the eCRFs.  All 
concomitant medications (dose and regimen) taken during the course of the study must be 
recorded on the Concomitant Medications eCRF.  In addition, any medications taken 21 days 
prior to enrollment in the study should be recorded on the Concomitant Medications eCRF. 
8.2.15 Tumor Assessment – Imaging/Radiologic Evaluation 
Whole bod
y radionuclide imaging (Te ch-99) and cross-sectional imaging of the 
chest/abdomen/pelvis should be performed in accordance with institutional standards.   Use of 
intravenous contrast is required unless contraindicated.  Magnetic resonance imaging (MRI) may 
be substituted for computed tomography (CT)
 per the Investigator’s discretion.   Disease status 
should be assessed using the PCWG2 criteria (see Appendix 3).   
Note:  To be assigned 
a status of PR or CR, changes in tumor measurements must be 
confirmed by [CONTACT_733907] [ADDRESS_1238305] and will include:   
 Part 1: Ophthalmic history, Snellen best corrected visual acuity (including refraction, if 
nee
ded), color vision testing (using standard HRR ps eudoisochr omatic plates), 
pupi[INVESTIGATOR_115726], confrontational visual field testing, intraocular pressure (using Goldmann 
tonometry or TonoPen tonometry), external eye and ocular motility exam and slit lamp 
biomicroscopy, indirect ophthalmoscopy, OCT optic nerve and macula tests, fundus 
photography, and other exams as clinically indicated. 
 Part 2: Ophthalmic history, Snellen best corrected visual acuity (including refraction, if 
nee
ded), color vision testing (using standard HRR pseudoisochromatic plates), 
pupi[INVESTIGATOR_115726], OCT optic nerve and macula tests, fundus photography, and other exams as 
clinically indicated. 
 
In both parts of the study, completion of the Qualitative Exploration of Visual Symptoms form 
(provided by [CONTACT_1034]) is required at time-points detailed in the Schedule of Assessments. 
 
At any time during the study should a clinica
lly meaningful change in visual symptoms occur, 
unscheduled ophthalmology assessments are to be performed. 
9. WITHDRAWAL OR EARL Y TERMINATION OF PATIENTS  
Patients are free to withdraw from study participation at any time for any reason.  Patients may 
discontinue treatment with ZEN003694 either at their request, at the discretion of the 
Investigator for medically indica
ted reasons or for protocol noncompliance.   
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 95 of 170 
 
 
 
 
 In the event of early termination, the patient should be instructed to report to the clinic as early as 
possible but within 1 week after the dec
ision to terminate from the study has been made or for 
the next scheduled clinic visit.  All End of Treatment visit procedures (see Section 8.1.9) and all 
Safe
ty Follow-up visit procedures (see Section 8.1.10) are to be conducted.  The Investigator 
shall make his or her best efforts to perform these procedures.  The Investigator should make all 
attempts to accurately identify the reason a patient withdrew from the study, while respecting the 
patient’s privacy.  The primary reason for the patient discontinuation should be documented as 
one of the following: 
 Clinical progression by [CONTACT_43877]2 criteria  
 Cli
nical progression by [CONTACT_43877]2 criteria with PSA progression  
 Radiographic progression by [CONTACT_43877]2 criteria  
 Radiographic progression by [CONTACT_43877]2 criteria with PSA progression  
 DLT 
 Adverse event  
 Treatment with or need for prohibited concomitant medication 
 Wit
hdrawal by [CONTACT_4676] 
 Withdrawa
l by [CONTACT_5936] 
 Non-compliance 
 Lost to follow-up 
 Dea
th 
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 96 of 170 
 
 
 
 
 10. SAFETY ASSESSMENTS  
Safety parameters monitored and recorded during this study include, physical examination 
findings, weight, vital signs, ECOG performance status, ECGs, AEs, laboratory variables 
(hematology, serum chemistries, serum troponin, coagulation tests and urinalysis).    
10.[ADDRESS_1238306] (i.e., study drug), whether or not considered related to the 
pharmaceutical product.   
The recording of AEs will begin at the start of the administration of the first dose of 
enzalutamide in the Lead-in phase of the study.  AEs should record the development of an 
undesirable medical condition, worsening of a pre-existing medical condition and any change in 
severity (increase or decrease) of a previously recorded AE, during or following exposure to 
study drug, regardless of relationship to study drug.  See Section 10.3 for additional information. 
10.1.2 Serious Adverse Event 
A serious adverse ev
ent (SAE) is any AE that: 
 Results in death 
 I
s life-threatening 
o A life-threatening SAE is any AE that places the patient at immediate risk of death 
from the reaction as it occurred, as assessed by [CONTACT_737].  This definition does 
not include a reaction that might have caused death if it occurred in a more severe 
form. 
 Requires in-patient hospi[INVESTIGATOR_72010] 
o For the purposes of this protocol, any hospi[INVESTIGATOR_740592]-
pati
ent hospi[INVESTIGATOR_059], regardless of duration.  An emergency room visit without 
hospi[INVESTIGATOR_256267] a SAE under this criterion, nor will 
hospi[INVESTIGATOR_5315] a procedure scheduled before study enrollment (first dose of study 
drug) or elective procedures 
scheduled during the study.  However, unexpected 
complications that occur during elective surgery should be recorded as AEs and 
assessed for seriousness. 
 Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 97 of 170 
 
 
 
 
  Results in a congenital anomaly or birth defect 
 Is any other important medical event 
 Othe
r medical events may be considered SAEs when, based on appropriate medical 
judgment, 
they may jeopardize the patient and may require medical or surgical 
intervention to prevent one of the other outcomes in the SAE definition.  Examples 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_65891] , 
or the development of drug dependency or drug abuse.   
10.1.3 Suspected Unexpected Serious Adverse Reaction   
A suspected unexpected serious adverse reaction  (S[LOCATION_003]R) is any AE for which there is evidence 
to suggest a causal relationship between the study drug and the AE (e.g., assessed as possibly or 
probably related), and which is both unexpected and serious.  An unexpected adverse reaction 
(i.e., any untoward and unintended response to the study drug) is one for which the nature and 
severity is inconsistent with the applicable reference safety information (e.g., Investigator’s 
Brochure). 
10.[ADDRESS_1238307] event information on the SAE Report Form, and submit the completed form 
with any other available pertinent information (e.g., hospi[INVESTIGATOR_1097], laboratory results, etc.) to 
Drug Safety (contact [CONTACT_885129]).   The minimum 
required information for an initial report is:  
 Reporter’s name [CONTACT_3669] [CONTACT_3031] 
 P
rotocol number 
 Site and patient identification information 
 Event term(s) (with a brief summary of the event[s] and causality assessment) 
If
 additional follow-up information is required or becomes available for a previously reported 
SAE or S[LOCATION_003]R, a follow-up SAE Report Form with the new information should be prepared 
and submitted WITHIN ONE BUSINESS DAY .  
For 
hospi[INVESTIGATOR_602], all attempts to obtain the hospi[INVESTIGATOR_885081].  Complete an SAE Report Form with any known information on the hospi[INVESTIGATOR_059], 
however minimal, and submit it to Drug Safety (detailed contact [CONTACT_885130]). 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 98 of 170 
 
 
 
 
 10.2.1 Disease-related Events That Are Endpoints 
For the purposes of this study, progression of the patient’s underlying disease (“diseas e 
progression”) should generally not be reported as an AE or SAE.  However, if the Investigator 
determines that there is evidence suggesting a causal relationship between the event and the 
study medication, immediately report the event to Drug Safety and record as an AE or SAE. 
Any event that results in death is to be reported as an SAE. Death is an outcome of an adverse 
event and not an adverse event in itself.  The underlying event leading to death is reported as the 
SAE. 
10.[ADDRESS_1238308] administration of study drug are not considered AEs, by 
[CONTACT_108] (Section 10.1.1); record these events on the Medical History CRF.   
The Investigator or a quali
fied designee will question and examine patients for evidence of AEs.  
Patients should not be asked about specific AEs.  Instead, they should be asked general questions 
(e.g. “How have you been feeling since your last visit?”).  Record all AEs on the AE CRF.  If a 
previously reported AE changes in severity, record the change in the AE severity on the AE 
CRF. 
For an event to be recorded as an AE, the onset must occur during or after the patient’s first 
exposure to study drug and no later than [ADDRESS_1238309] study drug dose.  However, there 
is no limit on reporting SAEs considered reasonably related to ZEN003694.  Immediately report 
all SAEs and deaths to Drug Safety (Section 10.2).  This requirement inclu des deaths within 
[ADDRESS_1238310] syndromes rather than individual signs or symptoms in order to avoid double reporting of 
events and facilitate meaningful interpretation of data.  For example, a patient presenting with 
rhinitis, fever, and headache should be reported as having “flu-like symptoms,” without 
independently recording each accompanying sign.  When no clearly recognizable clinical 
syndrome can be described, record individual clinical signs and symptoms. 
All AEs that occur during the study should be treated appropriately to protect and ensure the 
patient’s well-being.  If such treatment constitutes a deviation from this protocol, Drug Safety 
must be notified and the Investigator should comply with applicable Ethics Committee (EC) or 
Institutional Review Board (IRB) reporting requirements. 
The Investigator is responsible for determining whether or not an AE is severe enough to require 
the patient’s removal from treatment.  A patient may also voluntarily withdraw from treatment 
because of an AE.  If either occurs, the patient must receive appropriate medical care, and the 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238311] categorize the severity of each AE using the NCI CTCAE Version 4.03 
(see Appendix 2).   
It is 
important to distinguish between 
AE seriousness and severity; these terms are not 
interchangeable.  Severity is a measure of intensity whereas seriousness is defined by [CONTACT_572125] 10.1.2. 
10.3.[ADDRESS_1238312] decide whether there is a reasonable possibility that the event 
was caused by [CONTACT_885131]003694 (i.e., that the event was a suspected adverse 
reaction).  The Investigator should make this decision after careful consideration of the following 
questions: 
 Does the AE follow a reasonable temporal sequence from administration of study drug? 
 Can the AE be reasonably explained by [CONTACT_11564]’s clinical 
state, environmental or toxic factors, or other therapy? 
 Do the AE symptoms disappear or decrease on cessation of study drug or reduction in 
study
 drug dose?  (There are exceptions when an AE does not disappear on 
discontinuation of the drug, yet drug relatedness clearly exists [e.g., bone marrow 
depression, fixed drug eruptions, tardive dyskinesia, etc.]). 
 Does the AE reappear or worsen when the study drug is re-administered? 
 Does the AE follow an expected response pattern based on the established pharmacologic 
and toxicologic effects of the study drug? 
 Does the AE follow an expected response pattern based on the known effects of other 
produc
ts in the same class? 
For this assessment, the Investigator will classify each AE as one of the following: 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 100 of 170 
 
 
 
 
  Yes, Related:  The AE is definitely related or even considered possibly or probably 
related to study drug administration.  
 Not Related:  Th e AE is clearly due to other causes (e.g. concurrent medication, 
underlying disease, etc.). 
10.4 Abnormal Laboratory Results 
Abnormal laboratory results may occur in the context of an AE that is a clinical syndrome 
(e.g., elevated BUN and creatinine in the setting of an AE of renal failure, or elevated AST/ALT 
in the se
tting of an AE of hepatitis).  In these cases, do not record the abnormality itself as an 
AE. 
However, in the absence of an AE that encompasses an observed abnormal laboratory result, 
report the abnormality as an AE if the Investigator judges it to be clinically significant for the 
patient.  
For the purposes of this study, the c
riteria for a "clinically significant" abnormal laboratory result 
are any of the following: 
 It leads to DLT 
 I
t results in any therapeutic intervention 
 It is judged by [CONTACT_885132] 
10.[ADDRESS_1238313] medical practice
. 
Dosing details should be captured on the Study Drug CRF.  If the patient receives a dose of a 
study drug that exceeds protocol specifications and the patient is symptomatic, then the 
symptom(s) should be documented on the AE CRF and on a SAE form as appropriate.  Do not 
capture the event on the AE CRF or SAE form if the patient is not symptomatic. 
Should an overdose occur, the Inv
estigator should also monitor the patient with appropriate 
blood counts and serum chemistry tests and should also provide supportive therapi[INVESTIGATOR_885082].   
10.6 Study Safety Monitoring and Dose Escalation or Modification 
The CRC will review safety and available PK data (e.g., C max and AUC) for each cohort in the 
dose es
calation phase to decide when it is permissible to open a new cohort per the study design 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 101 of 170 
 
 
 
 
 described in the protocol.  Safety data will include but are not limited to SAEs, AEs and 
laboratory (protocol specified or ad hoc) data, as well as additional information provided by [CONTACT_885133].  Additionally, the accruing safety data for all patients to date will be 
included in the decision making process for dose escalation or modification.  Dose escalation or 
modifications will be allowed in the absence of an unreasonable and significant risk of illness or 
injury to patients.  In addition, Zenith will review the study safety data on an ongoing basis.  An 
independent specialist may participate in the safety review, if appropriate. 
10.[ADDRESS_1238314]  
Zenith or its designee will provide written safety reports or other safety-related communications 
to the Investigator.  The Investigator will ensure that these reports are reviewed and processed in 
accordance with regulatory and EC/IRB requirements and archived in the site’s study file.   
At the completion or early termination of the study, the Investigator will submit a final report to 
the EC/IRB in accordance with local requirements.  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 102 of 170 
 
 
 
 
 11. STUDY ENDPOINTS  
11.1 Primary Endpoints 
 Safety profile of ZEN003694 in combination with enzalutamide (Part 1) and 
abira
terone (Part 2) 
 DLT characteristics and MTD determination for ZEN003694 in combination with 
enz
alutamide (Part 1) and abiraterone (Part 2, if MTD is determined) 
 RP2D of ZEN003694 in combination with enzalutamide (Part 1) and abiraterone 
(Part 2)
 for further clinical investigation 
11.2 Secondary Endpoints
 
 Part 1: Plasma concentrations of ZEN003694, the active metabolite ZEN003791 
and 
enzalutamide and the active metabolite des-methyl enzalutamide.  The 
following PK  parameters, at a minimum, will be calculated as appropriate: AUC0-l ast 
and AUC 0-inf, Cmax and minimum or trough concentration (C min), dosing interval, 
and Tmax and half-life (t 1/2)  
 Part 2: Plasma concentrations of ZEN003694, the active metabolite ZEN003791 
and 
abiraterone.  The following PK parameters, at a minimum, will be calculated as 
appropriate: AUC 0-last and AUC 0-inf, Cmax and minimum or trough concentration 
(Cmin), dosing interval, and T max and half-life (t 1/2)  
 Overall response rate, complete response (CR) and partial response (PR) by 
[CONTACT_885134]2 criteria 
 PSA response by [CONTACT_43877]2 criteria 
 Median progression-free survival by [CONTACT_43877]2 criteria 
 CTC response (dose confirmation) 
11.3 Exploratory
 Endpoints 
 Baseline and change from baseline post-treatment in BET gene expression in whole 
blood  

 Baseline and change from baseline post-treatment in quantification of AR splice 
varia
nts in blood (dose confirmation) and post-treatment in tumor tissue* and 
response (CR, PR, PD) 
 Baseline and change from baseline post-treatment in MYC expression in tumor 
tissue* and response (CR, PR, PD) 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 103 of 170 
 
 
 
 
  Baseline and change from baseline post-treatment in GR expression in tumor 
tissue* and response (CR, PR, PD) 
 Possible relationship of baseline tumor abnormalities (such as mutations, 
transloca
tions, mRNA, protein expression and localization), in circulating tumor 
DNA (ctDNA), circulating tumor c
ells (CTC) and tumor biopsies and/or on-
treatment changes with any observed antitumor activity 
 Baseline and change from baseline post-treatment in immuno-oncology biomarkers, 
if observe
d. 
 Part 1: Correlation between ZEN003694, ZEN003791, enzalutamide and des-
methy
l enzalutamide plasma exposure
 levels and PD responses 
 Part 2: Correlation between ZEN003694, ZEN003791, abiraterone plasma exposure 
levels and PD re
sponses 
 Correlation between PSA and radiographic response (CR, PR, PD) 
* Tumor biopsi es are optional at baseline, on-study treatment, and at the time of 
progression in dose escalation; mandatory at baseline, on-study treatment, and 
optional 
at the time of progression in dose
 confirmation  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238315] deviation, median, 
minimum, and maximum.  Categorical variables will be summarized by [CONTACT_885135].  For ordinal-scaled variables, a combination of the above may be employed 
as appropriate:  frequency and percentage of observations within a category and means and 
standard deviations of the scores of the categories.  For categorical and ordinal variables, 
percentages will be calculated based on non-missing data. 
Base
d on the characteristics of the study design and lack of a concurrent control arm, formal 
testing of treatment effects (i.e., inferential statistics) will not be performed.  However, some 
measures will be summarized by [CONTACT_885099] 95% confidence 
intervals. 
12.2 Sample Size Determination 
A conventional alg
orithm (3+3 patients per dose level) will be used to identify the MTD, 
escalating on [ADDRESS_1238316] 2 of 3 or 2 of 6 patients experiencing a DLT.  With this design, there 
is a 71% chance of escalation if the true but unknown rate of DLT is 20%, and less than 50% 
chance of escalation if the true but unknown rate of DLT is higher than 30%. 
Part 1: Approximately 40 patients may be enrolled in the dose escalation phase of the study.  Up 
to 40 pa
tients in the dose confirmation phase may be enrolled at the MTD or RP2D.  The sample 
size is s
ufficient to support preliminary safet
y and pharmacologic assessments. 
Part 2: Approximately 15 patients may be enrolled in the dose escalation phase of the study.  Up 
to 40 pa
tients in the dose confirmation phase may be enrolled at the MTD or RP2D.   The sample 
size is sufficient to support preliminary safety and pharmacologic assessments. 
12.3 Analysis Populations  
Safety population:  Patients who receive at least one dose of ZEN003694. 
DLT population:  Patients who 
experience a DLT as defined in Section 5.1.2.  Patients who 
expe
rience a DLT within the first cycle of treatment and drop out of the study will be considered 
evaluable for DLT and will not be replaced.  
Part 1: No dose modification of enzalutamide (160 mg) is permitted during Cycle 1, including 
the 14-day Lead-in period; patients requiring dose modification during Cycle [ADDRESS_1238317] cycle will be conside
red unevaluable and will be replaced.  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 105 of 170 
 
 
 
 
 Part 2: No dose modification of abiraterone (1000 mg) is permitted during Cycle 1, including the 
14-day Lead-in period; patients requiring dose modification during Cycle [ADDRESS_1238318] cycle will be conside
red unevaluable and will be replaced.  
12.4 Data Handling  
Clinical data will be entered int
o a clinical data management system (CDMS), involving 
electronic data capture.  Criteria for such a CDMS are that it is Part 11 compliant, web-based and 
supports remote monitoring.  The handling
 of data, including data quality assurance, will comply 
with regulatory guidelines, and will be defined in the study-specific data management plan 
(DMP).  The DMP will define roles and responsibilities in regard to data quality processes and 
expectations, from study start-up to final databa
se lock.    
12.5 Statistical Analyses 
Prior to the analysis of the final study data, a detailed statistical analysis plan (SAP) will be 
written.  Detailed information regarding analysis datasets, summarization of the data and 
analyses will be provided in the SAP.  The SAP will contain any modifications to the analyse s 
described in this section.  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238319] undergo proper training on the study protocol and ancillary study procedures/documents 
through participation in an initiation visit or Investigator meeting.  Such training must take place 
before any patients are enrolled at that site.  Initiation visits and Investigator meetings will 
include but may not be limited to review of Good Clinical Practice (GCP) guidelines, study drug 
procedures, data collection requirements and patient eligibility requirements. 
Zenith or designee will 
make periodic visits to the investigational site to assess compliance with 
study procedures and regulatory requirements; to ensure that the safety, welfare and privacy of 
patients are being protected; and to verify the accuracy and integrity of the study data.   
In addition, Zenith will periodically review the study data to ensure that data are being 
appropriately collected and reported.  Logic checks will be also programmed and run to identify 
errors and data discrepancies.  Discrepancies will be reviewed with investigational site 
personnel, corrections will be made to the database, and a validated audit trail will be 
maintained.  The database will be locked and audited before it is released for analysis. 
13.1 Study Monitoring 
Before the initiation of the study, a representative from Zenith will visit the investigational site 
to: 
 Determine the adequacy of the facilities 
 Discuss the responsibilities of the Investigator(s) and other personnel involved with the 
study with regard to protocol adherence and the responsibilities of Zenith and their 
representatives 
During the study, the Study
 Monitor will have regular contact [CONTACT_375047], 
including visits to: 
 Provide information and support to the Investigator(s) 
 C
onfirm that facilities remain acceptable 
 C
onfirm that the investigational team is adhering to the protocol, that data are being 
ac
curately recorded on the CRFs, and that the investigational product accountability is 
being performed. 
 Perform source data verification (a comparison of the data on the CRFs with the patient’s 
rec
ords at the hospi[INVESTIGATOR_7117], and other records relevant to the study). This will 
require direct access to all original records for each patient e.g., clinic charts.  Incorrect or 
missing entries on to the CRFs will be queried and
 must be corrected immediately. 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238320] the review of the current study 
(e.g., Form 483, Inspectional Observations).  Zenith or their designee reserves the right to be at 
the investigational site during any regulatory inspection that involves this protocol. 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 108 of 170 
 
 
 
 
 14. ETHICAL AND LEGAL ISSUES 
14.1 Statement of Compliance 
This study will be conducted in accordance with the following: 
 Protocol-related and study-related documents 
 GCP
 as outlined in the International Conference on Harmonization (ICH) E6 guideline 
and re
gional regulations 
 Regional required patient data protection laws and regulations 
 Applica
ble regional regulations 
14.[ADDRESS_1238321] Approval 
The Principal Investigator [INVESTIGATOR_885083], Zenith-approved ICF/assent, patient information sheet, if applicable, and 
any advertisements to recruit patients.  Written approval of these documents must be obtained 
from the EC/IRB and a copy submitted to Zenith before any patient is enrolled at an 
investigational site. 
The Principal Investigator [INVESTIGATOR_885084]/IRB. 
 Obtaining EC/IRB approval for any protocol amendments and ICF/assent revisions 
befor
e implementing the changes 
 Providing the EC/IRB with any required information before or during the study 
 S
ubmitting progress reports to the EC/IRB as required during the conduct of the study, 
reque
sting re-review and approval of the study as needed, and providing copi[INVESTIGATOR_885085]/IRB renewal of approvals and relevant communication to Zenith and/or its 
representative 
 Notifying the EC/IRB of all serious and unexpected AEs related to the study medicatio n 
reporte
d by [CONTACT_885136]/or its representative, as required 
 Notifying the EC/IRB at the end of the study, in accordance with regional guidelines and 
reg
ulations 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 109 of 170 
 
 
 
 
 14.3 Patient Informed Consent/Assent 
The Investigator’s draft ICF/assent must be reviewed by [CONTACT_885136]/or its representative prior to 
submission to a regional EC/IRB for approval.  A copy of the ICF/assent approved by [CONTACT_28923]/IRB must be forwarded to Zenith and/or its representative. 
The consent of the patient to participa
te in the study has to be given in writing prior to 
enrollment.  It must be signed and personally dated by [CONTACT_102], parent, legal guardian or 
caretaker and by [CONTACT_737], Sub-investigator or study coordinator designated by [CONTACT_885137].  The signed and dated declaration of 
informed consent will remain at the Investigators’ site and must be safely archived by [CONTACT_885138], auditing and inspection 
purposes.  A copy of the signed and dated ICF should be provided to the patient prior to 
participation and the original maintained in the patient’s source documents or in a separate 
archive file for the informed consent documents for the study. 
14.4 Patient Compensation for Adverse Effects on Health 
Zenith and/or its representative will adhere to regional regulations regarding clinical trial 
compensation to patients whose health is adversely affected by [CONTACT_9286]. 
14.[ADDRESS_1238322] the patient, e.g., changes in procedures/assessments or matters relating to 
patient safety, require a 
favorable opi[INVESTIGATOR_349894]/IRB for the study sites prior to 
implementation.  Changes of a purely administrative nature should be notified to the 
committee(s) as applicable, but do not require formal approval.  However, a change to the 
protocol to eliminate an apparent immediate hazard to the patient may be implemented 
immediately provided the EC/IRB and applicable Regulatory Authorities are subsequently 
notified by [CONTACT_12548].  Any amendment affecting the patient requires further informed 
consent from each patient before implementation.  
14.5.2 Study Termination 
Zenith res
erves the right to terminate the study at any time for any reason.  The Investigator 
should notify the EC/IRB in writing of the completion or early termination of the study.  Zenith 
will promptly notify US FDA and other Regulatory Authorities if enrollment is terminated or 
suspended for any reason.  Upon study completion or termination, applicable regulatory 
reporting requirements will be followed. 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 110 of 170 
 
 
 
 
 15. INVESTIGATOR RESPONSIBILITIES  
The Investigators shall be responsible for ensuring that the study is performed in accordance with 
the protocol, Food and Drug Administration (F
DA)/ICH GCP regulations and applicable 
regional regulatory requirements.  
15.[ADDRESS_1238323] 
In signing this protocol, the Investigator agrees to: 
 Conduct the study in accordance with the relevant, current protocol and make changes 
only
 after notifying Zenith or its representative, except where necessary to eliminate 
apparent immediate hazards to human patients 
 Comply with the ICH guidelines on GCPs plus appropriate regional regulatory laws and 
require
ments 
 Personally conduct or supervise the described investigation 
 Inform any patients or persons used as controls that the study drugs are being used for 
investigational purposes 
 Ensure requirements relating to obtaining informed consent and EC or  IRB approval have 
been met 
 Report to Zenith or its representative any AEs that occur in the course of the 
investig
ations, as specified in Section 10  
 Read and understand the Investigator’s Brochure, including potential risks and side 
effects of the drug 
 Ensure all associates, colleagues, and employees assisting in the conduct of the study are 
informed of their obligations in meeting their commitments 
 Maintain ade quate and accurate records and make these available for inspection by 
[CONTACT_885136]/or its representative, or any regulatory agency authorized by [CONTACT_885139]003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 111 of 170 
 
 
 
 
  Promptly report to the EC or IRB all changes in research activity and all unanticipated 
problems involving risks to human patients or others 
 Comply with all other requirements regarding the obligations of clinical Investigators and 
all
 other pertinent requirements 
 Administer study drug only to patients who meet study entry criteria and are enrolled in 
the study
, and only according to the guidelines set forth in this protocol 
15.[ADDRESS_1238324] 
of the study, including but not limited to the following: 
 All versions of the Investigator’s Brochure and the signed protocol and amendments in 
eff
ect during the conduct of the study 
 Signed ICFs/assents 
 Source documents including adequate case histories 
 Signed, dated and completed CRFs or data collection forms and documentation of data 
cor
rections 
 Notification of SAEs and related reports 
 I
nvestigational product accountability logs and documentation of return of unused and 
used investi
gational product, if applicable 
 Dated and documented EC/IRB approvals 
 Nor
mal laboratory test values and laboratory certifications, if applicable 
 Curricula vitae of all clinical Investigators 
 Completed Forms US FDA 1572 
 Trial initiation documentation 
 De
legation of Authority Log 
 Signed Signature [CONTACT_460895] 
 Relevant communication, including that related to the Study Monitor’s  sit e visits 
(e.g., letters, meeting notes, notes from telephone calls) 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 112 of 170 
 
 
 
 
  Interim, annual or final reports to ECs/IRBs 
 Patient screening log, patient identification code list and patient enrollment log 
 Audit ce
rtificate if applicable  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238325] 30 days prior to their submission for publication or presentation.  Authorship among 
Investigators generally will be based on the extent of significant contribution, including scientific 
and clinical, to the publication.  
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238326] not reveal information relating to the 
Investigator’s Brochure, protocol, CRFs or associated documents to unauthorized third parties. 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 115 of 170 
 
 
 
 
 18. REFERENCES 
Aggarwal, R., Zhang, T., Small, E. J., & Armstrong, A. J. (2014). Neuroendocrine prostate 
cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw, 12 (5), 719-
726.  
Annala, M., Va
ndekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., . . . Chi, 
K. N. (2018). Circulating tumor DNA genomics correlate with resistance to abiraterone 
and enzalutamide in prostate cancer. Cancer Discov . doi:10.1158/2159-8290.CD-17-
0937 
Antonarakis, E. S
., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., . . . Luo, J. (2014). 
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New 
England journal of medicine, 371 (11), 1028-1038. doi:10.1056/NEJMoa1315815 
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., . . . 
Sawyers, C. L. (2013). Glucocorticoid receptor confers resistance to antiandrogens by 
[CONTACT_885140]. Cell, 155(6), 1309-1322. 
doi:10.1016/j.cell.2013.11.012 
Asang
ani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., . . . Chinnaiyan, A. 
M. (2014). Therapeutic targeting of BET bromodomain proteins in castration-resistant 
prostate cancer. Nature, 510 (7504), 278-282. doi:10.1038/nature13229 
Azad, A. A
., Eigl, B. J., Murray, R. N., Kollmannsberger, C., & Chi, K. N. (2015). Efficacy of 
enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-
resistant prostate cancer patients. Eur Urol, 67 (1), 23-29. 
doi:10.1016/j.eururo.2014.06.045 
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., . . . Chi, K. N. 
(2015). Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers 
of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res, 
21(10), 2315-2324. doi:10.1158/1078-0432.CCR-14-2666 
Basc
h, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Fe
yer, P. C., Somerfield, M. R., . . . 
American Society of Clinical, O. (2011). Antiemetics: American Society of Clinical 
Oncology clinical practice guideli
ne update. J Clin Oncol, 29 (31), 4189-4198. 
doi:10.1200/J
CO.2010.34.4614 
Beltran, H., Tomlins, S., Aparicio, A., Arora, V., Rickman, D., Ayala, G., . . . Rubin, M. A. 
(2014). Aggressive varian ts of castration -resistant prostate cancer. Clin Cancer Res, 
20(11), 2846- 2850. doi:10.1158/1078 -0432.CC R-13-3309 
Bianchini
, D., Lorente, D., Rodriguez-Vida, A., Omlin, A., Pezaro, C., Ferraldeschi, R., . . . de 
Bono, J. S. (2014). Antitumour activity of e nzalutamide (MDV3100) in patients with 
metastatic castration -resistant prostate cancer (CRPC) pre -treated with docetaxel and 
abiraterone. Eur J Cancer, 50 (1), 78-84. doi:10.1016/j.ejca.2013.08.020  
Blattner
, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., . . . Barbieri, C. E. 
(2017). SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate 
Regulation of PI3K/mTOR and AR Signaling. Cancer cell, 31 (3), 436-451. 
doi:10.1016/j.ccell.2017.02.004 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 116 of 170 
 
 
 
 
 Boysen, G., Barbieri, C. E., Prandi, D., Blattner, M., Chae, S. S., Dahija, A., . . . Rubin, M. A. 
(2015). SPOP mutation leads to genomic instability in prostate cancer. Elife, 4. 
doi:10.7554/eLife.[ZIP_CODE] 
Ceribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y., . . . Staudt, L. M. 
(2014). Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma 
by [CONTACT_885141]. Proceedings of the 
National Academy of Sciences of the [LOCATION_002] of America, 111 (31), [ZIP_CODE]-[ZIP_CODE]. 
doi:10.1073/pnas.[PHONE_18318] 
Chan, C. H., Fang, C., Qiao, Y., Yarilina, A., Prinjha
, R. K., & Ivashkiv, L. B. (2015). BET 
bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT 
signaling in a gene-specific manner in human monocytes. European journ al of 
immunology, 45(1), 287-297. doi:10.1002/eji.[ADDRESS_1238327], M. D., Miao, L., Bradner, J. E., . . . Dehm, S. M. 
(2015). Targeting chromatin binding regulation of constitutively active AR variants to 
overcome prostate cancer resistance to endocrine-based therapi[INVESTIGATOR_014]. Nucleic acids 
research, 43(12), 5880-5897. doi:10.1093/nar/gkv262 
Cho, H., He
rzka, T., Zheng, W., Qi, J., Wilkinson, J. E., Bradner, J. E., . . . Trotman, L. C. 
(2014). Rapi[INVESTIGATOR_773385], a novel GEM model for metastatic prostate cancer analysis and 
therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov, 4 (3), 318-
333. doi:10.1158/2159-
8290.CD-13-0346 
Dai, X., Gan, W., Li, X., Wang, S., Zhang, W
., Huang, L., . . . Wei, W. (2017). Prostate cancer-
associated SPOP mutations confer resistance to BET inhibitors through stabilization of 
BRD4. Nature medicine . doi:10.1038/nm.4378 
Dang, Q., Li, L., Xie, H., He, D., Chen, J., Song, W., . . . Chang, C. (2015). Anti-androgen 
enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering 
the infiltrated mast cells --> androgen receptor (AR) --> miRNA32 signals. Mol Oncol, 
9(7), 1241-1251. doi:10.1016/j.molonc.2015.02.010 
Dawson, M. A., Kouz
arides, T., & Huntly, B. J. (2012). Targeting epi[INVESTIGATOR_885086]. 
The New England journal of medicine, 367 (7), 647-657. doi:10.1056/NEJMra1112635 
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W. I., . . . 
Kouzarides, T. (2011). Inhibition of BET recruitment to chromatin as an effective 
treatment for MLL-fusion leukaemia. Nature, 478 (7370), 529 -533. 
doi:10.1038/nature10509  
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . Verweij, 
J. (2009). Ne w response evaluation criteria in solid tumours: revised RECIST guideline 
(version 1.1). Eur J Cancer, 45 (2), 228-247. doi:10.1016/j.ejca.2008.10.026  
Filippakopoulos, P., & Knapp, S. (2014). Targeting bromodomains: epi[INVESTIGATOR_885087].  Nat Rev Drug Discov, 13 (5), 337-356. doi: 10.1038/nrd4286  
Gallagher, S. J., Mijatov, B., Gunatilake, D., Gowrishankar, K., Tiffen, J., James, W., . . . 
Hersey, P. (2014). Control of NF-kB activity in human melanoma by [CONTACT_885142]-terminal protein inhibitor I-BET151. Pi[INVESTIGATOR_79306], 27 (6), 1126-
1137. doi:10.1111/pcmr.[ZIP_CODE]
 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 117 of 170 
 
 
 
 
 Gao, L., Schwartzman, J., Gibbs, A., Lisac, R., Kleinschmidt, R., Wilmot, B., . . . Alumkal, J. 
(2013). Androgen receptor promotes ligand-independent prostate cancer progression 
through c-Myc upregulation. PloS one, 8(5), e63563. doi:10.1371/journal.pone.0063563 
Gasi Tandef
elt, D., Boormans, J., Hermans, K., & Trapman, J. (2014). ETS fusion genes in 
prostate cancer. Endocr Relat Cancer, 21 (3), R143-152. doi:10.1530/ERC-13-0390 
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S
., . . . investigators, T.-A. 
(2017). Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. 
Cancer Discov . doi:10.1158/2159-8290.CD-17-0261 
Goodell, M. A., & Godley, L. A. (2013). Perspectives and future directions for epi[INVESTIGATOR_885088]. Blood, 121 (26), 5131-5137. doi:10.1182/blood-2013-04-427724 
Hnisz
, D., Abraham, B. J., Lee, T. I., L
au, A., Saint-Andre, V., Sigova, A. A., . . . Young, R. A. 
(2013). Super-enhancers in the control of cell identity and disease. Cell, 155(4), 934-947. 
doi:10.1016/j.c
ell.2013.09.053 
Isikbay, M., Otto, K., Kregel, S., Kach, J., Cai, Y., Vander Griend, D. J., . . . Szmulewitz, R. Z. 
(2014). Glucocorticoid receptor activity contributes to resistance to androgen-targeted 
therapy in prostate cancer. Horm Cancer, 5 (2), 72-89. doi:10.1007/s12672-014-0173-2 
Janouskova, H., El Tekle, G., Bellini, E., Udeshi, N. D., Ri
naldi, A., Ulbricht, A., . . . Theurillat, 
J. P. (2017). Opposing effects of cancer-type-specific SPOP mutants on BET protein 
degradation and sensitivity to BET inhibitors. Nature medicine . doi:10.1038/nm.4372 
Jin, R., Sterling, J. A., Edwards, J. R., DeGraff, D. J., Lee, C., Park, S. I., & Matusik, R. J. 
(2013). Activation of NF-kappa B signaling promotes growth of prostate cancer cells in 
bone. PloS one, 8(4), e60983. doi:10.1371/journal.pone.0060983 
Lamb, A.
 D., Massie, C. E., & Neal, D. E. (2014). The transcriptional programme of the 
androgen receptor (AR) in prostate cancer. BJU Int, 113 (3), 358-366. 
doi:10.1111/bju.[ADDRESS_1238328], C. 
(2013). Antitumour activity of abiraterone acetate against metastatic castration -resistant 
prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol, 
24(7), 1807- 1812. doi:10.1093/annonc/mdt13 6 
Lotan, T
. L., Gupta, N. S., Wang, W., Toubaji, A., Haffner, M. C., Chaux, A., . . . Netto, G. J. 
(2011). ERG gene rearrangements are common in prostatic small cell carcinomas. 
Modern pathology : an official journal of the [LOCATION_002] and Canadian Academy of 
Pathology, Inc, 24 (6), 820-828. doi:10.1038/modpathol.2011.7 
Loven, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., . . . Young, R. A. 
(2013). Selective inhibition of tumor oncogenes by [CONTACT_885143]-enhancers. Cell, 
153(2), 320-334. doi:10.1016/j.cell.2013.03.036 
Nadimint
y, N., Tummala, R., Liu, C., Yang, J., Lou, W., Evans, C. P., & Gao, A. C. (2013). NF-
kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen 
receptor and its variants. Molecular cancer therapeutics, 12 (8), 1629-1637. 
doi:10.1158/1535-
7163.MCT-13-0027 
Nakazawa, M., Antonarakis, E. S., & Luo, J. (201
4). Androgen receptor splice variants in the era 
of enzalutamide and abiraterone. Horm Cancer, 5 (5), 265-273. doi:10.1007/s12672-014-
0190-1 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 118 of 170 
 
 
 
 
 Neff, T., & Armstrong, S. A. (2013). Recent progress toward epi[INVESTIGATOR_468241]: the example 
of mixed lineage leukemia. Blood, 121 (24), 4847-4853. doi:10.1182/blood-2013-02-
[ADDRESS_1238329], S. L., & Chi, K. N. (2013). 
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant 
prostate cancer progressing after enzalutamide. Ann Oncol, 24 (7), 1802-1807. 
doi:10.1093/annonc/m
dt138 
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & 
Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol, 5 (6), 649-655.  
Quigley
, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., . . . Feng, F. Y. 
(2017). Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of 
BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer 
Discov. doi:10.1158/2159-8290.CD-17-0146 
Scher, H. I., Halabi, S., Tannock, I., Mor
ris, M., Sternberg, C. N., Carducci, M. A., . . . Prostate 
Cancer Clinical Trials Working, G. (2008). Design and end points of clinical trials for 
patients with progressive prostate cancer and castrate levels of testosterone: 
recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol, 
26(7), 1148-1159. doi:10.1200/JCO.2007.12.4487 
Schr
ader, A. J., Boegemann, M., Ohlmann, C. H., Schnoeller, T. J., Krabbe, L. M., Hajili, T., . . . 
Cronauer, M. V. (2014). Enzalutamide in castration-resistant prostate cancer patients 
progressing after docetaxel and abiraterone. Eur Urol, 65 (1), 30-36. 
doi:10.1016/j.e
ururo.2013.06.042 
Shah, N., Arora, V., Karthaus, W. R., Wongvipat, J., Zheng, D., & Sawyers, C. (2015). Luminal 
to Basal Epi[INVESTIGATOR_885089] a Mechanism of Resistance to Anti-Androgen 
Therapy in Prostate Cancer . Paper presented at the Keystone Symposium on Epi[INVESTIGATOR_885090], Keystone Resort, Keystone, Colorado, [LOCATION_003].  
Shah, N., Wang, P., Wongvipat, J., Karthaus, W. R., Abida, W., Armenia, J., . . . Sawyers, C. L. 
(2017). Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives 
antiandrogen resistance in prostate cancer. Elife, 6, e27861. doi:10.7554/eLife.[ZIP_CODE] 
Shi, J., & Vakoc, C. R. (2014). The mechanisms behind the therapeutic activity of BET 
bromodomain inhibition. Molecular cell, 54 (5), 728-736. 
doi:10.1016/j.molcel.2014.05.[ADDRESS_1238330], J., Cross, S. J., . . . Armitage, J. 
O. (2015). Recommendations for the Use of WBC Growth Factors: American Society of 
Clinica
l Oncology Clinical Practice Guideline Update. J Clin Oncol, 33 (28), 3199-3212. 
doi:10.1200/JCO.2015.62.3488 
Thieblemont, C., Stathis, A., Inghirami, G., Karlin, L., Morschhauser, F., Gleeson, M., . . . 
Facon, T. (2014). A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in 
Patients with Non-Leukemic Hematologic Malignancies. Blood, 124 (21), 4417-4417.  
Ware, K. E., Garcia-Blanco, M. A., Armstrong, A. J
., & Dehm, S. M. (2014). Biologic and 
clinical significance of androgen receptor variants in castration resistant prostate cancer. 
Endocr Relat Cancer, 21 (4), T87-T103. doi:10.1530/ERC-13-0470 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 119 of 170 
 
 
 
 
 Williamson, S. R., Zhang, S., Yao, J. L., Huang, J., Lopez-Beltran, A., Shen, S., . . . Cheng, L. 
(2011). ERG-TMPRSS2 rearrangement is shared by [CONTACT_885144]: evidence supporting monoclonal origin. Modern pathology : an official journal 
of the [LOCATION_002] and Canadian Academy of Pathology, Inc, 24 (8), 1120-1127. 
doi:10.1038/modpathol.2011.[ADDRESS_1238331], M. E. 
(2017). Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy 
in Prostate Cancer. Journal of the National Cancer Institute, 109 (12). 
doi:10.1093/jnci/djx118 
Wyatt, A. W., Azad, A. A., Volik, S. V., Annala, M., Beja, K., McConeghy, B., . . . Chi, K. N. 
(2016). Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in 
Castration-Resistant Prostate Cancer. JAMA Oncol . doi:10.1001/jamaoncol.2016.0494 
Wyatt, A. W., & Gleave, M. E. (2015). Targeting the adaptive molecular landscape of castration-
resistant prostate cancer. EMBO Mol Med, 7 (7), 878-894. 
doi:10.[ZIP_CODE]/emmm.201303701 
Wyce, A., Degenhardt, Y., Bai, Y., Le, B., Korenchuk, S., Crouthame, M. C., . . . Barbash, O. 
(2013). Inhibition of BET bromodomain proteins as a therapeutic approach in prostate 
cancer. Oncotarget, 4(12), 2419-2429.  
Zeng, W., Sun, H., Meng, F., Liu, Z., Xiong, J
., Zhou, S., . . . Liu, Z. (2015). Nuclear C-MYC 
expression level is associated with disease progression and potentially predictive of two 
year overall survival in prostate cancer. Int J Clin Exp Pathol, 8 (2), 1878-1888.  
Zhan
g, D., Wang, H., Sun, M., Yang, J., Zhang, W., Han, S., & Xu, B. (2014). Speckle-type 
POZ protein, SPOP, is involved in the DNA damage response. Carcinogenesis, 35 (8), 
1691-1697. doi:10.1093/carcin/bgu022 
Zhan
g, P., Wang, D., Zhao, Y., Ren, S., Gao, K., Ye, Z., . . . Huang, H. (2017). Intrinsic BET 
inhibitor resistance in SPOP-mutated prostate
 cancer is mediated by [CONTACT_885145]-mTORC1 activation. Nature medicine . doi:10.1038/nm.4379 
Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., . . . Chen, L. F. (2014). Brd4 
maintains constitutively active NF-ka
ppaB in cancer cells by [CONTACT_885146]. 
Oncogene, 33 (18), 2395-2404. doi:10.1038/onc.2013.179 
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., . . . Vakoc, C. R. 
(2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. 
Nature, 478(7370), 524-528. doi:10.1038/nature10334 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 120 of 170 
 
 
 
 
 Appendix 1:  ECOG Performance Status  
Grade ECOG 
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature (e.g., light housework, office work). 
2 Ambulatory and capable of all self -care but unable to carry out any work activities.  
Up and about more than 50% of waking hours.  
3 Capable of only limited self care, confined to bed or chair more than 50% of waking 
hours. 
4 Completely disabled .  Cannot carry on any self -care.  Totally confined to bed or 
chair. 
5 Dead. 
Source: (Oken et al., 1982 ) 
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 121 of 170 
 
 
 
 
 Appendix 2:  NCI CTCAE Version 4.03 Adverse Event Severity Grading 
Grade refers to the severity of
 the AE.  The NCI CTCAE displays Grades 1 through 5 with 
unique clinical descriptions of severity for each AE based on this general guideline as shown in 
the table below. 
Adverse Event Severity Grading — NCI CTCAE 
  Description  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated  
2 Moderate; minimal, local or noninvasive intervention indicated; limiting a ge-
appropriate instrumental ADLa 
3 Severe or medically significant but not immediately life threatening; hospi[INVESTIGATOR_12342]; d isabling; limiting self -care AD.b 
4 Life-threatening consequences; urgent intervention  indicated 
5 Death related to AE  
A semicolon (;) indicates “or” within the description of the grade.  A single dash (–) indicates a grade is not available.  Not all 
grades are appropriate for all AEs; therefore, some AEs are listed with fewer than 5 options for grade selection. 
Grade 5 (Death) is not appropriate for some AEs and therefore is not an option. 
Activities of Daily Living (ADL) 
a  Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing money, etc. 
b Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden 
 
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 122 of 170 
 
 
 
 
 Appendix 3:  Prostate Cancer Clinical Trials Working Group 2 Criteria   
MEASUREM
ENT OF RESPONSE 
Measurement of response in patients with measurable disease 
Response and progression will be evaluated in this study using the international criteria proposed 
by [CONTACT_8225] 1.1 (RECIST 1.1) criteria ( Eisenhauer et 
al., 2009).  Changes in the sum of the diameters of target lesions of the tumor lesions are used in 
the RECIS
T criteria. 
Note: lesions are either measurable or non-measurable using the criteria provided 
below. The term “evaluable” in reference to measurability will not be used 
because it does not provide additional meaning or accuracy.  All measurements 
should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning 
of treatment and never more than [ADDRESS_1238332] of a treatment. 
Clinical lesions.  Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes).  In the case of skin lesions, documentation by 
[CONTACT_6775], including a ruler to estimate the size of the lesion, is recommended. 
Chest x-ray.  Lesions on chest x-ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776].  However, CT is preferable. 
Conventional CT and MRI.   These techniques should be performed with cuts of [ADDRESS_1238333], abdomen, and pelvis.  Head and 
neck tumors and those of extremities usually require specific protocols.  
Measurable disease/ Target lesions 
All measurable lesions (lesions that can be accurately measured in at least one dimension 
[longest diameter to be recorded except for target lymph nodes with are measured on the 
short axis] as ≥ 10mm with spi[INVESTIGATOR_15143]) up to a maximum of 2 lesions per organ and 
5 lesions total, representative of all involved organs, should be identified as target lesions 
and r
ecorded and measured at baseline.  Target lesions should be selected on the basis of 
their size (lesions with the longest diameter) and the suitability for accurate repeated 
measurements (either by [CONTACT_14217]).  A sum of the LD for all target 
lesions will 
be calculated and reported as the baseline sum LD.  The baseline sum LD 
will be used as a reference by [CONTACT_14218]. 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238334] measure 1 cm or greater (with 
spi[INVESTIGATOR_92312]).  
Complete Response (CR):  Disappearance of all target lesions  
Partial Response (PR):  At least a 30%  decrease in the sum of the 
longest diameter (LD) of target lesions, taking as 
reference the baseline sum LD  
Progressive Disease (PD):  At least a 20% increase in the sum of the LD of 
target lesions, taking as reference the smallest 
sum LD recorded since t he treatment started 
(including baseline LD), or the appearance of 
one or more new lesions  
Evaluation of non-target lesions 
Complete Response (CR):  Disappearance of all non -target lesions and 
normalization of tumor marker level  
Incomplete Response/  
Stable Disease (SD):  Persistence of one or more non -target lesion(s), 
and/or maintenance of tumor marker level above 
the normal limits  
Progressive Disease (PD):  Appearance of one or more new lesions, and/or 
unequivocal progression of existing non -target 
lesions 
Although a clear progression of non-target lesions only is exceptional, in such 
circumstances, the opi[INVESTIGATOR_885091]. 
Evaluation of best overall response 
The best overall response is the best 
response recorded from the start of the treatment 
until disease progression/recurrence (taking as reference for progressive disease the 
smallest measurements recorded since the treatment started, including baseline; see table 
below).  The patient's best response assignment will depend on the achievement of both 
measurement and confirmation criteria. 
Confirmation 
To be assigned a status of PR or CR, changes in tumor measurements must be confirmed 
by [CONTACT_561722] [ADDRESS_1238335] met.  In the 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238336] once after 
study entry at a minimum of 12 weeks after study entry. 
Duration of overall response 
The duration of overall response is measured from the time measurement criteria are met 
for CR/PR (whichever is first recorded) until the first date that recurrent or progressive 
disease is objectively documented (taking as reference for progressive disease the 
smallest measurements recorded since the treatment started).  The duration of overall 
complete response is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 
Target Lesions Non-Target Lesions  New Lesions  Response  
CR CR No CR 
CR Incomplete 
response/SD  No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
Evaluation of non-measurable bone disease  
Bone scans obtained after the baseline evaluation will be used to evaluate post-treatment 
changes.  Bone scans obtained will be evaluated as either “no new lesions” or “new lesions” on 
the tumor measurement forms. 
a. For the first scheduled reassessment:  New lesions at the first scheduled evaluation will 
require a confirmatory bone scan [ADDRESS_1238337] reassessment scan. 
b. For subsequent scheduled reassessments:  If no new lesions are observed, study therapy 
will continue. If new lesions are observed, this is evidence of disease progression.  Date 
of progression is the date at which the scan was obtained. 
Post-treatment PSA Changes  
All patients, with or without measurable or non-measurable disease, will be evaluated for PSA 
decline.  Patients with disease that is not measurable will be eligible for this study and will be 
assessed for response based on changes in PSA and serial bone scans (if appropriate).  The 
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment [ADDRESS_1238338] 2 ng/mL.  Patients who show PSA increases will not be 
evaluated for PSA progression prior to 12 weeks of study therapy. 
a. 30% and 50% PSA Decline:  PSA decline of at least 30% and 50%, respectively, from 
baseline confirmed by a second measurement at least 3 weeks later.  The reference for 
these declines should be a PSA measured within 2 weeks prior to starting therapy.  
b. PSA Progression:  PCWG2 Criteria will be reported.  PSA progression occurs when the 
PSA has increased 25% or greater above nadir and an absolute increase of 2 ng/mL or 
more from the nadir is documented.  Where no decline is observed, PSA progression 
similarly occurs when a 25% increase from baseline value along with an increase in 
absolute value of 2 ng/mL or more.  Patients will receive a minimum of 12 weeks of 
therapy prior to being evaluable for this endpoint.  PSA progression (without evidence of 
progression on scans) will not be criteria for discontinuation of study therapy. 
c. PSA Response Duration:  The PSA response duration commences on the date of the first 
50% decline in PSA.  The response duration ends when the PSA value increases by 25% 
above the nadir, provided that the increase in the absolute-value PSA level is at least 
5 ng/mL or back to baseline, whichever is lower. 
d. Progressive Disease by [CONTACT_43876] (as defined by [CONTACT_885147]) 
e. Time 
to PSA Progression:  The start of the time to PSA progression is the day treatment 
is initiated.  The end date is the date of the first PSA rise over the determined PSA PD 
value. 
Progressive disease (PD) 
Progressive disease will be defined by [CONTACT_54747]: 
a. Appearance of new metastatic lesions outside the bone 
b. New metastatic lesions on bone scan confirmed as described above 
c. Development of an indication for radiotherapy while on treatment 
d. Unequivocal progression of non-target lesions 
e. Global 
deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression 
Note that PSA progression (as defined above) alone does not meet the criteria for 
progressive disease. 
Source: (Scher et al., 2008 ) 
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 126 of 170 
 
 
 
 
 Appendix 4:  XTANDI  Package Insert   
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 127 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 128 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Ze        70 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 130 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 131 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 132 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 133 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 134 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 135 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 136 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 137 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 138 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 139 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 140 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 141 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 142 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 143 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 144 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 145 of 170 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 146 of 170 
 
 
 
 
  
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 147 of 170 
 
 
 
 
  
Appendix 5:  ZYTIGA® Package Insert 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 148 of 170 
 
 
 
 
  
ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 149 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
 p g    g    0 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 151 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 152 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 153 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 154 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 155 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 156 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 157 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 158 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 159 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 160 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 161 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 162 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 163 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 164 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 165 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 166 of 170 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
       0 
 
 
 
 
  

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 168 of 170 
 
 
 
 
  
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 169 of 170 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ZEN003694-002 Clinical Study Protocol  Version:  Final 
Amendment 10  05 November 2018 
Zenith Epi[INVESTIGATOR_885060]. Confidential Page 170 of 170 
 
 
 
 
 Appendix 6:  Investigator Agreement Page 
 
Phase 1b Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide 
or Abiraterone in Patients with Me
tastatic Castration-resistant  
Prostate Cancer 
 
Protocol ZEN003694
-002 
Amendment 10:  [ADDRESS_1238339] this study in accordance with ICH Guidelines, all 
applicable [LOCATION_002] (US) Regulations (21 CFR parts 50, 54, 56 and 312) and Good Clinical 
Practice and applicable regulatory requirements. 
The information contained in this protocol is proprietary and provided to me in confidence, and 
may not be disclosed to any other party, in any form, without prior authorization from Zenith 
Epi[INVESTIGATOR_885060]., except to the extent necessary for the conduct of the study at this study site. 
I will provide all study personnel 
under my supervision copi[INVESTIGATOR_885092].   I will discuss this material with them to ensure 
that they 
are fully informed about the drugs and the study. 
 
Principal Investigator ’s Signature   [CONTACT_323026] ’s Name: 
(Print)  
Institution ’s Name, City, State :  
  
  
 